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ABSTRACT 
 Intrinsic antibiotic resistance is of growing concern in modern medical 
treatment. The primary action of multidrug resistant strains is through over-
expression of active transporters which recognize a broad range of antibiotics. In 
Escherichia coli, the TolC-AcrAB complex has become a model system to 
understand antibiotic efflux. While the structures of these three proteins (and 
many of their homologs) are known, the exact mechanisms of interaction are still 
poorly understood. By mutational analysis of the TolC turn 1 residues, a drug 
hypersensitive mutant has been identified which is defective in functional 
interactions with AcrA and AcrB. Antibiotic resistant revertants carry alterations 
in both TolC and AcrA act by stabilizing functional complex assembly and 
opening of the TolC aperture, as monitored by stability of a labile TolC mutant 
and sensitivity to vancomycin, respectively. Alterations in the AcrB periplasmic 
hairpin loops lead to a similar antibiotic hypersensitivity phenotype and 
destabilized complex assembly. Likewise, alterations in TolC which constitutively 
open the aperture suppress this antibiotic sensitivity. Suppressor alterations in 
AcrA and AcrB partially restore antibiotic resistance by mediating stability of the 
complex. The AcrA suppressor alterations isolated in these studies map to the 
three crystallized domains and it is concluded they alter the AcrA conformation 
such that it is permanently fixed in an active state, which wild type only 
transiently goes through when activated by AcrB. Through this genetic evidence, 
a direct interaction between TolC and AcrB which is stabilized by AcrA has been 
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proposed. In addition to stabilizing the interactions between TolC and AcrB, 
AcrA is also responsible for triggering opening of the TolC aperture by mediating 
energy flow from AcrB to TolC. By permanently altering the conformation of 
AcrA, suppressor mutants allow defective TolC or AcrB mutants to regain 
functional interactions lost by the initial mutations. The data provide the genetic 
proof for direct interaction between AcrB and that AcrA mediated opening of 
TolC requires AcrB as a scaffold. 
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Introduction 
Gram-Negative Bacteria 
Gram-negative bacteria contain two lipid membranes, separated by the 
periplasmic space. The outer membrane has two layers; the inner layer contains 
phospholipids while the outer layer contains primarily lipopolysaccharides (LPS). 
This LPS layer helps to act as an initial permeability barrier. It does this by its 
amphipathic nature, the polysaccharide portion is negatively charged to create a 
barrier to help prevent the entry of hydrophilic antibiotics from entering the cell, 
whereas the lipid portion (Lipid A) of LPS molecule is highly hydrophobic, which 
helps to prevent hydrophobic antibiotics from crossing the outer membrane 
(Raetz, 1990; Raetz and Whitfield, 2002). The inner membrane is a phospholipid 
bilayer, which acts as a final permeability barrier to prevent toxic molecules from 
entering into the cytoplasm and allowing desired molecules to be selectively 
transported into the cell. 
 
Outer Membrane 
 As stated above, the outer membrane is a bilayer comprised of primarily 
two different types of lipid molecules. The outer leaflet of the outer membrane is 
primarily composed of LPS molecules (Takeuchi and Nikaido, 1984). The lipid 
portion, lipid A, contains between 4 and 6 lipid molecules, depending on bacterial 
species and strain. The inner leaflet is composed of phospholipids, primarily 
phosphatidylethanolamine and secondarily, phosphatidylglycerol and 
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diphosphatidylglycerol (Lugtenberg and Peters, 1976; Harwood and Russell, 
1984). Many studies have been performed to look at protein interactions with 
various phospholipids. In particular, the β-barrel outer membrane proteins OmpF 
and OmpT show preferential interaction with phosphatidylethanolamine, the more 
abundant phospholipid head group (O’Keefe et al., 2000; Brandenburg et al., 
2004). In contrast, the outer membrane protein OmpA shows little distinction 
between phosphatidylethanolamine and phosphatidylglycerol (Kleinschmidt, 
2003; Ramakrishnan et al., 2004). All three OMPs show increased interaction 
with hydrocarbon chains in the range of 14 to 18 carbons, which is typical of the 
composition of bacterial membranes (Kleinschmidt, 2003, O’Keefe et al., 2000, 
Brandenburg et al., 2004). Taken together, the interactions between both the polar 
head groups and the hydrophobic acyl chains act to form a seam between outer 
membrane proteins and lipid molecules. It has also been found that some 
lipoproteins bind to phospholipid head groups. For example, the non-essential 
BamE lipoprotein binds to phosphatidylglycerol (Knowles et al., 2011). However, 
unlike the aforementioned interactions, these interactions are thought to primarily 
anchor lipoproteins to specific regions of the outer membrane. 
 The majority of proteins embedded in the outer membrane are β-barrel 
proteins. These β-barrel proteins typically have an even number of anti-parallel 
sheets which circle around to form pore proteins. The β-barrels have a hydrophilic 
core and a hydrophobic exterior. The length of the hydrophobic exterior of β-
barrel is such that it limits the hydrophobic mismatch between them and the 
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hydrocarbon chain of the lipids (O’Keefe et al., 2000). Additionally, the exterior 
surface contains a ring of charged or polar residues at the outer limits of the 
hydrophobic core in order to properly align with the phospholipid head groups. In 
several cases, the exterior loops act to gate the pore from allowing molecules to 
freely diffuse into the periplasm. Therefore the β-barrel proteins act in many ways 
as the initial barrier for hydrophobic molecules to enter into the cell.  
 It is the gated outer membrane proteins and the amphipathic nature of the 
LPS/phospholipid bilayer that prevents noxious chemicals from freely entering 
the cell. Commonly, mutations affecting the outer membrane, either through the 
LPS or OMPs, typically cause hypersensitivity to a wide array of antibiotics and 
detergents. Additionally, mutations which alter the charge of the outer membrane 
surface or decrease the permeability of the outer membrane can increase 
resistance to certain antimicrobial agents. 
 
Inner Membrane 
 Unlike the outer membrane, the inner membrane is composed of a 
phospholipid bilayer. However, this bilayer is enriched with 
phosphatidylethanolamine. The inner membrane is often characterized by its 
abundance of cytochromes, which are atypical of the outer membrane. The 
integral proteins of the inner membrane are typically α-helical bundles, which 
typically lie at a tilt to the membrane instead of being perpendicular. This allows 
the helices to shift their orientation as the membrane thickness changes. This 
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movement prevents drastic changes in the hydrophobic mismatch (O’Keefe et al., 
2000; Deol et al., 2004; Sansom et al., 2005). While these changes allow for 
stabilization of the hydrophobic mismatch, in some cases, it also allows the 
protein to function properly. Many of these α-helical bundle proteins function as 
transporters which must be energized for functionality. In the case of secondary 
transporters, which are energized by a proton gradient, the proper alignment of 
charged and polar residues within the membrane must be properly aligned. While 
minor changes in the tilt of the α-helices can cause little change, these small 
changes can drastically influence the functioning of the protein. 
 Besides allowing nutrients to enter into the cell, the transporters of the 
inner membrane also allow for the removal of toxic molecules from the cytoplasm 
or inner membrane. This important function is performed by various classes of 
efflux systems, the majority of which are secondary transporters.   
 
Periplasmic Space 
 The periplasmic space is an aqueous environment which separates the 
inner and outer membranes. This region is home to the peptidoglycan, which 
gives rigidity to the cell. As this cell wall is unique to bacteria, many antibiotics 
target the peptidoglycan and cause cell death. There are many types of proteins 
within the periplasmic space, varying in nature from chaperones to assist in OMP 
assembly to enzymes which assist in cell wall synthesis and maintaining nutrients 
within the cell. Chaperones, such as SurA, act to sequester the greasy OMPs on 
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their way to the Bam (β-barrel assembly machinery) complex and prevent 
aggregation of these proteins. In cells lacking SurA, there is an abundance of mis-
folded OMPs which cause toxicity in the cell. The periplasmic protease DegP acts 
to degrade mis-folded OMPs and potentially as a chaperone at low temperatures. 
While mis-folded OMPs are a major substrate for DegP, DegP is also responsible 
for the degradation of other periplasmic proteins, such as AcrA. Gerken and Misra 
showed that the stability of the mutant AcrAL222Q is dependent on the presence of 
DegP; without DegP, AcrAL222Q is stable (2004). 
 In addition to the aforementioned chaperones and proteases, the periplasm 
is home to enzymes such as maltose binding protein (MBP). MBP helps in the 
transport of maltodextrins from LamB (the OMP which allows uptake of 
maltodextrins into the cell) to inner membrane transporter proteins MalG and 
MalF (Duplay et al., 1984). The periplasm is also home to other enzymes such as 
β-lactamase. β-lactamase is encoded by the ampC and is responsible for intrinsic 
resistance of E. coli to many β-lactam antibiotics. Clinical and zoological isolates 
of extended spectrum β-lactam resistant enteric bacteria have become an epidemic 
plaguing current medical treatments.  
 
Antibiotics and Their Resistance 
Antibiotics are compounds which are either naturally produced by one 
microorganism to kill or inhibit the growth of other microorganisms, or 
synthesized with the active portion of a naturally occurring chemical. Bacteria and 
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other microorganisms have evolved many ways of combating these antibiotics 
either by inactivating the antibiotic, preventing their entry into the cell, or actively 
transporting them out of the cell. As the focus of this study will be on active 
transport of the antibiotics from the cell, the other mechanisms of resistance will 
only be briefly discussed. 
In order to inactivate the antibiotic, specific enzymes must be present in 
the bacteria which physically alter the antibiotic so as to disrupt its natural 
function. An example of this would be β-lactamase, which acts to destroy the 
lactam ring in the β-lactam antibiotics. This then prevents this class of antibiotics 
from inhibiting cell wall synthesis. To prevent entry of the antibiotic into the cell, 
LPS can be modified to change its overall net charge. These modifications are set 
in motion by the activation of the PmrAB two-component system (Herrera et al., 
2010). While inactivation of antibiotics and modification of the cell wall are two 
important means of obtaining antibiotic resistance, active transport of antibiotics 
from the cell is of major importance. Many clinical isolates of antibiotic resistant 
strains increase the expression of efflux pumps (Bratu et al., 2009; Fralick 1996; 
Dastidar et al., 2007; Fabrega et al., 2010; Pages and Amaral, 2009; Srikumar et 
al., 1998; Swick et al., 2011; Zgurskaya et al., 2009). In gram-negative bacteria, 
efflux pumps are comprised of an outer membrane factor (OMF), membrane 
fusion protein (MFP), and a pump protein. The major antibiotic efflux pump 
system in E. coli is the TolC-AcrAB system.  
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TolC 
 Unlike most other OMPs, TolC is an outer membrane protein with the 
three monomers each contribute one third of the trimeric, 12 stranded, β-barrel 
protein. In addition to the 12-stranded β-barrel, the protein also contains a 100Å 
α-helical barrel that protrudes into the periplasmic space (Fig 1). The α-helical 
barrel constricts at the equatorial domain, below which sits the aperture. In the α-
helical barrel, each monomer contributes four full and four pseudo helices 
(Koronakis, 2003; Koronakis et al., 2000; Koronakis et al., 2004). These full and 
pseudo helices act in a pairwise fashion, such that a full length helix is connected 
to a pseudo helix via the two β-sheets on one end and a periplasmic turn at the 
other. For example, H2 and H4 contribute to one pseudo helix while H3 is paired 
with it. H3 and H4 are connected by turn 1 and remain static during aperture 
opening. The other two “helices” consist of H6, H7, and H8, of which H7 and H8 
are connected by turn 2 and swing outward during aperture opening. In its closed 
state, the channel is constricted to a diameter of 3Å (Federici et al., 2004) from an 
internal diameter of about 35Å (Andersen et al., 2003). This allows TolC to 
selectively allow the passage of antibiotics through the channel. 
 The aperture is kept closed by a network of salt and hydrogen bonds 
consisting of residues Q136, T152, D153, E359, Y362, and R367, with R367 
playing the primary role in maintaining a locked aperture (Bavro et al., 2008; 
Koronakis et al., 2000; Andersen et al., 2002). Alterations of R367 cause a severe 
antibiotic hypersensitivity phenotype, which is presumably due to antibiotic influx  
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Figure 1. A cartoon schematic of the E. coli envelope showing the AcrAB-TolC 
complex. X-ray crystal structures of TolC (1EK9), AcrA (2F1M), and AcrB 
(2GIF) are shown. The membrane proximal domain of AcrA has not been 
crystallized and is shown as an oval protruding from the β-barrel. The periplasmic 
domains of each of the proteins are indicated next to the protein. 
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(Andersen et al., 2002; Augustus et al., 2004). Recently, crystal structures have 
been solved for two different mutants of R367, each showing the aperture is in a 
dilated conformation (Bavro et al., 2008, Pei et al., 2010). These crystal structures 
of TolC show significant rearrangement of the inner helices (H7/H8), while the 
outer helices (H3/H4) remain fairly static.  
 
AcrB  
 AcrB is also a trimeric protein. It utilizes the proton gradient of the inner 
membrane to derive energy and acts as a proton/drug antiporter. Each monomer 
contributes 12 transmembrane helices and two large periplasmic loops (Fischer et 
al., 2011; Seeger et al., 2006; Takatsuka and Nikaido, 2006; Takatsuka et al., 
2010; Fig 1). The transmembrane helices contain a proton relay system, which has 
been clearly defined. Alterations to three specific charged residues, D407, D408, 
R971, completely abolish proton translocation, thereby stopping antibiotic efflux 
(Takatsuka and Nikaido, 2006). The large periplasmic loops contain the drug 
binding pocket and tunnels used for drug capture and release (Bohnert et al., 
2010; Seeger et al., 2006; Husain and Nikaido, 2010). When properly folded, this 
domain spans 70Å into the periplasm to potentially meet TolC at its lowest point 
there. This large periplasmic structure is divided into two domains, the TolC 
docking (D) and periplasmic porter (P), which are further subdivided based on the 
N-terminal (PN1, PN2, DN) and C-terminal (PC1, PC2, DC) region (Seeger et al., 
2006; Murakami et al., 2006; Yu et al., 2003). The exterior surface of AcrB is 
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used to dock AcrA along a specified grove running along DN, DC, PN2, and PC1 
(Symmons, 2009). This cross-linking analysis led to the conclusion that AcrA, 
AcrB, and TolC interact in a 1:1:1 manner. Interestingly, as AcrB goes through its 
conformational changes, PC2 is shown to go through signification movement at 
the surface, whereas the area where AcrA is proposed to lie remains relatively 
static (Symmons et al., 2009). This indicates that AcrA may not gain 
conformational energy from AcrB for complex assembly and TolC aperture 
opening (see below). Recent co-crystals of CusBA, the homologous copper/silver 
efflux pump in E. coli, show CusB, the AcrA homologue, interacts with CusA and 
CusC, the AcrB and TolC homologues, respectively, in a 2:1:1 manner. If this is 
the case for AcrAB/TolC, it could be possible for AcrA to derive conformational 
energy from AcrB to transmit to TolC for aperture opening (Su et al., 2011). 
Additionally, by the use of Surface Plasmon Resonance (SPR) Tikhonova et al. 
(2009) showed two independent binding affinities for AcrA and TolC, as well as 
other membrane fusions proteins. This was further validated when they showed 
similar results between AcrA and AcrB (Tikhonova et al., 2011). 
 While the exterior of the periplasmic domain acts as a scaffold for AcrA, 
its interior contains the tunnels and pocket used for drug capture and release 
(Seeger et al., 2006; Murakami et al., 2006). The drug transport pathway begins 
with two entrance tunnels, which are positioned facing the periplasmic space and 
the surface of the outer leaflet of the inner membrane and are used by AcrB to 
sequester antibiotics (Loose). During its functional rotation, these tunnels will 
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close and a drug binding pocket will open (Tight). This pocket is highly 
hydrophobic, containing 6 phenylalanine residues. The final stage of functional 
rotation causes the drug binding pocket to be collapsed and a third tunnel to open 
toward the TolC docking domain (Seeger et al. 2006; Murakami et al., 2006). 
Once the antibiotic has reached this location, it is then transferred to TolC to be 
expelled directly into the extracellular milieu, thus bypassing the periplasmic 
space. 
 
AcrA 
 Unlike TolC and AcrB, the crystal structures of AcrA and its homologue 
in Pseudomonas aeruginosa, MexA, do not show trimeric assemblies. AcrA 
contains four structurally distinct domains; a membrane proximal (MP), β-barrel, 
lipoyl, and α-helical (Mikolosko et al., 2006; Symmons et al., 2009; Vacaro et al., 
2006; Fig 1). The membrane proximal domain is the most unstructured domain, 
showing multiple confirmations. This region also contains the only native 
cysteine residue in AcrA, which becomes lipidated to anchor AcrA to the outer 
leaflet of the inner membrane. The β-barrel domain has been proposed to lie at the 
interface between the TolC docking and porter domains. It contains six anti-
parallel β-sheets and a single α-helix. The lipoyl domain can be divided into the 
N- and C-termini, each of which consists of four β-sheets. The two halves are 
separated by the coiled α-helices (Mikolosko et al., 2006). This domain sits at the 
crown of AcrB in a cleft between the DN and DC domains (Symmons et al., 
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2009). These three domains have been shown to interact directly with AcrB. 
Finally, cysteine mediated chemical cross-linking experiments showed that the α-
helical domain interacts with TolC in a coiled-coil manner, whereby the coils of 
AcrA align themselves with TolC (Lobedanz et al., 2007). It has been proposed 
that the coiled-coil alignment of the α-helices of AcrA and TolC are such that the 
first AcrA α-helix lies in a groove between the TolC α-helices H3, H8, and H7, 
known as the intraprotemer groove.  
 When AcrA was crystallized, there appeared to be four different 
conformations of the protein. These four different isoforms suggest that AcrA is a 
relatively flexible protein to allow for proper interaction with both AcrB and 
TolC. If the lipoyl domain is fixed in space, the α-helical domain shows a 15° 
rotation (Mikolosko et al., 2006). Like AcrA, the MexA α-helical domain shows a 
35° rotation (Symmons et al., 2009; Vaccaro et al., 2006). In addition to this 35° 
rotation for the α-helical domain, the MP and β-barrel domains show a 25° 
rotation from the lipoyl domain. From the β-barrel domain, the MP domain shows 
a further 25° rotation. These combined rotations would allow AcrA to transmit 
conformational energy from AcrB to TolC and also allow AcrA to be completely 
aligned with both proteins. Initial studies attributed the conformational flexibility 
of AcrA to AcrA unfolding and elongating to connect to the outer membrane. By 
the use of electron paramagnetic resonance and site-directed spin labeling, 
specific residues within the MP domain show a high degree of conformational 
flexibility independent of pH (Ip et al., 2003). Additionally, spin labels added to 
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the α-helical domain showed a high degree of conformational flexibility at pH 7. 
However, when the pH was dropped to pH 5, these same residues showed a 
broadening of the peak. This shows that the helices of AcrA have conformational 
flexibility, which can become fixed into a specific conformation. 
 
Mechanisms of Tripartite Complex Assembly 
 Originally, it had been proposed that AcrA interacted with AcrB and TolC 
in a 1:1:1 ratio, whereby one monomer of AcrA interacted with one monomer of 
AcrB and TolC (Fernandez-Recio et al., 2004; Misra and Bavro, 2009; Symmons 
et al., 2009). This interaction had been proposed by chemical cross-linking 
analysis using cysteine engineered AcrB/AcrA and TolC/AcrA complexes 
(Lobedanz et al., 2007; Symmons et al., 2009). Through structural analysis, 
Symmons et al. proposed the first model of the trimeric assembly of the complex. 
Through these studies, it had been proposed that AcrB and TolC directly 
interacted with one another. This was further supported by direct disulfide bond 
formation of AcrB and TolC proteins modified with single cysteine substitutions 
in their hairpin loop and periplasmic turn regions, respectively (Tamura et al., 
2005). 
 In addition to chemical cross-linking experiments which have been done 
to determine specifically where AcrA and its homologues aligned with AcrB or 
TolC and their respective homologues, analysis of chimeric complexes has been 
used to map the potential sites of interaction between members of the complex 
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(Bai et al., 2010; Elkins and Nikaido, 2003; Krishnamoorthy et al., 2008; 
Vediyappan et al., 2006; Welch et al., 2010). Chimeric complexes typically are 
not functional; however, gain-of-function point mutations can be (and have been) 
isolated that make these complexes functional. These mutations have been helpful 
in determining where the proteins potentially align. When the P. aeruginosa TolC 
homologue, OprM, containing a mutation of its C-terminus was combined with 
the Vibrio cholerae AcrAB homologues, VceAB, the chimeric complex showed a 
drug hypersensitivity phenotype. Gain-of-function mutations mapped to the VceA 
α-helical tip region, indicating the α-helical region was important for interaction 
between the membrane fusion protein (MFP, AcrA) and outer membrane factor 
(OMF, TolC) (Bai et al., 2010). Additional chimeric studies of VceC, the V. 
cholerae TolC homologue, and E. coli AcrAB led to drug hypersensitivity, which 
was suppressed by mutations in VceC within the intraprotomer groove 
(Vediyappan et al., 2006). A similar analysis was performed using the chimeric 
complex of TolC and MexAB. Gain-of-function mutations found within TolC 
mapped to the same groove as those isolated within VceC (Bokma et al., 2006). 
Taken together, these gain-of-function mutations help to identify the interacting 
surfaces of the MFP and OMF.  
 In an attempt to identify exactly where OMF and MFP interact, 
reconstituted proteoliposomes of MexA and OprM were mixed and used for cryo-
electro tomography. By analyzing the images and constructing tomograms of the 
MexA-OprM complexes, it was determined that the α-helices of MexA lie along 
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the face of the α-helical barrel near the tip of the aperture (Trépout et al., 2010). 
While this alignment is slightly offset from the data observed by Symmons et al. 
(2009), the authors proposed that the MFP and OMF may initially interact via the 
lower regions of the aperture and upper regions of the α-helices and then slide 
into one another, allowing the proton-antiporter (PAP) and OMF to interact. This 
alignment was also constructed using parameters similar to those used by 
Symmons et al., such that MexA is in an extended form like AcrA. Additionally, 
this alignment used data previously published on suppressor mutations mapping 
within OprM of a MexA α-helical inactivating mutation. 
 Mapping of gain-of-function mutations between OMF and MFP chimeras 
and intergenic suppressors of interaction defective mutants within native 
complexes has been useful in potentially identifying interaction domains of OMF 
to MFP. However, gain-of-function mutations between MFP and PAP have not 
shown similar results. An analysis of AcrA and MexB gave mutations in AcrA 
that are not directly in contact with the PAP, as well as mutations within MexB 
that are in varied locations, including a mutation within the transmembrane 
helices (Krishnamoorthy et al., 2008). The gain-of-function mutations isolated in 
this study may be stabilizing complex assembly of the trimeric complex and not 
directly between the bipartite complex of MFP and PAP.  
 These findings from chemical cross-linking, engineered disulfide bond 
formation, and gain-of-function suppressor analyses lead to the conclusion that 
OMF and PAP directly interact with one another and that the MFP helps to 
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facilitate this interaction and stabilize it. In this mechanism of interaction, the 
initial stages of interaction begin between loop 1 of AcrB and turn 1 of TolC 
(Weeks et al., 2010). This initial interaction then facilitates the interaction 
between loop 2 and turn 2, which in turn destabilizes the salt bridges that keep the 
TolC aperture locked. At this time AcrB will go through its functional rotation 
and will stimulate conformational changes in AcrA. These conformational 
changes will be transmitted from the α-helices to the coiled-coils of TolC. This 
will cause the full alignment of the AcrA α-helices with the intraprotomer groove, 
causing full dilation of the aperture. At this point, the drug will have moved from 
the entrance tunnels, through the drug binding pocket, and finally to the exit 
tunnels, where it will enter TolC and be extruded to the extracellular space (Fig 
36). 
 In opposition to this proposed mechanism of interaction, data exist that the 
MFP interacts in a 2:1:1 fashion with the PAP and OMF. The recent co-crystal of 
the E. coli CusBA copper/silver efflux system, homologous to AcrAB, 
respectively, showed that CusB had 2 monomers per monomer of CusA (Su et al., 
2011). If this is the case, the MFP would be properly positioned to receive and 
transmit conformational energy to the OMF and facilitate aperture opening. In 
addition to these data, the MFP from the macrolide-specific efflux system, 
MacAB, has been shown to interact as a hexamer (Yum et al., 2009, Xu, et al., 
2010).  This hexameric conformation of the MFP causes a loss of interaction 
between the PAP and the OMF. In this model, the α-helices interact side by side 
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and form a stem-like structure extruding from the funnel-like conformation of the 
lipoyl and β-barrel domains. The tip of this stem-like structure has an internal 
diameter of ~30Å, which is roughly equivalent to the internal diameter of the 
open aperture of TolC, as well as the internal diameter of the upper half of the 
TolC α-helical barrel (Yum et al., 2009). In addition to the identification of MacA 
acting as a trimer of dimers, a covalently linked AcrA dimer was found to 
functionally replace the native AcrA, indicating AcrA functionally acts as a dimer 
(Xu et al., 2011). Additionally, when analyzing column elutes from size-exclusion 
chromatography, the covalently linked AcrA dimer showed a peak at the same 
position as the Actinobacillus actinomycetemcomitans MacA, which has been 
shown to spontaneously form hexamers and that the hexameric state is 
functionally relevant. 
 While analyzing the polymeric state of AcrA and MacA, Xu et al. (2010) 
and Kim et al. (2010) have identified three key residues at the extreme tip region 
of AcrA and MacA. When looking at the hexameric assembly of MacA, these 
residues form a pocket where it has been proposed that the open TolC aperture 
turns fit. Xu et al. (2011) later cloned the DNA encoding the extreme tip regions 
of AcrA’s α-helices and TolC’s turn regions into E. coli macA and A. 
actinomycetemcomitans macA, respectively (Kim et al., 2008). These two hybrid 
proteins were able to interact via size exclusion chromatography and analyzing 
negatively stained protein samples through electron microscopy. By analyzing 
these protein samples, a density map was constructed and modeled proteins were 
18 
 
inserted. This showed the TolC aperture turns situated, as proposed at the extreme 
α-helical tip region of AcrA. This led the authors to the conclusion that the MFP 
forms a hexameric structure, which sits on the periplasmic crown of the PAP. The 
opening of the OMF is facilitated entirely by the extreme α-helical tip regions of 
the MFP. Additionally, this model of interaction places no interaction between 
PAP and OMF due to the 40 - 50Å length of the α-helical barrel formed by the 
MFP α-helices. 
 Through mutational analysis of TolC turn 1, the AcrB hairpin loops 1 and 
2, and reversion analysis, there is proposed to be a direct interaction between 
AcrB and TolC. In these studies, the importance of TolC turn 1 residues in 
functional complex assembly have been identified. Additionally, a TolC mutant 
that was completely defective in export functions, but maintained import function 
was isolated. Furthermore, residues of AcrB’s hairpin loop 1 which are important 
in maintaining antibiotic resistance were identified. By utilizing antibiotic 
hypersensitive mutants of TolC and AcrB, alterations in all three proteins which 
primarily restore interaction through stabilizing functional complex assembly and 
secondarily open the TolC aperture have been isolated. These intra- and 
intergenetic suppressor alterations, as well as the original defective proteins, give 
cues to the defects and evidence to the direct interaction between AcrB and TolC. 
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Mutational and Suppression Analysis 
 In order to determine the function of a gene or important domains of a 
protein, mutations are commonly introduced which alter the functionality of the 
protein. These mutations can cause the protein to simply not be expressed or 
change protein through physical alteration. Once a protein has been rendered non-
functional, the effects within the cell can be monitored to determine the functional 
role of the protein or a domain within the protein. In order to determine the 
function of specific residues, three common techniques are put to use: deletions, 
frameshift, and alanine scanning. These cause mutations within the coding region 
of the gene to determine the importance of specific amino acids within the 
structure of a protein. After a protein has been rendered non-functional, reversion 
analysis is commonly used to determine other domains within the protein which 
are important and to determine other proteins which may be important in 
functionality of the original protein. The term intragenic suppressor refers to a 
secondary mutation within the coding region of the gene of a protein being 
studied, while maintaining the original mutation within the gene. Intragenic 
suppressors often will shed light upon the original defect and how the mutation is 
acting to restore the functionality of the original mutant. On the other hand, 
intergenic suppressors are mutations within other genes which overcome the 
defect caused by the mutation of the first. These types of mutations give clues to 
the network of interactions involved in maintaining a specific phenotype. In 
addition to identifying genes which interact to restore a phenotype, intergenic 
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suppressors can identify the specific regions of interaction between the two 
proteins.  
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Results 1: Importance of TolC’s periplasmic turn 1 
Identification of Turn 1 Residues Involved in Functional Complex Assembly 
 After the structure of AcrB was determined, it was proposed that the 
hairpin loops of AcrB could directly interact with the α-helix-turn-α-helix 
structures of TolC (Murakami et al., 2006). Initial evidence for this came when 
Tamura et al. showed that when the hairpin residues of AcrB and the turn residues 
of TolC were both mutated to cysteines, TolC and AcrB could form spontaneous 
disulfide bonds (2005). This direct interaction between AcrB and TolC was 
further supported when Tikhonova et al. showed, using Surface Plasmon 
Resonance, that TolC and AcrB directly bind to one another with as strong of a 
binding affinity as either AcrA/AcrB or AcrA/TolC (2011). Additionally, these 
data were confirmed by the first model of interaction proposed through molecular 
docking using cysteine mediated cross-linking data (Symmons et al., 2009). This 
docked model showed the TolC turns embedded within groves created by the 
hairpin turns of AcrB. 
 If the turns of TolC do interact directly with AcrB, it is possible that 
alteration of either of the two TolC turn residues may disrupt interactions with 
AcrB and prevent functional complex assembly. However, the second turn 
residues are shown to lock the aperture in a closed state. Alterations of these 
residues, primarily R367 and Y362, leads to a leaky phenotype whereby 
antibiotics are able to pass back through TolC into the periplasmic space 
(Augustus et al., 2004; Bavro et al., 2008). Therefore it was decided to investigate 
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the importance of the turn 1 residues for their function in interacting with AcrB. 
The turn 1 is situated between the more static helices, H3 and H4, of TolC and 
consists of the residues 147GLVA150.  
 To investigate the importance of these turn 1 residues, mutations were 
introduced into the pTrc9a plasmid containing the tolC gene expressed from the 
IPTG inducible promoter. Without induction using IPTG, wild type TolC is 
expressed to nearly the same level from the chromosomal copy and complements 
the chromosomal deletion. The plasmids expressing the turn 1 mutant TolC 
proteins were transformed into a chromosomal ∆tolC::Cmr strain and examined 
for their ability to complement the chromosomal deletion. In order to test the 
importance of these residues two approaches were taken: alanine scanning and 
localized frameshift mutagenesis (Fig 2A). Three alanine mutants were created, 
147ALVA150, 147GAAA150, and 147AAAA150, of which only the 147AAAA150 
derivative had a modest antibiotic hypersensitivity phenotype (Fig 2B). 
Interestingly, both the 147ALVA150 and the 147AAAA150 mutants had similar 
protein levels, roughly 50% of wild type, indicating that reduced protein levels 
was not the sole reason for 147AAAA150’s reduced antibiotic resistance. That 
TolC147GAAA150 level is not significantly reduced, indicating that G147 is most 
likely important in proper folding of TolC. Since L148 and V149 both have 
hydrophobic side chains, they are not expected to be surface exposed and form 
contacts with AcrB. Most likely, these hydrophobic residues are important in 
hydrophobic packing and are turned away from the solvent exposed surface, as  
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Figure 2. Mutagenesis of TolC turn 1 residues and characterization of various 
TolC turn 1 mutants.  
A. The wild type TolC turn 1 residues 147GLVA150 were substituted with alanine 
[1] or subjected to -2 frameshift [2] mutagenesis. The TolC frame was 
subsequently restored either through reversion analysis [3] or by +2 frameshift 
site-directed mutagenesis [4]. Open diamonds point to the sites of frameshift 
mutations. The two residues of the resulting frameshift mutant [4] were further 
altered by site directed mutagenesis [5]. Individual alterations of the wild type 
turn 1 residues were made by site-directed mutagenesis [6]. All mutant residues 
are underlined. Western blots to determine the levels of various TolC turn 1 
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alanine (B) and framshift-derived (C) mutants (amino acid substitutions in 
mutants are underlined). Protein extracts from approximately 5 x 107 cells grown 
overnight at 37°C were analysed by SDS-PAGE and electro-transferred to PVDF 
membranes. Membranes were blotted with primary antibodies against TolC-MBP 
(maltose binding protein). MBP was used as a gel loading control. Protein levels 
were quantified using Quantity One software (Bio-Rad). Wild type TolC level 
was taken as 1 and other values were adjusted relative to wild type TolC. Zones of 
inhibition around pre-soaked novobiocin disks (30 µg) are shown in millimeters 
(mm). Average inhibition zones recorded from two independent assays are shown, 
with zones varying no greater than 10%. 
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seen in the closed, partially open, and fully opened TolC structures (PDB ID 
1EK9, 2WMZ, and 2XMN, respectively; Koronakis et al., 2000; Pei et al., 2011). 
Thus substitution of these residues to a less hydrophobic side chain would prevent 
the backbone from being exposed for interaction with the hairpin loops of AcrB. 
However, this importance could only be revealed when reduced protein levels, 
G147A, as well as reduced hydrophobic packing, 148LV149  148AA149, were 
combined. 
 The second approach was to induce a frameshift at the beginning of the 
turn (Fig 2A). As this frameshift would cause a premature stop codon, TolC 
would not be properly synthesized and would cause a drug hypersensitivity 
phenotype. This was used to isolate spontaneous revertants that restored the 
reading frame and produced a functional TolC protein. Through this analysis the 
flexibility of the turn residues and those in the surrounding helices could be 
gauged. However, after being exposed to selection with substrate antibiotics, all 
revertants restored the original turn sequence. This indicated that all the turn 
residues were important for functional efflux function. In addition to looking for 
spontaneous antibiotic resistant revertants, the reading frame was restored after 
the fourth residue of the turn to create the 147AGSG150 mutant. This mutant 
showed a dramatic drug hypersensitivity phenotype, equivalent to null, again 
underscoring the importance of this region in antibiotic efflux (Fig 2C and Table 
1). 
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 After creating the 14AGSG150 frameshift mutant, the goal was to identify 
which residues were most important by individually restoring the residues to 
restore antibiotic resistance. As had been observed with mutation of G147, 
restoring individual residues increased in TolC protein levels, which was 
accompanied by a marked increase in antibiotic resistance. Simultaneous 
restoration of G147 and L148 lead to complete restoration of protein levels and 
antibiotic resistance (Fig 2C). These findings indicate that the combination of 
reduced protein levels (G147) and reduced hydrophobicity (L148) are important 
in maintaining functional interactions involved in antibiotic efflux (Vakharia et 
al., 2001). Interestingly, when any of the turn residues are individually altered, 
there is no increase in antibiotic hypersensitivity, indicating that it is the 
combined action of multiple alterations which causes the increase in antibiotic 
sensitivity. Additionally, when either L148 or V149 was mutated to serine, the 
presence of the polar side chain did not cause an increase in sensitivity. 
 
Phenotypic Investigation of the TolC 147AGSG150 Turn 1 Mutation 
 After observing that the TolC147AGSG150 turn 1 mutation was not able to 
complement the tolC deletion with regards to resistance to novobiocin and 
erythromycin, further investigation of the phenotypes associate with TolC were 
observed. TolC is used as a receptor for the bacteriophage TLS, as well as a 
secondary receptor for colicin E1. Without TolC, cells are resistant to both of 
these toxic agents. The TLS phage uses the external loops of TolC, as well as 
LPS, to mediate infection of E. coli (German et al., 2006). Colicins are a group of  
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Table 1. Detailed characterization of the TolC turn 1 147AGSG150 mutant. 
 Sensitivity to Inhibitors 
Inhibitorsa TolCWT TolC
- TolCQ
b 
Novobiocin 15.8 1.0 1.0 
Erythromycin 61.6 1.9 1.2 
CCCP 11.2 1.1 1.0 
Vancomycin (8.4) (6.6) (6.6) 
HlyA + - - 
TLS Phage 1 >10-6 1 
Colicin E1 1 2-12 1 
    
a Numbers for novobiocin, erythromycin, and CCCP represent minimal inhibitory 
concentration. For vancomycin, zones of inhibition in mm are shown in 
parenthesis. A 10 µl of solution containing 75 µg of vancomycin was spotted on 
paper disks of 6.5 mm diameter. Average inhibition zones recorded from two 
independent assays are shown, with diameter varying no greater than 10%. Plus 
and minus signs indicate the presence (+) or absence (-) of hemolytic zones on 
blood agar medium. Sensitivity to TLS phage is measured as efficiency of 
plaquing. Colicin E1 sensitivity data report inhibition zones after spotting 10 µl of 
twofold serial dilutions of colicin E1 stock on an agar plate overlayed with 
bacterial cultures. 
b TolCQ denotes TolC turn 1 147AGSG150 quadruple mutant. 
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proteins synthesized by certain strains of E. coli to kill other E. coli. Colicin E1 
specifically uses TolC as a secondary receptor for entry into the cell, after initially 
interacting with the vitamin B1 receptor, BtuB (Masi et al., 2007; reviewed in 
Cascales et al., 2007). When bacteria harboring the plasmid encoding the 
TolC147AGSG150 mutant were tested for their sensitivity to TLS phage or colicin E1, 
the bacteria showed the same sensitivity to TLS phage and colicin E1 as bacteria 
expressing wild type TolC (Table 1). This sensitivity indicates that the mutant 
protein is able to properly fold and insert into the outer membrane and that the 
effects of 147AGSG150 did not propagate up the portion of TolC exposed to the 
extracellular environment. 
 In addition to testing the import functions of the mutant TolC protein, it 
was asked whether the TolC147AGSG150 mutant had specifically lost functional 
interaction with AcrA and AcrB to pump out novobiocin or whether it had 
additionally lost the ability to functionally interact with other efflux pumps. In 
order to test this, the 147AGSG150 mutant was tested for its ability to confer 
resistance to novobiocin, erythromycin, and carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP), as well as to secrete α-haemolysin. Novobiocin and 
erythromycin are both substrates of AcrAB-TolC, while CCCP is a substrate of 
the EmrAB-TolC complex. Finally, α-haemolysin is secreted through the HlyDB-
TolC complex. When all of these substrates were tested for their ability to be 
extruded from cells expressing the turn 1 mutant TolC protein, the bacteria 
showed an inability to pump out the substrate, equivalent to null (Table 1). 
29 
 
Additionally, the antibiotic vancomycin was used to determine the status 
of the TolC aperture. Vancomycin is a large antibiotic, which normally cannot 
permeate the outer membrane. Only when alterations which force open the TolC 
aperture or otherwise compromise the outer membrane do cells become sensitive 
(Vuong et al., 2008; Bavro et al., 2008). Cells expressing TolC147AGSG150 
remained resistant to vancomycin indicating that the mutation in TolC turn 1 does 
not cause the aperture to remain in an open state or the protein does not mis-insert 
into the outer membrane causing a permeability defect. Thus, TolC147AGSG150 is 
the first mutant of its kind, being completely wild type in its ability to import 
lethal agents, but unable to export substrates.  
 
Alterations in TolC Turn 1 Prevent Functional Complex Assembly While 
Maintaining Physical Interaction 
 In observing the lost ability to remove antibiotics and secrete haemolysin, 
it was questioned whether the turn 1 147AGSG150 mutant TolC protein was now 
unable to physically interact with efflux complex components. It is possible that 
disruption of these turn residues prevents the proper physical interaction with the 
AcrAB proteins, thus preventing assembly of the complex and antibiotic efflux. If 
this is the case, the mutant TolC protein should not be able to be chemically cross-
linked to either AcrA or AcrB. In order to test this, in vivo cross-linking was 
carried out using the amine-specific cross-linker dithiobis 
(succinimidylpropionate), DSP (Husain et al., 2004; Fig 3A). When the mutant  
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Figure 3. In vivo cross-linking analysis to probe TolC-AcrAB interactions and 
TolC-AcrA interactions. 
A. To analyse TolC-AcrAB interactions, freshly grown bacterial cultures were 
incubated with or without DSP. TolCHis was purified through a Ni
2+ affinity 
column, and AcrB and AcrA for two identical sets of elutes were probed by 
Western analysis using AcrBHis or AcrAHis antibodies. These antibodies also 
recognize TolC due to the presence of a C-terminal 6XHis tag in TolC. Note that 
the wild type (lanes 1, 2, 5, and 6) and mutant TolC14AGSG150 (lanes 3, 4, 7, and 8) 
proteins can pull down AcrB and AcrA only in the presence of DSP cross-linker. 
All protein samples were boiled in sample buffer containing β-mercaptoethanol 
prior to gel electrophoresis.  
B and C. To analyse TolC-AcrA interactions, a Q142C substitution was 
introduced into both wild type (TolC-WT) and the TolC turn 1 147AGSG150 
mutant (TolC-Q) to facilitate SPDP-mediated cross-linking. Both wild type and 
mutant TolC proteins contain a 6XHis tag at the C-terminal end of the protein for 
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affinity purification. TolC from cultures incubated with DSP, SPDP, or no cross-
linker (CL) was affinity purified through Ni2+ affinity columns, AcrA and TolC 
from two identical sets of elutes were detected through Western blots using 
AcrAHis antibodies, which also recognize TolCHis. Prior to gel electrophoresis, 
protein samples were boiled either without (B) or with (C) β-mercaptoethanol. 
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TolC protein was compared with wild type TolC, we saw no difference in the 
ability of the mutant or wild type proteins to pull down either AcrA or AcrB in a 
DSP dependent manner was observed, indicating no gross defect in the ability of 
the mutant to interact with the other two members of the complex. 
 As TolC and AcrA share a larger surface area, it is possible that the 
147AGSG150 mutation has disrupted this, causing the drug hypersensitivity 
phenotype. To determine the status of interaction between TolC and AcrA with  
more stringency, a more specific cross-linking was carried out utilizing the amine-
to-sulfhydryl specific cross-linker succinimidyl 3-(2-pryidylthio) propionate, 
SPDP. As TolC does not contain any native cysteine residues, a Q142C 
substitution was introduced into both wild type and the 147AGSG150 mutant TolC 
protein. This substitution was previously shown useful in gauging TolC-AcrA 
interactions (Lobedanz et al., 2007). Introduction of a 6 His-tag and the Q142C 
substitution into either wild type or the 147AGSG150 mutant did not alter the 
phenotype of each protein (data not shown). After cross-linking, cell lysates were 
applied to a Ni-NTA Spin Column, and elutes were probed for the presence of 
AcrA pulled down with TolC. As seen with DSP, AcrA was effectively pulled 
down with both TolC proteins in the presence of either cross-linker (Fig 3B and 
C). 
 In order to determine the defect in TolC147AGSG150 mediated interactions, 
novobiocin and erythromycin resistant suppressors of the TolC147AGSG150 protein 
were isolated. All of these suppressors mapped to AcrA, leading to the belief that  
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Figure 4. Effect of TolC on AcrAL222Q and wild type AcrA levels. AcrA levels 
from approximately 5 x 107 cells grown overnight at 37°C were determined by 
Western blot analysis using antibodies against AcrAHis. AcrAL222Q (A) and wild 
type (B) levels from the wild TolC background were taken as 1 and other values 
were adjusted relative to it. 
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the mutant TolC was unable to make functional interactions with AcrA. 
Alternatively, it is possible that TolC and AcrB are not able to make functional 
interactions, but the suppressor mutations in AcrA are able to restore these 
interactions. (Isolation, characterization, and determining the mechanisms of 
suppressors for AcrA mapping suppressors will be discussed in Chapter 3) 
 As no apparent defect in interaction could be readily observed through 
chemical cross-linking a second and perhaps more sensitive means of determining 
the in vivo interactions between AcrAB-TolC complex members was utilized. A  
labile AcrA mutant, AcrAL222Q, has previously been characterized (Gerken and 
Misra, 2004). The stability of this mutant protein is dependent on the ability to 
interact with TolC; without TolC, AcrAL222Q is readily degraded by the 
periplasmic protease DegP (Gerken and Misra, 2004; Weeks et al., 2010). In 
addition to being dependent on TolC, AcrAL222Q levels are dependent on the 
presence of AcrB. To test the stability of AcrAL222Q, strains where AcrAL222Q was 
expressed from the native chromosomal locus were transformed with plasmids 
expressing tolC mutants. As expected, in the absence of TolC, AcrAL222Q was 
readily degraded (Fig 4A). In the presence of TolC turn 1 mutants expressing 
single or double substitutions, AcrAL222Q was stabilized to the same extent as with 
wild type TolC. However, in the TolC turn 1 triple (147GGSG150) or quadruple 
(147AGSG150) mutant, AcrAL222Q was modestly or significantly degraded, 
respectively (Fig 4A). Additionally, these mutants showed a moderate to severe 
drug hypersensitivity phenotype, showing the AcrAL222Q stability test is a more 
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sensitive means of determining functional interaction than in vivo chemical cross-
linking data (Fig 3). Note that wild type AcrA is typically a stable protein 
regardless of whether or not TolC is expressed (Fig 4B). 
 
Loosening of the TolC Aperture Can Suppress the Turn 1 Mutation 
 As it was shown that the TolC turn 1 147AGSG150 mutant is defective in 
functional interaction with AcrA and potentially AcrB, it is believed that the final 
step of TolC aperture opening has been precluded. If this is the case then it is 
possible that alterations which open TolC may be able to suppress the turn 1 TolC 
mutant defects. In order to test this, two different alterations which have been 
shown to induce aperture opening were introduced into the TolC147AGSG150 mutant 
background. A R367E or R390E mutation was separately introduced into the 
TolC147AGSG150 background. These alterations cause TolC aperture opening either 
by preventing the salt bridges directly (R367) or by preventing supercoiling of the 
inner helices (R390) (Andersen et al., 2002; Augustus et al., 2004; Bavro et al., 
2008; Fig 5A, B, and C). 
 When tested for their susceptibility to substrate antibiotics, it was 
observed that the R367E and R390E mutations cause sensitivity to both 
novobiocin and vancomycin, as predicted, due to the aperture being unable to 
close, with R367E expressing a leakier phenotype. The TolC147AGSG150, R367E and 
TolC147AGSG150, R390E mutants showed a marked reduction in sensitivity to 
vancomycin compared to their wild type counterparts, as well as being  
36 
 
 
Figure 5. Effects TolC aperture/channel opening on TolC147AGSG150.  
A. A cartoon of the TolC structure (1EK9) in which the two R367 and R390 have 
been identified. These residues are involved in maintaining TolC aperture closed. 
R367 (green) is directly involved in the network of salt bridges at the aperture, 
whereas R390 (red) is distal to the aperture and is thought to maintain the 
supercoiling of the inner helices. 
B and C. These cartoons show the TolC aperture in its resting, closed state (B, 
1EK9) or open state (C, 2XMN). Note turn 1 remains static while turn 2 moves 
out, opening the channel. R367 is directly involved in the network of salt bridges 
responsible for maintaining the closed aperture. 
D. Effects of mutations R367E and R390E, which increase the aperture/channel 
opening, on TolC levels and novobiocin and vancomycin sensitivities. The TolCQ 
denotes the turn 1 147AGSG150 mutant. Proteins were detected by Western blots as 
described in Fig. 2 legend. Antibiotic sensitivities were described as in Fig. 2 and 
Tables 1 legends. Average inhibition zone diameters were plotted from two 
independent experiments, with zones varying no greater than 10%. 
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accompanied by a significant reduction in protein level, compared to 
TolC147AGSG150 (Fig 5D). Interestingly, the TolC147AGSG150, R367E mutant showed 
increased sensitivity to the substrate novobiocin, whereas the TolC147AGSG150, R390E 
mutant showed reduced sensitivity. It is worth noting that the protein levels of 
both the TolC147AGSG150, R367E and the TolC147AGSG150, R390E mutants showed 
significantly reduced protein levels. As the protein levels decreased similarly in 
both mutants, while antibiotic sensitivity decreased in the TolC147AGSG150, R390E, 
but not the TolC147AGSG150, R367E mutant it seems that alterations distal to the 
aperture loosen the helices in such a way that functional interaction resulting in 
antibiotic resistance can be partially obtained. Said differently, this seems to 
indicate that loosening of the TolC aperture by alterations distal to the aperture 
allows slight changes in the helices, which partially decreases sensitivity to 
antibiotics. 
 
Alterations within the α-Helices of TolC Suppress the Turn 1 Defect 
 It was observed that the TolC turn 1 147AGSG150 mutant did not stabilize 
the AcrAL222Q protein, nor did the AcrAL222Q mutation suppress the TolC147AGSG150 
hypersensitivity phenotype. Mutations were sought that could restore antibiotic 
resistance, and simultaneously stabilize the AcrAL222Q protein. Approximately 5 X 
108 cells from 8 independent cultures of the TolC147AGSG150/AcrAL222Q mutant 
were plated onto medium containing novobiocin and erythromycin, and incubated 
at 37°C for 20 hours. Each of the eight independent cultures gave rise to an  
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Figure 6. Location of TolC mutations which suppress the 
TolC147AGSG150/AcrAL222Q drug hypersensitivity. A cartoon showing the X-ray 
structure of TolC (1EK9) shows the TolC mapping suppressors of 
AcrAL222Q/TolC147AGSG150. Mutations are depicted using the mature residue 
numbering. The molecule has been aligned to show the intraprotomer groove, 
with the adjacent monomers in the background. 
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average of 15 antibiotic resistant mutants, at a frequency of about 10-8, indicating 
the presence of missense mutations. From these antibiotic resistant mutants, 28 
revertants were selected based on colony size. To test whether the mutation 
mapped in the tolC gene, plasmids were extracted and transformed into ∆tolC 
acrA (AcrAL222Q) and tested for their ability to support growth on medium 
supplemented with novobiocin and erythromycin. Transformants from 9 of the 28 
spontaneous mutants were able to grow on medium supplemented with 
novobiocin and erythromycin. The tolC gene was then sequenced for those 
transformants. The suppressors contained one of three TolC alterations, D153E, 
S350A, and R390C, as well as the original 147AGSG150 substitution. These 
mutations were isolated a total of one, one, and seven times, respectively. 
Additionally, a second similar selection was performed in which two additional 
substitutions were isolated, A128V and I133S. In addition to these 5 missense 
alterations in the TolC147AGSG150 background, we isolated secondary missense 
alterations in acrA (AcrAL222Q) gene, which will be described in detail in Chapter 
3. 
 These five mutations all map to the bottom half of the α-helical barrel of 
TolC, below the equatorial domain (Fig 6). Interestingly, R390C has previously 
been isolated as an open state alteration, conferring a leaky phenotype. While 
R390 does not directly influence gating of the aperture, it is believed to be 
important in maintaining the inner coils H7/H8 in their packed position (Augustus 
et al., 2004; Bavro et al., 2008). Residue D153 is directly involved in the network 
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of salt bridges at the aperture; however, alteration of D153 typically has less 
severe consequences than mutation of R367 which is the main residue involved in 
gating the aperture (Andersen et al., 2002; Augustus et al., 2004). Residues A128 
and I133 lie on helix H3 in the intraprotomer groove, with A128 on the exterior 
surface and I133 pointed toward H4 close to the interior surface of the channel. 
The final substitution isolated in this study, S350A, is the only residue to reside in 
the interprotomer groove. It is located on helix H7, partially exposed to the 
exterior surface and directly pointed toward H4. Additionally, in the crystal 
structure of TolC (Andersen, 2002; Eswaran et al., 2003), S350 forms an 
important hydrogen bond with D162 of the neighboring protomer. An alteration 
of this residue is thought to cause defects in trimerization and maintaining the 
supercoiling of the inner helices. 
 The isolated suppressors showed significant increases in resistance to 
erythromycin and novobiocin, as expected, as well as increased resistance to 
CCCP. In some cases, the TolC14AGSG150 suppressor alterations exhibit an 
increased ability to secrete α-haemolysin (Table 2). When tested for their ability 
to confer resistance to CCCP in an acrB null or emrAB null background, the 
suppressors showed a subtle decreased in resistance compared to when both 
complexes were intact (Table 3). This indicates the TolC mutants have partially 
restored interaction with both EmrAB and AcrAL222Q/AcrB to remove CCCP. 
Likewise, the TolC147AGSG150 suppressors were tested for their ability to secrete α-
haemolysin in the absence or presence of AcrAL222Q. TolC147AGSG150, I133S, 
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TolC147AGSG150, S350A, and TolC147AGSG150, R390C showed hemolytic zones on blood 
agar plates whether AcrAL222Q was present or not, however these zones were still 
comparably smaller than when wild type TolC was expressed. The requirement of 
both the AcrAB and the EmrAB efflux complexes to remove CCCP and the 
increased ability to secrete α-haemlysin, regardless of the absence or presence of 
AcrAL222Q, indicates these suppressors are partially restoring interaction with the 
membrane fusion proteins, which had been lost by the TolC turn 1 147AGSG150 
mutation. 
In order to determine how these alterations were able to restore efflux 
functions of TolC, it was desired to determine whether or not the aperture was 
being opened. When zones of inhibition were measured for vancomycin, it was 
seen that the single amino acid substitutions increased sensitivity to vancomycin. 
This indicates that AcrAL222Q is now acting to open the TolC147AGSG150/suppressor 
proteins.  
 
Suppressor Alterations Stabilize Interactions with the Membrane Fusion Protein 
 While examining the various phenotypes of the suppressor mutants, the 
TolC or AcrA levels were analyzed. It is possible that the mutations were acting 
to restore proper folding of TolC, which would be reflected by increased mutant 
TolC protein levels. When TolC levels were analyzed, the alterations did not 
increase protein levels (Fig 7A). Interestingly, when analyzing AcrA levels, only 
two of the suppressors, S350A and R390C, significantly stabilized AcrAL222Q (Fig  
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Table 2. TolC mapping suppressors restore efflux functions. 
 Sensitivity to Select Inhibitorsa 
Nature of TolC Proteinb Novo Ery Vanco CCCP HlyA 
TolCWT   9.9 13.5   8.9 (9.7) +++ 
TolCQ 21.6 19.9   8.0 (1.1) - 
TolCQ, A128V 11.6 16.1   9.8 (3.0) - 
TolCQ, I133S 10.0 16.8   9.7 (3.4) + 
TolCQ, D153E 10.9 10.5 11.3 (3.0) - 
TolCQ, S350A 10.7 10.5 12.5 (3.4) ++ 
TolCQ, R390C   9.5  9.9   8.9 (3.3) + 
      
a Novo is novobiocin, Ery is erythromycin, Vanco is vancomycin, CCCP is 
carbonyl cyanide m-chlorophenyl hydrazone, and HlyA is the α-haemolysin toxin. 
Numbers for CCCP represent minimal inhibitory concentrations. For novo, ery, 
and vanco, zones of inhibition in mm are shown in parenthesis. Novo (30 µg) and 
Ery (15 µg) pre-soaked disks or 10 µl of solution containing 75 µg of vancomycin 
was spotted on paper disks of 6.5 mm diameter. Average inhibition zones 
recorded from two independent assays are shown, with diameter varying no 
greater than 10%. 
b TolCQ denotes TolC turn 1 147AGSG150 quadruple mutant. 
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Table 3. TolC mapping suppressors restore efflux functions independent of AcrA. 
 Haemolysin 
Secretiona 
 CCCP Minmal Inhibitory 
Concentrationb 
TolC Proteinc AcrAL222Q
d ∆acrA  AcrAL222Q ∆acrA ∆emrAB 
TolC- - -  NDe ND ND 
TolCWT +++ +++  9.7 8.7 5.5 
TolCQ - -  1.1 1.0 0.6 
TolCQ, A128V - -  3.0 ND ND 
TolCQ, I133S + +  3.4 1.9 2.8 
TolCQ, D153E - -  3.0 ND ND 
TolCQ, S350A ++ ++  3.4 ND ND 
TolCQ, R390C + +  3.3 2.1 3.1 
 
a Haemolisin secretion was determined using strains containing the pSF4000- 
hlyCABD (Cmr) plasmid expressing the α-haemolysin toxin and its native ABC 
transporter. 
b Numbers for CCCP are minimal inhibitory concentrations. 
c TolCQ denotes TolC147AGSG150, subsequent suppressor mutations are listed in 
addition. 
d AcrAL222Q denotes the native acrA sequence contains a point mutation, whereas 
acrA indicates the acrA gene has been deleted as described previously (Augustus 
et al., 2004) non-polar to the acrB gene. The emrAB locus was deleted using the 
Waner and Datsenko method (2000) by a Kmr and transduced into a strain 
containing acrA (AcrAL222Q). 
e ND indicates No Data. 
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Figure 7. Effects of TolC mutations on TolC and AcrAL222Q. Protein extracts from 
cultures grown at 37°C for 16 h were used to detect TolC and MBP (A) or AcrA 
and LamB (B). MBP and LamB were used as gel loading controls. Whole cell 
extracts from approximately 5 x 107 cells were used to determine TolC (A), while 
membrane extracts from approximately 7.5 x 108 cells were used to determine 
AcrA levels (B). TolC variants are expressed from a plasmid replicon, whereas 
AcrAL222Q is expressed from its native chromosomal replicon. TolC and 
AcrAL222Q levels in the wild type TolC were taken as 1 and TolC variants or 
AcrAL222Q levels were calculated relative to expression in the wild type TolC. 
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Figure 8. TolC mapping suppressors restore antibiotic efflux with AcrAP265R 
while stabilizing this labile AcrA variant. Membrane extracts from approximately 
7.5 x 108 cells, grown at 37°C for 16 h, were used to determine AcrAP265R levels. 
Sensitivity to novobiocin (30 µg), erythromycin (15 µg), and vancomycin (75 µg) 
were determined by measuring zones of inhibition around disks of 6.5 mm 
diameter. Values are the average from two independent cultures varying no 
greater than 10% are listed.  
46 
 
7B). 
 In addition to the AcrAL222Q mutant, a second labile AcrA mutant has been 
described, AcrAP265R. Both of these mutations were identified in a screen to find 
suppressors of the labile TolCP246R, S350C protein. Like AcrAL222Q, the stability of 
AcrAP265R is dependent on functional interactions with TolC (Gerken and Misra, 
2004, Figure 8). When the TolC147AGSG150 mutant is introduced into the AcrAP265R 
background, the AcrA protein is readily degraded. In addition to the decreased 
protein levels, increased sensitivity to antibiotics was observed. When the TolC 
turn 1 mapping suppressors were introduced into the AcrAP265R background, all 
suppressors acted to reduce antibiotic hypersensitivity. As in the AcrAL222Q 
background, AcrAP265R protein levels increased significantly in two of the mutant 
backgrounds. TolC14AGSG150, S350A and TolC147AGSG150, R390C. It is worth noting that 
TolC147AGSG150, S350A showed decreased TolC levels in the presence of AcrAL222Q, 
but increased AcrA levels most significantly in both the AcrAL222Q and AcrAP265R  
backgrounds, and showed most significant improvement in haemolysin secretion. 
Also the three mutations, TolC147AGSG150, A128V, TolC147AGSG150, I133S, and 
TolC147AGSG150, D153E do not appear to stabilize AcrAP265R and only partially 
stabilize AcrAL222Q, but significantly reduce sensitivity to substrates. This seems 
to indicate that these suppressor alterations are subtly changing the TolC 
conformation in such a way to reduce antibiotic hypersensitivity, but only two of 
these mutants, S350A and R390C, drastically stabilize the two labile AcrA mutant 
proteins. 
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Figure 9. TolC suppressors show specificity towards mutant AcrA alleles. 
Sensitivity to the substrate inhibitors novobiocin (A) and erythromycin (B) are not 
decreased when wild type AcrA was combined with the TolC147AGSG150 
suppressors as with AcrAL222Q or AcrAP265R.Vancomycin sensitivity (C) shows 
the TolC aperture is constitutively dilated in the presence of the D153E and 
S350A mutant, whereas the other three revertants show minimal increases in 
sensitivity. Zones of inhibition around pre-soaked novobiocin (30 µg) and 
erythromycin (15 µg) disks are shown in millimeters (mm). For vancomycin, a 10 
µl of solution containing 75 µg of vancomycin was spotted on paper disks of 6.5 
mm diameter. Average inhibition zones recorded from two independent assays are 
shown, with zones varying no greater than 10%. 
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α-Helical Alterations in TolC147AGSG150 Require Constitutively Active AcrA 
 As these TolC alterations were isolated in the presence of AcrAL222Q, it 
was inquired whether they were able to suppress the TolC147AGSG150 defect in the 
wild type AcrA background. Interestingly, when wild type AcrA was combined 
with the TolC turn 1 mutant, A128V and D153E did not decrease sensitivity to 
novobiocin (Fig 9A). The remaining three point mutations, I133S, S350A, and 
R390C, did partially reduce the turn 1 antibiotic hypersensitivity phenotype, but 
not to the extent as in the AcrAL222Q or AcrAP265R backgrounds (Fig 9A). These 
three alterations also partially restored haemolysin secretion indicating their 
ability to restore interaction with the HlyCABD complex (Table 3). When tested 
for sensitivity to erythromycin, all the suppressors showed little to no suppression 
of the hypersensitivity phenotype (Fig 9B). Additionally, sensitivity to 
vancomycin was determined to see whether the point mutations caused the TolC 
aperture to open, as was observed when these altered proteins were combined  
with AcrAL222Q. TolC147AGSG150, S350A and TolC147AGSG150, D153E showed sensitivity 
to vancomycin greater than TolCWT/AcrAWT indicating that the aperture of these 
two mutants is remaining in a partially open state (Fig 9C). 
 After seeing that the TolC mapping suppressors were able to reduce 
antibiotic hypersensitivity of the TolC147AGSG150 mutant in the presence of 
AcrAL222Q and AcrAP265R but unable to suppress this phenotype in the presence of 
wild type AcrA, it was asked whether these suppressors can reduce the antibiotic 
hypersensitivity phenotype in the presence of constitutively active forms of AcrA. 
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In order to test this, the plasmids containing wild type TolC, the TolC turn 1 
mutant, or the TolC147AGSG150 suppressors transformed into strains lacking tolC, 
while expressing one of five mutant AcrA proteins from the native chromosomal 
locus: AcrA∆217-218, AcrAT30A, AcrAN146T, AcrAS83G, and AcrAT153P. These AcrA 
alterations were isolated among antibiotic resistant revertants of the antibiotic 
hypersensitive mutants TolCP246R, S350C or TolC147AGSG150 (Gerken and Misra, 
2004; Weeks et al., 2010; Chapter 3). As these alterations all support functional 
complex assembly, as seen by stabilization of a labile TolC mutant and reduced 
antibiotic hypersensitivity in the background in which they were isolated (Gerken 
and Misra, 2004; Weeks et al., 2010, Chapter 3), it is believed that they cause 
AcrA to stay in an active state, which wild type only transiently adopts during 
antibiotic efflux.  
 The alterations map to the three crystallized domains of AcrA: ∆217-218 
and T30A, as well as L222Q and P265R, map to the β-barrel; S83G and N146T 
map to the α-helical domain; and T153P maps to the lipoyl domain (Fig 10). Wild 
type TolC confers resistance to antibiotics with AcrA∆217-218, AcrAT30A, AcrAS83G, 
and AcrAT153P, like AcrAL222Q and AcrAP246R, whereas AcrAN146T only confers 
partial resistance to antibiotics. As AcrAS83G and AcrAT153P were isolated as 
suppressors of TolC147AGSG150, these alterations caused reduced sensitivity to 
antibiotics. Of the three additional alterations isolated against TolCP246R, S350C, 
AcrAT30A and AcrA∆217-218, did not suppress the hypersensitivity caused by 
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TolC147AGSG150, whereas AcrAN146T was able to partially reverse the antibiotic 
hypersensitivity (Fig 11 and 24). 
 When the TolC147AGSG150 suppressors were tested for their ability to reduce 
sensitivity to antibiotics in the mutant AcrA backgrounds, there was an overall 
trend that the TolC147AGSG150 mapping suppressors decreased sensitivity to 
novobiocin more than they did with AcrAWT (Fig 11A). This indicates that 
TolC147AGSG150 suppressors are able to more properly interact with the 
constitutively active forms of AcrA to reduce the hypersensitivity phenotype. 
However, when comparing resistance to erythromycin, the TolC mapping 
suppressors can be divided into two classes, those that marginally increase 
resistance and those drastically reduce sensitivity (Fig 11B). TolC147AGSG150, A128V 
and TolC147AGSG150, I133S marginally increase resistance to erythromycin in the 
presence of the “active” forms of AcrA. Interestingly these two suppressors did 
not drastically increase levels of AcrAL222Q or AcrAP265R (Fig 7B and 8). The 
residues A128 and I133 are located on the intraprotomer groove and are not 
involved in constricting the TolC aperture. Additionally, these two revertants 
show no increase in sensitivity to vancomycin in the presence of wild type AcrA 
(Fig 9C), as well as showing an overall trend of subtly increasing vancomycin 
sensitivity in the altered AcrA backgrounds (Fig 11C). 
 While TolC147AGSG150, D153E did not significantly increase AcrA levels of 
the two labile mutant AcrA proteins, D153 is one of the residues directly involved 
51 
 
 
Figure 10. A cartoon showing X-ray structures of AcrA (2F1M). Locations of five 
AcrA substitutions obtained in this study and those obtained previously (Gerken 
and Misra, 2004) are shown in A and B, respectively. AcrA residue numbering 
corresponds to that of the mature protein. 
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Figure 11. TolC suppressors show specificity towards constitutively active forms 
of AcrA. Sensitivity to the substrate inhibitors novobiocin (A) and erythromycin 
(B) are decreased when the point mutations are combined with the TolC147AGSG150 
mutant and conformationally active forms of AcrA. As seen by increased 
sensitivity to vancomycin (C), the combination of mutations in AcrA and TolC 
causes the aperture to open. Zones of inhibition around pre-soaked novobiocin (30 
µg) and erythromycin (15 µg) disks are shown in millimeters (mm). For 
vancomycin, a 10 µl of solution containing 75 µg of vancomycin was spotted on 
paper disks of 6.5 mm diameter. Average inhibition zones recorded from two 
independent assays are shown, with zones varying no greater than 10%. 
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in forming the salt bridges which lock the TolC aperture (Fig 7B and 8). 
Additionally, S350 and R390 are distally involved in holding the inner helices in 
their closed conformation. These three suppressors (D153E, S350A, and R390C) 
all drastically reduced the hypersensitivity to erythromycin (Fig 11B). 
Interestingly, when comparing sensitivity to vancomycin (Fig 11C), all of the 
TolC mapping suppressors tend to increase sensitivity over 
TolC147AGSG150/AcrAWT, showing the TolC aperture is being opened. While 
R390C is an open state mutant of TolC (Augustus et al., 2004), when in 
combination with TolC147AGSG150, this mutation does not increase sensitivity to 
vancomycin over TolCWT/AcrAWT. However TolC147AGSG150, R390C does confer 
sensitivity greater than the parental strain expression TolC147AGSG150 alone. 
 Taken together the data indicates that the novobiocin/erythromycin 
antibiotic resistant revertants of TolC147AGSG150/AcrAL222Q act primarily to loosen 
the TolC aperture in such a way that constitutively active forms of AcrA are able 
to act upon the mutant TolC proteins to reduce antibiotic hypersensitivity of the 
parental strain. While not all of the TolC147AGSG150 suppressors act equally to 
reduce the antibiotic hypersensitivity of the TolC147AGSG150 mutant with each of 
the AcrA suppressor proteins, the overall trend is such that the altered TolC 
proteins interact better with these mutant forms of AcrA. Additionally, the 
TolC147AGSG150 suppressors show increased sensitivity to vancomycin indicating 
the TolC aperture is able to be opened alterations in the AcrA protein. 
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Results 2: Genetic Evidence for the Importance of AcrB’s Periplasmic 
Hairpin Loops 
AcrB’s Periplasmic Hairpin Loops Interact Via both Side Chain and Backbone 
Mediated Interactions 
 Previously it has been reported that AcrB’s periplasmic hairpin loops 
directly interact with TolC’s periplasmic turns via spontaneous disulfide 
formation of cysteine-derived TolC and AcrB variants (Tamura et al., 2005). 
Additionally, in the proposed tripartite model based on chemical cross-linking 
experiments, these regions of the two proteins directly intermesh (Symmons et al., 
2009). These data suggest that D256 and D795 of AcrB’s periplasmic hairpin 
loops 1 and 2, respectively, are important in facilitating interaction with TolC. 
However, when these residues were mutated, either individually or 
simultaneously, there was no increase in sensitivity (Fasahath, 2006). In order to 
determine whether residues of the hairpin loops do in fact play a role in functional 
complex assembly, two approaches were employed. The two approaches were 
designed to determine side chain importance and backbone importance. In the 
first approach all loop 1, loop 2 or both loop residues were simultaneously 
replaced by alanines. In the second approach, either loop 1 or loop 2 residues 
were deleted. In loop 1, this affected residues 252KVNQD256. In loop 2, the first 
two residues are already alanines, which left 795DGQ797 to be substituted with 
alanines, while a deletion removed residues 793 to 797 (Fig 12).  
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Figure 12. Schematic of AcrB hairpin loop residues and mutational analysis.  
A. A cartoon showing the asymmetric AcrB (2GIF) where each of the monomers 
has been colored corresponding to the Loose (L, yellow), Tight (T, green), and 
Open (O, pink) conformation. Loop residues are colored and have been pointed 
out in the loose monomer. 
B. In order to determine the importance of the hairpin loops, either deletion 
analysis or poly alanine mutagenesis was performed. Loop residues are noted for 
each of the mutations. For the deletion mutants, the residues have been crossed 
out. Loop residues correspond to residues 252-256 and 793-797 for loop 1 and 
loop 2, respectively. 
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 In order to determine the ability of the AcrB hairpin loop engineered 
mutants to form a functional complex AcrA and TolC, drug sensitivity assays 
were performed and relative growth on medium supplemented with substrate 
drugs. In an acrAB null mutant there is a severe antibiotic hypersensitivity 
phenotype, however, the presence of wild type copies of these genes 
complemented the drug sensitivity phenotype (Fig 13A and C). When only one of 
the two AcrB hairpin loops was substituted with alanines (AcrBPAL1 or AcrBPAL2) 
the mutant AcrB proteins were able complement the ∆acrAB phenotype. 
However, substitutions of both loop residues with alanines (AcrBPAL1/L2) failed to 
fully complement. Deletion of loop 1 (AcrB∆L1), but not loop 2 (AcrB∆L2) failed 
to complement the hypersensitivity phenotype. Taken together these data show 
the side chains of both AcrB loops are functionally interchangeable, but that loop 
1 residues are more important since deletion of loop 1, but not loop 2 disabled 
AcrB’s activity. Additionally, these data indicate that the side chains of loop 1 
and 2 have a conserved function. Thus without the side chains of both loops, the 
protein partially looses functionality. 
 
Identification of AcrB Hairpin Loop Residues Which Facilitate Functional 
Interaction 
 In observing the loss of activity of the AcrBPAL1/L2 mutant, it was 
questioned which side chains were important for AcrB activity. In loop 1 there are 
4 charged or polar residues which could be important in potentially interacting  
57 
 
 
Figure 13. Phenotypic characterization of AcrB loop mutants.  
A. Sensitivity to select inhibitors was determined by performing disk assays. 
Zones are an average of two independent cultures varying no greater than 10%. 
For SDS, 1 mg was spotted onto blank disks. Deletion analysis shows loop 1 is 
more important in antibiotic efflux as deletion of loop 1, but not loop 2 causes 
increased sensitivity to the three inhibitors. However, both loops are important in 
maintaining proper interactions as poly alanine mutagenesis requires mutation of 
both loops simultaneously to cause increased sensitivity. 
B and C. Relative growth of the AcrB mutant strains on medium without (B) or 
with (C) the substrate inhibitors: novobiocin, erythromycin, and SDS. A single 
colony was purified on medium with or with substrates and growth was 
determined after 16 hr at 37°C. Medium was supplemented with 5 µg ml-1 
novobiocin and erythromycin, and 0.1% SDS. Deletion of AcrB loop 1, but not 
loop 2 residues leads to a drug hypersensitivity phenotype. Simultaneous 
alteration of both loop 1 and loop 2 residues leads to a hypersensitivity phenotype. 
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Figure 14. Characterization of single charged/polar side chain restoration mutants. 
As simultaneous mutation of both loops 1 and loop 2 residues to alanine caused 
increased sensitivity to substrate inhibitors, restoration of residues important in 
maintaining proper interaction should reduce antibiotic sensitivity. Restoration of 
either N254 or D256 leads to reduced sensitivity of the PAL1/L2 AcrB mutant. 
Sensitivity assays were performed as described in Figure 2 and Table 1. 
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with TolC, whereas in loop 2 there are 2 charged or polar residues. In order to 
determine which residues were important, each alanine residue was individually 
restored to its original side chain. Interestingly, only restoration of N254 or D256 
was able to restore antibiotic resistance (Fig 14). In order to test whether it was 
the presence of a charged residue at position 256 that was important for 
functionality, a K256 alteration was created. This variant was unable to 
complement the drug sensitivity phenotype of the AcrBPAL1/L2 mutant, indicating 
that it is specifically the presence of a negatively charged residue at position 256 
that is important for AcrB activity. 
 Together with the disulfide bond formation data by Tamura et al, (2005), 
these results revealed for the first time (a) the significance of loop 1 over loop 2, 
and (b) exposed the importance of the D256 residue of loop 1 for AcrB activity. 
 
AcrB Loop Alterations Destabilize Functional Interactions with TolC and AcrA 
 To assess mutant AcrB’s ability to interact with TolC, an attempt to repeat 
the experiments of Tamura et al. (2005) was made. In this study spontaneous 
disulfide bond formation between cysteine derivatives of AcrB and TolC was 
demonstrated. However, when tested it was found that cysteine derivatives of 
wild type TolC and AcrB caused a synthetic lethal phenotype. This lethal 
phenotype could be partially reversed in a DsbA- background (data not shown). 
Because of this synthetic lethal phenotype, a further protein analysis could not be 
carried out. 
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 In order to determine whether loss of physical interaction between mutant 
AcrB and TolC caused the increased drug sensitivity, an attempt was made to co-
purify AcrA and TolC with AcrB. If the alterations in the loops caused AcrB to 
not to physically interact with AcrA or TolC, AcrA and TolC should not be able 
to co-purify with AcrB. To test this, membranes were prepared from cells 
expressing a His-tagged and cysteine-less AcrB, as well as AcrB∆L1 and 
AcrBPAL1/L2 followed by overnight solubilization in AcrB extraction buffer (5 mM 
imidazole, 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 1% DDM). Insoluble 
fractions were spun down and the soluble fraction was applied to a nickel 
chelating column (GE Healthcare) pre-equilibrated with AcrB extraction buffer 
containing 0.03% DDM. The samples were washed in a similar buffer (20 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 0.03% DDM, 2 mM PMSF) with increasing 
concentrations of imidazole (5 mM, 20 mM, 50 mM, and 100 mM). Finally the 
protein was eluted with AcrB Elution Buffer and analyzed on a 7.5% SDS 
polyacrylamide gel. 
 By Coomassie staining, the eluted protein was determined to be of 
relatively high purity (data not shown). Additionally, when the samples were 
probed for AcrA it co-puirified with AcrB, AcrB∆L1, and AcrBPAL1/L2 at relatively 
similar levels (Tikhonova and Zgurskaya, 2004; Fig 15A). This indicates that 
even though the complex is not functioning properly to pump out antibiotics, 
AcrA and mutant AcrB are able to interact with one another physically.  
61 
 
 
Figure 15. Deletion of AcrB Loop 1 causes defects in interaction with TolC. 
A. AcrB proteins was performed as described by Tikhonova et al. 2011. Elutes 
were probed for TolC and AcrA using α-TolC-MBP and α-AcrAHis antibodies. 
Mutation of AcrB hairpin loops prevents TolC, but not AcrA, from co-purifying 
with AcrB. The AcrB∆L1 mutant is designated by ∆L1, while PAL indicates the 
AcrBPAL1/L2 mutant. 
B. Stabilization of TolCP26R, S350C was determined by analyzing whole cell extracts 
from overnight cultures as described in Figure 2. Wild type TolC is normally 
stable and does not depend on functional interaction with AcrA or AcrB. The 
labile TolCP246R, S350C mutant is readily degraded in the absence of AcrA and 
AcrB, as well as in the AcrB∆L1 mutant background.  
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Interestingly, no TolC was able to be co-purified with the AcrB mutants, 
indicating an aberrant interaction between the mutant AcrB protein and TolC. 
 A second method to investigate interaction between the mutant AcrB 
proteins and TolC was employed. For this a labile TolC mutant (TolCP246R, S350C), 
whose stability is dependent on functional complex assembly with AcrA and 
AcrB was utilized (Gerken and Misra, 2004). As can be seen, when AcrA and  
AcrB are missing, the TolC protein is readily degraded, however, when AcrA and 
AcrB are normally expressed from the plasmid vector, the protein is stabilized. 
When the mutant TolC was combined with AcrB∆L1, TolC is again readily 
degraded, indicating that AcrB∆L1 is unable to properly recruit and stabilize TolC 
(Fig 15B). 
 After observing that AcrB∆L1 is unable to stabilize TolCP246R, S350C, it was 
questioned whether the AcrB mutant is defective in interaction with wild type 
TolC. To test this, the technique of surface plasmon resonance (SPR) was 
employed. (This work was carried out in collaboration with the lab of Dr. Helen 
Zgurskaya.) In short, variants of TolC containing a single cysteine in the exterior 
loops were used for biotinylation and adherence to a glass chip. These cysteine 
variants were tested for their ability to complement a tolC null strain. Both of 
these cysteine derivatives of TolC were able to fully complement tolC null with 
regards to both export and import related functions. Sensitivity to novobiocin, 
erythromycin, and SDS were used to determine that the TolC cysteine variants 
maintained functional interaction with AcrA and AcrB (Table 4). Additionally,  
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Table 4. Characterization of TolC cysteine mutants used in Surface Plasmon 
Resonance. 
 Sensitivity to Select Inhibitorsa 
TolC Proteinb Novo Ery SDS TLS E1 
TolC- 19.1 17.4 23.0 10-10 2-11 
TolCWT   9.2 12.6   6.6 1 1 
TolCA269C 10.1 12.6   6.6 1 2
-1 
TolCT272C 10.5 13.3   6.6 1 2
-1 
 
a Numbers for Novo, Ery, and SDS indicate zones of inhibition as described in 
Figure 2 and Table 1. Sensitivity to TLS phage and colicin E1 were determined 
by spotting either 10- or two-fold serial dilutions onto a lawn of bacteria, fold 
differences are listed. 
b TolC proteins were expressed from the pTrc99a vector in a ∆tolC strain. 
Alterations are of the mature protein sequence.  
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sensitivity to TLS phage and colicin E1 were used to determine whether the TolC 
variants were properly folding and inserting into the outer membrane. Both of 
these variants show no defect in their abilities to be used as a receptor for the TLS 
phage or colicin E1. These data indicate that both of these mutants could be used 
for immobilization and examination of their ability to bind to AcrB wild type or 
the loop mutants. After immobilizing the TolCA269C mutant to the glass chip, 
purified AcrB or mutant AcrB was passed over and allowed to bind and washed 
with buffer. By observing the association/dissociation rates, it was determined 
that both the ∆L1 and PAL1/L2 variants showed a reduction in binding affinity 
compared with wild type AcrB (data not shown). The binding association between 
the immobilized TolC and free-floating AcrB is comparable to that obtained for 
immobilized AcrB and free-floating TolC (Tikonova et al., 2011). 
 
Loop Alterations do not Alter Protease Sensitivity despite Reduced Protein Levels 
 While characterizing the AcrB loop mutants, it was noticed that alterations 
of loop 2 caused complete loss of visualization of the AcrB protein levels using 
polyclonal AcrBHis antibodies, indicating either reduced protein levels or altered 
recognition by these antibodies. In order to determine the effects on protein levels, 
the AcrB loop mutations were moved into pACYC184- acrA acrB (6His), which 
allowed for protein visualization via HisProbe (Sigma). When comparing protein 
levels, it can be seen that protein levels were significantly reduced in the 
PAL1/L2 variant, the N254 and D256 derivatives, and AcrBΔL1, Q737L. Thus it is  
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Figure 16. AcrB levels do not correlate with antibiotic resistance.  
A. Membranes isolated from approximately 7.5 x 108 cells were heated to 60°C 
for 10 min and analyzed on 7.5% acrylamide gels. Samples were probed with 
HisProbe-HRP to determine relative amounts of AcrB mutant proteins. While 
AcrB∆L1 shows the greatest sensitivity to substrates, it shows no decrease in 
HisProbe recognition. AcrBPAL1/L2 shows the lowest protein levels, yet has a less 
severe phenotype than AcrB∆L1. 
B and C. Relative growth of the AcrB mutant strains on medium without (B) or 
with (C) the substrate inhibitors: novobiocin, erythromycin, and SDS. A single 
colony was purified on medium with or with substrates and growth was 
determined after 16 hr at 37°C. Medium was supplemented with 5 µg ml-1 
novobiocin and erythromycin, and 0.1% SDS. Deletion of AcrB loop 1 residues 
leads to a drug hypersensitivity phenotype which is reversed by the Q737L 
intragenic suppressor. Similarly, simultaneous alteration of both AcrB loop 
residues to alanine increases sensitivity to substrate drugs, which is reversed by 
restoring N254 or D256 in the AcrBPAL1/L2 mutant. 
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Figure 17. AcrB thermostability and protease sensitivity profiles. 
A and B. Thermostability of AcrB wild type and mutants was determined by 
exposing purified AcrB to varying temperatures (60-99°C) for 10 min. Mutant 
AcrB proteins do not show an increased propensity to aggregate at elevate 
temperatures compared to wild type. Approximately 4 µg of purified protein was 
loaded for each temperature. 
C.  Approximately 4 µg of purified AcrB protein was treated for 5 min with 
Proteinase K (PK; 10 µg) at 25°C. Samples were analyzed by SDS-PAGE and 
proteins were visualized after staining with Coomassie brilliant blue. Mutant 
AcrB proteins do not cause significant changes in the degradation fragments 
generated by PK. 
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possible that the reduced protein levels contribute to the antibiotic 
hypersensitivity phenotype observed. It has been shown that increasing expression 
of AcrAB leads to increased resistance to the substrate antibiotics. However it can 
be seen that the AcrB∆L1 protein is present at roughly the same level as wild type 
AcrB, but confers significantly less resistance, whereas AcrB∆L1, Q737L is present at 
even lower levels and yet confers resistance similar to wild type. Additionally, 
AcrBPAL1/L2, AcrBAANAA L1/PAL2 and AcrBAAAAD L1, PAL2 are present at similar 
levels, but AcrBAANAA L1/PAL2 and AcrBAAAAD L1/PAL2 confer antibiotic resistance 
but AcrBPAL1/L2 does not (Fig 16). In order to determine whether the loop 
alterations cause AcrB to become unstable and therefore unable to interact with 
TolC, the thermostability and protease sensitivity of the purified AcrB mutant 
proteins were tested. If the mutants showed different profiles than wild type AcrB, 
it would show that these alterations are causing a gross defect in protein structure, 
resulting in premature aggregation of the protein or exposing protease sensitive 
sites which are typically buried in the protein but are now exposed to due to 
altered conformation. To test the thermostability of the AcrB mutants, equivalent 
amounts of purified protein were heated to temperatures between 60 and 99°C in 
10°C intervals. Samples were then analyzed on 7.5% acrylamide gels and stained 
with coomassie brilliant blue. As can be seen, the three mutants (AcrB∆L1, 
AcrB∆L1, Q737L, and AcrBPAL1/L2) show no difference in thermostability compared 
to wild type AcrB (Fig 17A and B). Additionally, after incubation with proteinase 
K for 5 minutes, wild type and mutant proteins showed the same pattern of 
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degradation (Fig 17C). This indicates that while the mutant protein levels are 
decreased in vivo, the population that localizes to the membrane has 
conformations similar to wild type. 
 
Intragenic Suppressor of AcrB ∆Loop 1 Acts by Promoting Functional Complex 
Assembly 
 Since the AcrB∆L1 mutant showed a more drastic phenotype, it was 
favorable to look for spontaneous antibiotic resistant suppressors. These 
suppressor mutations could potentially identify other regions of importance 
involved in complex assembly. The majority of suppressors mapped to AcrA and 
will be discussed in Chapter 3. However, a single AcrB missense mutation was 
obtained through selection in the presence of novobiocin, erythromycin, and 
sodium dodecyl sulfate (SDS). This mutation was then confirmed by site-directed 
mutagenesis on the pACYC184- acrA acrB (AcrB∆L1) plasmid. Additionally, this 
alteration was introduced into the pACYC184- acrA acrB (AcrBPAL1/L2) plasmid. 
 When the alteration was moved into these plasmids, its ability to suppress 
both AcrB mutant proteins was tested by growth on plates and disk sensitivity 
assays (Fig 18B). As seen by both increased growth on plates containing 
inhibitors (16B) and smaller zones of inhibition (Fig 18B), this intragenic 
suppressor is able to reduce antibiotic sensitivity of cells expressing AcrB∆L1 or 
AcrBPAL1/L2 mutant proteins (Fig 18B and C). This indicates that while these two  
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Figure 18. Intragenic suppression of an AcrB loop mutant. 
A. A cartoon showing the X-ray structure of AcrB (2GIF). The location of the 
intragenic suppressor of AcrB ∆ Loop 1 is shown in relation to the hairpin loops. 
Loop 1 and Loop 2 are shown in each of the monomers and pointed out in 
monomer A and monomer B, respectively. 
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B and C. Sensitivity to substrate inhibitors. Zones of inhibition around pre-soaked 
novobiocin (30 µg) and erythromycin (15 µg) disks are shown in millimeters 
(mm). For SDS, a 10 µl of solution containing 1 mg of SDS was spotted on paper 
disks of 6.5 mm diameter.  Average inhibition zones recorded from three 
independent assays are shown, with zones varying no greater than 10%. 
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Figure 19. Intragenic suppressor of AcrB∆L1 acts to stabilize functional complex 
assembly. Whole cell extracts from approximately 5 x 107 cells from overnight 
cultures were probed for the stabilization of TolCP246R, S350C. Relative amounts of 
TolC were determined using either BamA or the Loading Control (LC). TolCP246R, 
S350C levels for wild type AcrB were taken as 1 and mutant levels were adjusted 
accordingly. Protein levels were determined from four independent gels with 
amounts varying no greater than 10%.  
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loop alterations show slightly different phenotypes, they both cause a similar 
defect. 
 Next it was inquired whether the Q737L substitution caused increased 
resistance to antibiotics by stabilizing complex assembly. This was tested by 
examining the in vivo stability of a labile TolCP246R, S350C protein that readily 
degrades in the absence of other complex members. An increase in the TolCP246R, 
S350C level in the AcrB∆L1, Q737L background would indicate stable complex 
formation. As can be seen in Figure 19, AcrB∆L1, Q737L increases TolCP246R, S350C 
protein levels roughly 2-fold over AcrB∆L1. 
 
Opening of the TolC Aperture Restores Antibiotic Resistance of the AcrB Loop 
Mutants 
 In the proposed mechanism of TolC-AcrAB interaction, it is thought that 
TolC and AcrB directly interact with one another to facilitate the initial steps of 
aperture opening. If alterations in the AcrB loops disrupt this interaction, thus 
preventing TolC aperture opening, it is possible that an alteration in TolC that 
forces the TolC aperture open could reverse the antibiotic hypersensitivity 
phenotype of AcrB∆L1 and AcrBPAL1/L2 mutants. To test this, two different TolC 
alterations were employed. In one case, the aperture closing was directly 
influenced by a R367E substitution that disrupts critical salt bridges at the 
aperture (Andersen et al., 2002; Augustus et al., 2004; Bavro et al., 2008). In the 
second case, the aperture closing was indirectly influenced by a R390E 
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substitution that affects supercoiling of TolC inner helices guarding the aperture 
(Augustus et al., 2004; Bavro et al., 2008). 
 As can be seen by decreased zones of inhibition, forced opening of the 
TolC aperture can partially reverse the hypersensitivity phenotype observed in the 
AcrB∆L1 (Fig 20). Interestingly, when grown on plates containing the same 
concentration of antibiotics used for selection of spontaneous drug resistant 
mutants, neither of the two open state TolC substitutions with AcrB∆L1 were able 
to grow indicating that while forcing open the TolC aperture decreases sensitivity 
to substrate antibiotics, permanent opening of the aperture cannot completely 
complement the hypersensitivity to the same degree as suppressor alterations in 
AcrB or AcrA (data not shown). Permanent opening the aperture may allow 
substrates to pass back through the open TolC channel and was ultimately 
selected against in our genetic selection. While the open state TolC mutants 
showed limited restoration of growth for AcrB∆L1 on plates containing substrate 
inhibitors, these TolC alterations significantly improved growth of AcrBPAL1/L2 on 
selection medium (data not shown). 
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Figure 20. Opening of the TolC aperture suppresses AcrB ∆loop 1 mutation. 
Sensitivity assays were performed as described in Figure 2 and Table 1. While 
mutations which affect the TolC aperture cause increased sensitivity to substrate 
inhibitors, these mutations reduce the hypersensitivity phenotype observed in the 
AcrB∆L1 mutant. Zones are an average of two independent cultures and vary no 
greater than 10%.  
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Results 3: AcrA Suppressors of TolC and AcrB Interaction Defective 
Mutants 
Isolation of Suppressors of the TolC Turn 1 Drug Hypersensitive Mutant 
 Chemical cross-linking failing to reveal defects in interaction of 
TolC147AGSG150 turn 1 with AcrA and AcrB.Thus, reversion analysis was carried 
out to look for suppressors that could provide insight into the mutant TolC’s 
defect. The TolC turn 1 147AGSG150 mutant is unable to stabilize AcrAL222Q, 
indicating that the mutant TolC protein is unable to functionally interact with 
AcrA or AcrB. If so, it is possible that compensatory alterations in TolC, AcrA, or 
AcrB would be able to restore functional interaction between the members of the 
complex and restore efflux activity. In order to obtain antibiotic resistant 
revertants, two antibiotics, novobiocin and erythromycin, were simultaneously 
used in selection so as to prevent mutations which affect the cellular targets of 
these antibiotics. Approximately 5 X 108 cells from 24 independent cultures were 
incubated on selection medium at 37°C for 20 h. Nineteen of the 24 cultures 
produced a total of 55 antibiotic resistant revertants at a frequency of about 5 x 
10-8, indicating the presence of missense mutations. To determine whether the 
mutations mapped with the plasmid DNA, which expresses the tolC gene, 
plasmids were extracted and transformed into a ∆tolC strain and transformants 
were grown on selection medium. In no cases did the mutation move with the 
plasmid. P1 transductional mapping using a linked marker, Tn10-Tcr, which co- 
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Figure 21. A cartoon showing X-ray structures of AcrA (2F1M). Locations of five 
AcrA substitutions obtained in this study and those obtained previously (Gerken 
and Misra, 2004) are shown in A and B, respectively. AcrA residue numbering 
corresponds to that of the mature protein. 
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transduces with the acrAB loci (40% co-transducible by P1 phage) was carried 
out. In all cases the mutation moved with the Tn10 marker at the expected  
 
frequency, indicating the mutations mapped in or near the acrAB genes.  
 Nucleotide sequence analysis was carried out from PCR-amplified acrAB 
DNA for 24 of the 55 revertants, representing different phenotypes and multiple 
independent cultures. Five different missense mutations were identified in the 
acrA gene corresponding to single amino acid substitutions within the mature 
AcrA sequence: an A135T alteration was isolated once, while S83G, T111P, 
T153P, and L252R were obtained in seven, three, eight, and five isolates, 
respectively. These alterations map to three crystallized domains of AcrA: S83G, 
T111P, and A135T to the α-helical hairpin, T153P to the lipoyl, and L252R to the 
β-barrel domain (Fig 21A). Despite affecting some of the same domains, the five 
suppressors isolated in this study affect different AcrA residues than 10 
previously isolated AcrA suppressors of an assembly defective TolC (Gerken and 
Misra, 2004; Fig 21B). 
 As expected, the AcrA suppressors decreased the hypersensitivity 
phenotype observed in the TolC147AGSG150 mutant. The increase in resistance to 
CCCP is consistent with this data and that of Colmer et al. (1998) that shows 
AcrAB can confer resistance to this inhibitor independent of EmrAB (Table 5 and 
6). The suppressors, however, do not restore interaction with other efflux pumps 
nor have they gained a new ability to secrete substrates which are not recognized  
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Table 5. Sensitivity of wild type TolC, mutant TolC, and mutant TolC containing 
AcrA suppressors to various inhibitors. 
TolC and AcrA 
proteinsa 
Sensitivity to inhibitorsb 
Novobiocin Erythromycin CCCP HlyA 
TolCWT AcrAWT 15.80 61.60 11.20 + 
TolCQ AcrAWT   1.00   1.82   0.97 - 
TolCQ AcrAS83G   2.00   7.15   1.05 - 
TolCQ AcrAT111P   3.60 24.60   2.50 - 
TolCQ AcrAA135T   3.80 13.50   1.20 - 
TolCQ AcrAT153P   7.70 13.70   2.70 - 
TolCQ AcrAL252R 14.50 31.10   4.20 - 
     
a TolCQ denotes the turn 1 TolC147AGSG150 mutant. 
b Numbers for novobiocin, erythromycin, and CCCP represent minimal inhibitory 
concentrations (µg ml-1). Plus and minus indicate the presence (+) or absence (-) 
of hemolytic zones on blood agar medium. For hemolysin sensitivity tests, strains 
were transformed with a plasmid containing the entire hemolysin operon. 
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Table 6. Effects of acrAB and emrAB mutations on CCCP resistance. 
Strain MICa 
Wild type 8-16 
∆acrAB 4-8 
∆emrAB 4-8 
∆acrAB, ∆emrAB 2-4 
∆tolC 1 
 
a Minimal inhibitory concentrations were done by a two-fold dilution method. The 
inhibitor was mixed with approximately 5 x 105 cells/ml. Cultures were incubated 
at 37°C for 18 h without shaking. 
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Table 7. Effects of TolC and AcrA levels in the turn 1 147AGSG150 mutant and 
wild type TolC backgrounds. 
AcrA protein 
TolC147AGSG150 mutant TolC wild type 
TolC levelsa AcrA levels TolC levels AcrA levels 
AcrAWT 0.50 1.00 1.00 1.00 
AcrAS83G 0.48 1.01 1.05 0.93 
AcrAT111P 0.54 0.64 0.87 0.66 
AcrAA135T 0.59 1.12 0.97 1.49 
AcrAT153P 0.49 1.09 0.89 1.40 
AcrAL252R 0.58 0.94 1.00 1.25 
 
a Protein levels are an average of two independent cultures obtained from 
approximately 5 x 107 cells. Wild type TolC and AcrA levels were taken as 1 and 
the mutant TolC and AcrA protein levels were determined relative to wild type 
TolC and AcrA, respectively. 
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by the AcrB pump, as seen by no increased ability to secrete α-haemolysin (Table 
5). The suppressor alterations do not increase TolC levels. In only one case were 
AcrA levels altered: the T111P mutant showed decreased AcrA protein levels 
regardless of whether it was in the turn1 147AGSG150 or wild type TolC  
background (Table 7). Thus, this alteration appears to change AcrA’s 
conformation and stability independent of TolC. Isolation of mutations in acrA 
which suppress the TolC turn 1 147AGSG150 quadruple mutant, along with the 
observation that this mutant TolC is not able to stabilize AcrAL222Q or AcrAP265R 
suggests the mutant TolC causes a defect in interaction with wild type AcrA and 
that specific alterations in AcrA are able to restore the aberrant interaction 
between the mutant TolC and AcrB. 
 
AcrA Mapping Suppressors Act to Open the TolC Aperture 
 Several proposed mechanisms of the interaction between the three 
members of the complex predict that AcrA plays an active role to transmit 
conformational energy from AcrB to TolC (Fernández-Recio et al., 2004; 
Murakami et al., 2006; Seeger et al., 2006; Bavro et al., 2008; Misra and Bavro, 
2009). This mechanism envisages the large periplasmic domain of AcrB changing 
at its surfaces when drug/proton bound. These large shifts on AcrB’s surface are 
felt by the membrane proximal (MP), β-barrel, and lipoyl domains of AcrA and 
transmitted through the α-helical hairpin of AcrA to the aperture of TolC, thereby  
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Figure 22. AcrA suppressor alterations induce opening of the mutant TolC 
aperture. Vancomycin sensitivity, which reflects an open state of the TolC 
aperture, was tested in wild type and suppressor AcrA strains expressing 
TolC14AGSG150, wild type TolC (TolC-WT), or no TolC (TolC
-). A strain 
expressing AcrAL222Q, which does not suppress TolC147AGSG150, was included as a 
control. Zones of inhibition around disks soaked with vancomycin (75 µg) were 
measured after incubating plates for 16 h at 37°C. Average inhibition zones were 
recorded from three independent assays are shown as relative increase, where 
wild type AcrA has been taken as 1. Zones varied no greater than 10%. 
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forcing the aperture into an open state to allow antibiotics to be extruded from the 
exit ducts of AcrB into the open channel of TolC. The conformational changes 
AcrA is thought to undergo would allow for stable interaction between the AcrA 
hairpin helices and the grooves of the TolC helices. It is possible that the AcrA 
suppressors identified here are in a constitutively “active” form of AcrA, which 
wild type AcrA only transiently goes through. If this is so, it is conceivable that 
these AcrA suppressors would cause TolC to remain in a constitutively open state. 
In order to test this, vancomycin sensitivity was tested as it has been shown 
previously to be an effective way to monitor the open or closed state of the TolC 
aperture/channel in vivo (Augustus et al., 2004; Bavro et al., 2008). 
 When the TolC turn 1 147AGSG150 suppressors were tested, four of the five 
suppressors significantly increased sensitivity to vancomycin. These suppressors 
specifically increased this sensitivity in the TolC147AGSG150 mutant background 
(Figs 22, 23, and 25). This indicates the mode of suppression for these AcrA 
suppressors involves constitutively dilating the TolC aperture. The last 
suppressor, AcrAT111P, was able to modestly (11%) increase sensitivity to 
vancomycin. This mutant also showed decreased AcrA levels, so it is possible that 
this mutant does not show as high of sensitivity to vancomycin due to the 
decreased AcrA level.  
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Figure 23. AcrA suppressor mediated opening of TolC is dependent on AcrB as a 
scaffold.  
A. Sensitivity to vancomycin was used to determine whether opening of the TolC 
turn 1 147AGSG150 mutant was dependent on the presence of AcrB. Only in the 
presence of AcrAS83G and AcrB was the TolC147AGSG150 (TolCQ) mutant able to be 
opened, causing sensitivity to vancomycin. As can be seen in the control 
experiments, the absence of TolC, AcrA, or AcrB cause increased sensitivity.  
B. As sensitivity to vancomycin was only observed in the presence of AcrAS83G 
along with wild type, we tested whether this was attributed to the functionality of 
AcrB. A D407A mutation was introduced in AcrB which prevents proton 
translocation and therefore functional rotation. Vancomycin sensitivity caused by 
AcrAS83G was still observed in the AcrBD407A mutant, indicating AcrAS83G 
mediated vancomycin sensitivity requires the physical presence of AcrB. 
Assays were performed as described in Figure 2 and Table 1. Zones are of two 
independent cultures and vary no greater than 10%.  
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AcrA Suppressors Require AcrB to Open the TolC Aperture 
 After observing that the AcrA suppressors act to open the TolC aperture in 
the presence of the mutant TolC, it was inquired whether the opening of TolC was 
dependent on AcrB. To test this, the AcrAS83G mutant was introduced into the 
pACYC184 plasmid containing the acrA gene (Weeks et al., 2010). This, along  
with wild type AcrA, or the empty vector were introduced into a ∆tolC ∆acrA 
acrB
+ or ∆tolC ∆acrAB strain in which TolC wild type, TolC147AGSG150, or 
pTrc99a empty vector had also been transformed. Vancomycin sensitivity was 
observed in these strains. Interestingly, increased sensitivity to vancomycin was 
only observed in the presence of the TolC turn 1 mutant, AcrAS83G, and AcrB (Fig 
23A). The AcrA suppressor showed sensitivity to vancomycin in the presence of 
AcrB, which could have been used as a scaffold, a source of energy or both. To 
determine this, an AcrBD407A alteration was introduced into plasmids expressing 
wild type AcrA and AcrAS83G. In AcrB, D407 is one of the key residues involved 
in proton translocation and therefore energizing AcrB (Takatsuka and Nikaido, 
2006). In addition to the two plasmids expressing either AcrAS83G or wild type 
AcrA along with AcrBD407A, plasmids expressing either wild type or AcrAS83G 
with or without wild type AcrB were transformed into a ∆tolC ∆acrAB/pTrc99a-
tolC (TolC147AGSG150) strain. When tested for sensitivity to vancomycin, the 
AcrAS83G suppressor showed sensitivity in the presence of both wild type and the 
AcrBD407A mutant backgrounds. From this, it was concluded that the AcrA 
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suppressors are in a conformation such that AcrB is required only as a scaffold in 
order to open the TolC aperture (Fig 23B). 
 
Combined Effects of TolC Open State Mutants and AcrA Suppressors 
 After observing the AcrA suppressors increased sensitivity to vancomycin 
and the TolC147AGSG150, R390E mutant was able to partially reverse the antibiotic 
hypersensitivity phenotype of the TolC147AGSG150 mutation, it was inquired 
whether the AcrA suppressors and the TolC open state mutants would act in the 
same pathway to reduce sensitivity to substrate antibiotics. If the AcrA 
suppressors and TolC147AGSG150, R390E were both acting to open the TolC aperture, 
an additive affect might be observed with regards sensitivity to novobiocin and 
vancomycin. Plasmids expressing the TolC147AGSG150, R367E or TolC147AGSG150, R390E 
mutants were introduced into a ∆tolC acrA strain, where the AcrA proteins 
expressed were either wild type or a suppressor variant.  
 All of the AcrA suppressors reduced novobiocin sensitivity in both the 
TolC147AGSG150, R367E (Fig 24A) and TolC147AGSG150, R390E (Fig 24B) backgrounds 
while increasing mutant TolC levels between 18 and 200%. This indicates that the 
AcrA suppressors are acting to stabilize the complex. Interestingly, when the 
AcrA suppressors were in a TolC147AGSG150 background, they showed different 
increases in vancomycin sensitivity without significantly altering TolC levels (Fig 
22 and 25, Table 7), but in the TolC147AGSG150, R367E or TolC147AGSG150, R390E 
background all the suppressors showed similar sensitivities to vancomycin (Fig  
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Figure 24. Combined effects of TolC alterations which influence the TolC 
aperture/channel opening and various AcrA suppressors on TolC147AGSG150. 
Effects of various AcrA suppressors on TolC147AGSG150, R367E (A) and 
TolC147AGSG150, R390E (B) levels and novobiocin and vancomycin sensitivities. 
TolCQ denotes the turn 1 147AGSG150 mutant. Proteins were detected by Western 
blots as described in Fig. 2 legend. Antibiotic sensitivities were described as in 
Fig. 2 and Tables 1 legends. Average inhibition zone diameters were plotted from 
two independent experiments, with zones varying no greater than 10%. 
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24). This seems to show that increased vancomycin sensitivity is a product of 
increased TolC stability and not due to individual effects of the AcrA suppressors. 
In other words, there was not an additive effect of the open state TolC alterations 
and the activity of AcrA suppressors to further open the TolC aperture/channel. 
 
Suppression Specificity 
 Previously an assembly-defective TolC mutant (TolCP246R, S350C) and 10 
AcrA mutants which stabilize the defective TolC were described (Gerken and 
Misra, 2004). These alterations affect different residues within the same domains 
of AcrA. In order to determine whether these alterations could reverse the defect 
caused by the TolC147AGSG150 turn 1 mutant, the plasmid expressing this mutant 
was transformed into each of the 10 AcrA mutant backgrounds and sensitivity to 
both novobiocin and vancomycin was determined. Six of the 10 AcrA suppressors 
of TolCP246R, S350C were unable to suppress the novobiocin hypersensitivity 
phenotype, indicating an allelic bias towards TolCP249R, S350C (Fig 25). The 
remaining four AcrA alterations caused a modest decrease in novobiocin 
sensitivity, however showed minimal increase in vancomycin sensitivity (less 
than 8% of wild type AcrA; Fig 24). In contrast, the majority of the AcrA 
suppressors isolate in this study showed significant (greater than 28%; Figs 22 
and 25) increases in vancomycin sensitivity, suggesting the cross suppression of 
the previous AcrA suppressors is through complex stabilization and not TolC 
aperture/channel opening. 
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Figure 25. Effects of different AcrA suppressors on efflux function and TolC 
aperture in a background expressing the TolC turn 1 mutant (TolC147AGSG150). 
These were assessed by the use of novobiocin and vancomycin, respectively. 
Control strains expressing wild type AcrA expressing no TolC (TolC-), wild type 
TolC (TolC-WT), or TolC turn 1 mutant (TolC147AGSG150) were observed 
simultaneously. AcrA suppressors of TolCP246R, S350C show allelic specificity 
against TolC147AGSG150 turn 1 mutation and those suppressors that do decrease 
sensitivity to novobiocin do so without altering the aperture. Conversely, 
suppressors isolated against TolC147AGSG150 increase sensitivity to vancomycin, 
indicating aperture opening. Zones of inhibition are shown as the average of two 
independent cultures with zones varying less than 10% and were carried out as 
described in Figure 2 and Table 1. 
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Figure 26. AcrA suppressors of TolC14AGSG150 stabilize TolCP246R, S350C. By 
introducing TolCP246R, S350C into the AcrA suppressors of TolC147AGSG150 
backgrounds, stabilization of TolCP246R, S350C could be measured and sensitivity to 
inhibitors was measured. These AcrA suppressors are generally able to restore 
antibiotic resistance lost by the TolC mutant. Additionally, these suppressors 
increase TolC levels significantly. Relative protein levels were assessed on cell 
extracts from approximately 5 x 107 cells. Wild type TolC levels were determined 
using MBP as a loading control and mutant TolC levels were adjusted relative to 
wild type TolC. Zones of inhibition are the average of three independent cultures 
with zones varying no greater than 10% and were performed as described in 
Figure 2 and Table 1.   
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 It was subsequently questioned whether the AcrA mutants isolated in this 
study could stabilize the labile TolCP246R, S350C protein and reverse the antibiotic  
sensitivity phenotype. All of the AcrA mutations significantly (2 to 10 fold) 
increased TolCP246R, S350C levels, as well as reduced antibiotic sensitivity, 
indicating functional complex assembly (Fig 26). As was seen with wild type 
TolC, the AcrA mutants showed no increase in sensitivity to vancomycin; 
suggesting that aperture opening as a means of suppression was specific to 
TolC147AGSG150 and that cross suppression is primarily achieved through inducing 
functional complex assembly. 
 
Secondary Alterations within AcrA Stabilize AcrAL222Q 
 As described in the first chapter, AcrAL222Q’s stability is dependent on 
TolC. Accordingly, the mutant AcrA protein is readily degraded in the 
TolC147AGSG150 mutant background, indicating weak interactions between 
AcrAL222Q and TolC turn 1 147AGSG150. Antibiotic resistance revertants of the 
TolC147AGSG150/AcrAL222Q mutant were sought, so that AcrAL222Q’s stability can be 
used to determine the suppression mechanism. In nine of the 28 revertants, the 
suppressor mutations were mapped to the plasmid DNA expressing the tolC gene. 
For the remaining 19 revertants, genetic mapping using a Tn10 marker linked to 
the acrAB loci (40% co-transducible) was carried out. In nine cases, the 
suppressor mutation was found to be linked to the Tn10 marker. DNA 
corresponding to the acrAB region was amplified by PCR from these revertants  
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Figure 27. Secondary site substitutions within AcrA restore interaction between 
the TolC turn 1 147AGSG150 mutant and AcrAL222Q. 
A. A cartoon showing the X-ray structure of AcrA (2F1M). Locations of seven 
substitutions obtained in a screen of the TolC147AGSG150 and AcrAL222Q strain.  
AcrA numbering corresponds to that of the mature protein. 
B. AcrA protein levels were compared from whole cell extracts of approximately 
5 X 108 cells from overnight cultures. Wild type AcrA was taken as 1.0 and 
mutant levels are relative to this. Sensitivity to select inhibitors is listed as zones 
of inhibition (mm) around 6 mm disks soaked with novobiocin (30 µg), 
erythromycin (15 µg), or vancomycin (75 µg) and are an average of at least 3 
independent cultures with zones varying less than 10% . 
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and subjected to nucleotide sequencing analysis. In all cases, the DNA contained 
the original mutation as well as a missense mutation within the acrA gene leading 
to the following single amino acid substitutions in mature AcrA sequence: S83G, 
G110A, G110D, T111A, T111S, A135V, and N146Y. Interestingly, with the 
exception of G110, all of these locations have been previously identified in 
genetic screens and substitutions in these locations have been shown to stabilize 
functional complex assembly (Fig 27A). S83G was the only identical substitution, 
while the others were previously isolated at the same amino acid position. It is 
also interesting to note that when suppressor mutations were previously isolated 
there was little conservation as to which domain the suppressor alterations 
mapped to, however, when using the labile AcrA and turn 1 mutant TolC proteins, 
all the suppressor alterations map to the α-helical hairpin domain, while 
maintaining the original β-barrel alteration (L222Q). 
 In order to determine whether these suppressors were acting to stabilize 
the labile AcrA to restore interaction with the mutant TolC, AcrA levels were 
examined (Fig 27B). All of the suppressors showed increases in AcrA levels 
(ranging between 1.75 and 6 fold increase). Not surprisingly, the AcrA mapping 
suppressors of the labile AcrAL222Q and TolC turn 1 147AGSG150 mutant increased 
resistance to novobiocin and erythromycin (Fig 27B). When comparing the 
sensitivity to vancomycin, three (S83G, A135V, and N146Y) substitutions 
increase sensitivity to vancomycin (35 to 45% increase in sensitivity), whereas the 
remaining four substitutions (G110A, G110D, T111A, T111S) did not  
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Figure 28. Location of AcrA suppressors of AcrB∆L1. A cartoon showing the X-
ray structure of AcrA (2F1M). Locations of ten substitutions obtained in this 
study are shown. AcrA numbering corresponds to that of the mature protein.  
  
95 
 
significantly alter vancomycin sensitivity. It appears that alterations in the 
extreme tip region of AcrA, while able to restore complex assembly, do not 
induce constitutive TolC aperture/channel opening, as the remaining suppressors 
do.  
 
Suppressors that Overcome the Drug Hypersensitive Phenotype of the AcrB 
∆Loop 1 Mutant 
 It was determined that the perplasmic hairpin loop 1 of AcrB is critical for 
drug efflux. This defect of the AcrBΔL1 could be due to aberrant AcrB-TolC 
interactions. Drug resistant revertants of AcrBΔL1 were sought to identify 
suppressor mutations that can help better understand the cause of the AcrBΔL1 
defect. To obtain suppressor alterations, approximately 5 X 108 cells from 46 
independent cultures were plated onto selection medium containing novobiocin, 
erythromycin and SDS. These three inhibitors were used to prevent mutations in 
the target genes and assure mutations were primarily isolated within the acrAB-
tolC genes. Twenty of the 46 independent cultures gave rise to drug resistant 
revertants at a frequency of about 5 X 10-8. A total of 24 revertants, 
representingall of the 20 independent cultures and distinct growth phenotypes on 
selection medium were selected for further analysis. Plasmids containing the 
acrAB loci were extracted and transformed into a fresh ∆acrAB background to 
determine whether the suppressor mutations moved with the plasmid DNA. In 21 
of the 24 revertants, the suppression mutation moved with the plasmid DNA.  
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Figure 29. Antibiotic resistance is partially restored by AcrA suppressors. AcrA 
suppressors of AcrB∆L1. Selected revertants of the antibiotic hypersensitive 
AcrB∆L1 mutant completely restore resistance to novobiocin and erythromycin, 
while partially restoring resistance to SDS. Sensitivity assays were performed as 
described in Figure 2 and Table 1. Zones are an average of two independent 
cultures varying no greater than 10%. 
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Figure 30. Effect of AcrB∆L1 suppressors on AcrA protein levels. Most AcrA 
suppressors show no difference in protein levels or running on 11% acrylamide 
gels. AcrAE43K, AcrAL222Q, AcrAL222R, and AcrA∆222-224 show decreased protein 
levels indicating decreased stability of the mutant protein. AcrAF230S and 
AcrAG248E show slower migration through 11% acrylamide gels. Whole cell 
extracts from approximately 5 x 107 cells from overnight cultures were probed for 
AcrA and LamB. LamB was used as a loading control and AcrA wild type levels 
were taken as 1. Mutant protein levels were adjusted accordingly. 
* ∆ indicates the AcrA∆222-224 alteration. 
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Sequence analysis revealed that 19 of the 21 revertants, the acrA gene carried a 
mutation. The residues affected by these mutations of the mature AcrA sequence 
were E43K, V44I, S195P, L222Q, L222R, ∆222-224, T224S, F230S, G248E, and 
S249C. These were each isolated 1, 1, 1, 5, 2, 1, 1, 1, 5, and 1 times, respectively. 
Two of the alterations mapped in the lipoyl domain of AcrA (E43K and V44I), 
while the remaining substitutions mapped in the β-barrel (Fig 28). The suppressor 
alterations L222Q and L222R have been isolated in previous studies conducted by 
our lab and have been shown to stabilize functional complex assembly of the 
labile TolCP246R, S350C, while they themselves destabilize the AcrA protein. 
 As stated above, AcrAL222Q and AcrAL222R are labile proteins which are 
readily degraded without TolC and AcrB (Gerken and Misra, 2004; Weeks et al. 
2010; Figs 4, 7, and 27). Not surprisingly, their levels were found to be markedly 
reduced in the AcrB∆L1 background (Fig 30). Additionally, AcrA∆222-224 showed a 
significant reduction in AcrA levels, also not surprising as the other two 
alterations at L222 showed similar reduction. AcrAE43K was the only other mutant 
to show decreased protein levels when compared to wild type AcrA. When 
comparing antibiotic sensitivity of the mutants to the parental AcrB∆L1, all 
suppressors reduce sensitivity to novobiocin and erythromycin back to wild type 
levels (Fig 29). The suppressors vary in their abilities to suppress sensitivity to 
SDS, but all show a significant reduction in sensitivity compared to the parental 
AcrB∆L1.  
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Figure 31. AcrA α-helical mutations suppress AcrB∆L1.  
A. Mutations within the α-helices of AcrA restore resistance to novobiocin and 
erythromycin while partially restoring resistance to SDS, similar to revertants 
selected. Sensitivity assays were performed as described in Figure 2 and Table 1. 
Zones are an average of two independent cultures. 
B and C. Relative growth on plates without (B) or with (C) the substrate inhibitors 
(novobiocin, erythromycin, and SDS) was observed after 16 h. Mutations within 
the α-helices of AcrA show decreased growth compared to the selected revertant 
AcrAL222Q, but still show significant increase in growth compared to AcrB∆L1.  
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Forced Mutation of AcrA’s α-Helix Suppresses the Drug Hypersensitivity Defect 
 All the suppressor alterations described above were localized to the β-
barrel and lipoyl domains of AcrA, indicating suppression specificity. To test this 
further, suppressor alterations mapping within the α-helical domain of AcrA, 
which were isolated through a different selection strategy, were introduced in an 
AcrB∆L1 background and drug sensitivity was tested of the resulting strains. More 
specifically, four alterations which had previously been identified as those that  
stabilize functional complex assembly were introduced via site-directed 
mutagenesis into the pACYC184- acrAB (AcrB∆L1) plasmid. The alterations – 
S83G, T111P, A135T, and N146T – localize to either α-helix 1 (S83G), α-helix 2 
(A135T and N146T), or the extreme tip turn between α-helix 1 and α-helix 2 
(T111P). Once introduced, the antibiotic hypersensitivity of these mutants were 
compared to those carrying alterations in the β-barrel domain. Surprisingly, when 
individual antibiotics were tested, these forced α-helical alterations showed 
similar zones of inhibition to those carrying the original suppressors altering the 
β-barrel domain of AcrA, with sensitivity to novobiocin and erythromycin 
sensitivity returning to a wild type level and slightly elevated zones of inhibition 
for SDS (Fig 31A). However, when strains carrying these forced α-helical 
alterations were grown on selection medium simultaneously containing these 
three inhibitor substrates, they grew significantly weaker than a strain carrying an 
alteration in the AcrA β-barrel domain (AcrAL222Q; Fig 31B). This indicates that 
while the α-helical alterations in AcrA can reduce sensitivity to antibiotics similar 
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to those revertants carrying β-barrel alterations, the combination of inhibitors used 
for selection may have biased against selecting the former alterations due to their 
limited ability to grow in the presence of all three substrates simultaneously. 
 The ability of AcrA α-helical alterations to suppress the antibiotic 
sensitivity phenotype of the AcrBPAL1/L2 mutant was also tested. It was speculated 
that this AcrB mutant has a similar defect in its ability to interact with TolC 
directly, or with TolC and AcrA. If this is the case, the alterations in either the α-
helical or β-barrel domains of AcrA should be able to reverse the antibiotic 
hypersensitivity phenotype of AcrBPAL1/L2 as they do for the AcrB∆L1 mutant. 
AcrAS83G, AcrAA135T, AcrAL222Q, and AcrAG248E were selected for introduction 
into the AcrBPAL1/L2 background. These four alterations map to different areas 
within the α-helices and β-barrel, additionally, L222Q and G248E were isolated 
most frequently in the AcrB∆L1 background, potentially indicating a preference of 
these alterations to suppress the antibiotic hypersensitivity. When comparing 
growth on selection medium containing all three antibiotics, the four AcrA 
suppressor alterations showed complete restoration of growth indicating these 
substitutions were also able to suppress the AcrBPAL1/L2 mutant just as well as the 
AcrB∆L1 mutant (Fig 32A and B). Sensitivity assays showed these AcrA 
alterations reduce inhibition zones against the inhibitors back to wild type levels 
(Fig 32C). These results indicate that these two AcrB mutants share a common 
defect in interaction with other members of the complex, which can be suppressed 
by the same alterations in AcrA. 
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Figure 32. AcrA mutations restore drug efflux of AcrBPAL1/L2.  
A and B. Relative growth was compared for AcrA mutations with the AcrBPAL1/L2 
mutant without (A) or with (B) the substrate inhibitors novobiocin, erythromycin, 
and SDS. Growth was compared after 16 h. 
C. Antibiotic resistance was compared for resistance to antibiotics as described in 
Figure 2 and Table 1.AcrA mutants restore antibiotic resistance comparable to 
resistance of wild type AcrA and AcrB. Zones are an average of two independent 
cultures varying less than 10%.  
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AcrA Mapping Suppressors Act to Stabilize Functional Complex Assembly 
 The AcrB∆L1 mutant is unable to stabilize the labile TolCP246R, S350C 
mutant, indicating a defect in complex assembly. If AcrA suppressor alterations 
restore complex stability, they may also stabilize the labile TolC protein in the 
presence of AcrB∆L1. All but one of the AcrA alterations were able to stabilize 
TolCP246R, S350C significantly (Fig 33). This led to an increase in TolCP246R, S350C 
levels from 0.06% to between 47 and 83% of that found in the wild type 
AcrA/AcrB background, indicating that these suppressors were acting to stabilize 
the functional complex assembly between AcrB∆L1, mutant AcrA and TolC. The 
remaining mutant, AcrA∆222-224, was the least stable of the AcrA mutants and it is 
reasonable to expect that the combination of its intrinsic reduced stability 
interfered with its ability to stabilize the labile TolC. 
 
Conformational Active AcrA Mutants Cannot be Biochemically Differentiated 
from Wild Type AcrA 
 In an attempt to determine whether the mutated forms of AcrA are in a 
constitutively activated form that may have changed their biochemical properties, 
protease sensitivity assays were carried out. Three AcrA variants were selected to 
begin analyzing the differences between wild type and mutant AcrA: E43K, 
L222Q, and G248E. When comparing steady state levels of AcrA, the E43K and 
L222Q alterations caused significant decreases in AcrA levels (0.70 and 0.57 of 
wild type, respectively; Fig 30). G248E does not cause a significant reduction in 
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Figure 33. AcrA suppressors of AcrB∆L1 act to stabilize TolCP246R, S350C. 
Suppressor mutations in AcrA function by stabilizing functional complex 
assembly as measured by stabilization of the TolCP246R, S350C mutant. All 
suppressors except AcrA∆222-224 increased protein levels between 8 and 14-fold. 
Whole cell extracts from approximately 5 x 107 cells grown overnight were 
probed for TolC and a loading control (LC). TolCP246R, S350C levels in wild type 
AcrA and AcrB were taken as 1 and mutants were adjusted relative to this. 
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protein levels, 0.94 of wild type, but it does produce a slight shift in mobility 
when analyzed on 11% acrylamide gels. To determine whether additional 
differences could be observed between these mutants and wild type AcrA, limited 
proteolysis using trypsin and proteinase K was conducted (Ge et al., 2009). Cell 
membranes were prepared from fresh cultures, OD600 ~1.0, which were then 
subjected to 5 minute treatment with trypsin or proteinase K. All three mutants 
show degradation profiles similar to wild type AcrA after treatment with trypsin 
(Fig 34). Additionally, AcrAL222Q, when treated with proteinase K, showed the 
same degradation profile as wild type AcrA (Fig 34). Thus, the protease 
sensitivity assay cannot distinguish between the subtle conformational changes 
between wild type AcrA and the mutant counterparts. However, the steady state 
AcrA levels or altered gel mobility, along with the increased ability to stabilize a 
labile TolC mutant and increased antibiotic efflux, tend to point to an altered state 
of AcrA. 
 
AcrA Suppressors Specifically Fix Defects in Complex Assembly 
 The results above showed that alterations in AcrA were able to restore 
interactions between defective forms of AcrB and TolC. Next it was determined 
whether the AcrA mutants could restore other defects in AcrB, such as proton 
translocation or drug-binding. If the AcrA alterations can, it may suggest that 
AcrA plays roles besides relaying conformational energy from AcrB to TolC. To 
test this hypothesis, acrA alterations AcrAL222Q and AcrAG248E were introduced 
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Figure 34. AcrA suppressors show no physical difference between wild type 
AcrA when exposed to trypsin. Membrane samples were exposed to varying 
concentrations of trypsin for 5 min. Mutations in AcrA do not alter stability of 
AcrA by protecting or exposing trypsin cleavage sites within AcrA. Membranes 
from approximately 7.5 x 108 cells were loaded and probed for AcrA. Units of 
trypsin (T) are in µg µl-1. 
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Figure 35. Wild type AcrA and AcrAL222Q show no difference in proteinase K 
sensitivity. Limited proteolysis using proteinase K (PK) was performed as with 
trypsin. Both AcrA wild type and AcrAL222Q show similar degradation profiles, 
indicating PK cleavage sites have not been protected or exposed by the L222Q 
mutation. 
  
108 
 
into pACYC184-acrAB which expressed AcrB bearing either a D407A or F610A 
substitution. The D407A alteration disrupts one of the key residues in the proton 
transport chain within the transmembrane domain of AcrB, thus preventing AcrB 
from becoming energized and subsequently expelling antibiotics from the cell 
(Takatsuka and Nikaido, 2006). The F610A alteration is located within the drug-
binding cavity of AcrB and prevents substrates from being moved from the entry 
tunnels to the exit tunnel facing TolC (Bohnert et al., 2010; Husain and Nikaido, 
2010). By disrupting either of these, AcrB loses its ability to translocate drugs 
from the cell and into the extracellular milieu. 
 Neither alteration in AcrA was able to suppress the AcrB defect in proton 
translocation, supporting a view that AcrA plays no role in energizing AcrB (Fig 
36B). Additionally, neither of these AcrA alteration showed increased ability to 
stimulate drug-binding in the AcrBF610A mutant (Fig 35A), indicating that unlike 
the copper efflux pump, CusAB, AcrA does not help facilitate drug-binding of 
AcrB (Bagai et al., 2007; Bagai et al., 2008). Taken together, these data indicate 
that alterations within AcrA can restore complex assembly between defective 
AcrB and TolC proteins, but cannot fix intrinsic defects of AcrB involving proton 
or drug translocation. 
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Figure 36. AcrA β-barrel mutations which suppress defects in tripartite complex 
assembly do not correct AcrB defects in drug-binding or proton translocation. 
A. AcrA β-barrel mutations were examined for their ability to restore drug efflux 
for the drug-binding deficient mutant (F610A). Sensitivity to novobiocin was 
tested without (DMSO) or with (PAβN) the efflux pump inhibitor phenylalanine-
arginine-β-naphtylamide. Zones are an average of three independent cultures with 
zones varying no greater than 10%. As PAβN is soluble in DSMO, 10 µl of 
DMSO or 25 mg ml-1 PAβN in DMSO were spotted onto pre-soaked novobiocin 
disks (30 µg). 
B. Sensitivity to novobiocin and erythromycin were observed in the proton 
translocation defective AcrB mutant (D407A) with the AcrA β-barrel mutations. 
Zones of inhibition are and average of three independent cultures with zones 
varying less than 10%. Sensitivity was determined as described in Figure 2 and 
Table 1. 
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Discussion: 
 This work describes the isolation and characterization of TolC and AcrB 
mutants of Escherichia coli that are defective in proper interactions with other 
complex members. The TolC turn 1 147AGSG150 mutant is the first of its kind, 
being completely defective in efflux functions, while maintaining its ability to 
properly insert into the membrane and act as a receptor for both TLS phage and 
colicin E1. The AcrB hairpin loop mutations (∆L1 or PAL1/L2) express a similar 
defect in their inability to properly interact, likely with TolC, so as to allow proper 
alignment with TolC and stimulate opening of its aperture/channel. Functional 
defects of TolC and AcrB can be overcome by compensatory alterations in AcrA 
that primarily act to facilitate proper complex assembly to allow TolC aperture 
opening. Interestingly, compensatory alterations in AcrA did not lead to changes 
in the proteins conformations that allowed for interactions only with the protein 
against which they were isolated. In other words, suppressor mutations were not 
strictly allele specific. Thus, suppressor alterations likely restored broad surface 
interactions and not side chain-specific interactions. Alterations within TolC that 
cause TolC to exhibit a leaky phenotype, by preventing complete aperture closing, 
appear to be able to restore antibiotic efflux function lost when AcrB and TolC 
cannot properly interact with one another.  
 While there are two reported models of interaction, the data presented here 
tends to support direct interactions between AcrB and TolC (Tamura et al., 2005, 
Bavro et al., 2008; Misra and Bavro, 2009; Symmons et al., 2009; Tikhonova et 
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al., 2011). The similar phenotypes observed between the TolC147AGSG150 and 
AcrB∆L1 mutant indicate that the affected regions of the two proteins may directly 
interact with one another. In the AcrB-TolC distal model of interaction, it is 
possible that the TolC turn 1 mutation disrupts interaction with AcrA, but a 
mutation in the AcrB hairpin loops should show little to no phenotype as a direct 
interaction between AcrB and TolC should not occur in this model and the AcrB 
hairpin loops should have little to no physical interaction with AcrA (Kim et al., 
2010; Xu et al., 2010; Xu et al., 2011). In the AcrB-TolC tip-to-tip model of 
interaction, D256 of AcrB has been proposed to mediate interaction directly 
between AcrB and TolC (Tamura et al., 2005; Symmons et al., 2009; Bavro et al., 
2008). In the poly alanine AcrB Loop 1 and Loop 2 mutants (AcrBPAL1/L2), 
restoration of aspartate at position 256 fully restored the protein’s function, thus 
providing genetic evidence for the importance of D256 in AcrB’s function. 
Similarly, restoration of N254 in the poly alanine background restored AcrB’s 
function. Both of these residues are located on the hairpin loop 1 and appear to be 
directed toward where the TolC turns have been proposed to sit in the docked 
model of TolC-AcrAB (Symmons et al., 2009). Additionally, the MexB hairpin 
loop 1 shows an incredible identity with AcrB loop 1 and structurally, the aspartic 
acid and asparagine residues are oriented in a near identical fashion. Unlike 
hairpin loop 1 residues, residues of hairpin loop 2 show little conservation. 
Moreover, D795 of AcrB is replaced by K794 of MexB, both of which are 
112 
 
pointing into the periplasm and free to make interactions with TolC or OprM 
respectively. 
 The TolC turn 1 residues are primarily hydrophobic and facing away from 
the periplasm, leaving the peptide backbone free to hydrogen bond with the 
charged and polar side chains of the AcrB hairpin loops (Koronakis et al., 2000; 
Koronakis et al., 2004; Bavro et al., 2008; Pei et al., 2011). It is interesting to 
think that in the case of E. coli, where TolC is the only channel protein which 
interacts with multiple drug transporter pumps, a lack of sequence specificity for 
interaction at the turn would allow interactions of TolC with the multitude of 
transporters. Previous reports of gain of function mutations that allow VceC, the 
Vibrio cholerae TolC homologue, to function with AcrAB, showed compensatory 
mutations not within the tip region, but within the intraprotomer groove, allowing 
VceC to function with AcrAB (Vediyappan et al., 2006). Additionally, Nehme 
and Poole (2007) characterized gain of function mutations in MexA and OprM 
which act to facilitate functional complex assembly in a defective MexA 
background. The alterations in OprM localized to the intraprotomer groove and 
acted to enhance MexA interactions lost by a point mutation in the α-helical tip of 
MexA. This indicates that the specificity of interaction between outer membrane 
factor and membrane fusion protein is not at the TolC turn regions, but further up 
the α-helical barrel of the channel protein. 
 According to the favored tip-to-tip model shown in figure 37, initial 
interactions begin between TolC turn 1 backbone and charged/polar residues of  
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Figure 37. Proposed mechanism of interaction between members of the TolC-
AcrAB complex. Initial interaction between TolC loop 1 and AcrB loop 1 cause 
proper alignment of TolC to AcrB (1). This interaction is stabilized by TolC turn 
2 and AcrB loop 2, leading to the disruption of salt bridges holding the TolC 
aperture in the closed position (2). AcrB, after going through functional rotation, 
stimulates the β-barrel of AcrA (3) leading to conformational changes transferred 
through the lipoyl domain allowing alignment of the α-helices with the TolC 
colied-coils (4). This alignment causes rearrangement of TolC’s helices and the 
iris-like opening of the aperture (5). After TolC has been opened by AcrA through 
energy derived from AcrB, the drug is released from the AcrB exit ducts directly 
into the open TolC channel. 
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AcrB hairpin loop 1. This will lead to proper alignment between TolC and AcrB, 
allowing for disruption of salt bridges which keep the TolC aperture locked (Fig 
37). These initial disruptions would allow for AcrA to align its α-helices in a 
coiled-coil manner with TolC helices. Conformational activation of AcrA via 
AcrB would allow a complete alignment of AcrA and TolC helices and full 
dilation of TolC aperture, allowing antibiotics to be directly transferred from 
AcrB’s exit tunnels into TolC’s open channel. 
 Alterations within the turn regions and hairpin loops of TolC and AcrB, 
respectively, lead to an antibiotic hypersensitivity phenotype. This is consistent 
with the proposed mechanism of direct interaction between the two proteins. It 
was found that single amino acid substitutions within AcrA which overcome the 
antibiotic hypersensitivity phenotype, do so by stabilizing functional complex 
assembly in all cases. This leads to the conclusion that AcrA is acting to stabilize 
the weakened interaction between AcrB and TolC. In the case of the TolC turn 1 
147AGSG150 mutant, AcrA suppressors additionally stimulate TolC aperture 
opening in an AcrB-dependent manner. This tends to indicate that disruption of 
the turn 1 residues abolishes proper interactions with AcrB and therefore 
precludes TolC aperture opening. This then must be fixed through modified 
alterations within AcrA , which both stabilizes TolC-AcrB intreactions and 
induces TolC aperture opening. Additionally, a synthetically introduced alteration 
of R390E is able to partially restore functionality of the turn 1 mutant. This 
finding supports the notion that disruption of the TolC turn 1 prevents AcrA and 
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AcrB to open the mutant TolC protein. The isolation of alterations in both TolC 
and AcrA that increase sensitivity to vancomycin, indicating the TolC aperture 
had been opened. 
 Taken together, the data presented indicate a direct interaction between 
AcrB and TolC to expel antibiotics from the cell as indicated in Figure 36. In this 
mechanism of interaction, AcrB hairpin loop 1 interacts directly with TolC turn 1 
to mediate initial interaction, which allows hairpin loop 2 to interact with turn 2, 
of AcrB and TolC respectively. This interaction begins to disrupt the salt bridges 
locking TolC’s aperture. At this point, AcrB undergoes its conformational 
changes upon binding to substrates and transferring them to the exit tunnel as well 
as translocating protons across the inner membrane. These changes induce 
conformational changes on the external clefts of AcrB which AcrA sits. These 
conformational changes in AcrB are then transferred through the AcrA membrane 
proximal, β-barrel, and lipoyl domains to the α-helical hairpin domain of AcrA, 
which aligns itself with the coiled-coils of TolC, allowing the aperture to become 
fully dilated and the substrate to be transferred from AcrB directly through the 
TolC channel. 
 Chemical cross-linking was inefficient at revealing defective interaction 
between the mutant TolC turn 1 and AcrB loop mutations, whereas stabilization 
of labile AcrA and TolC proteins was able to indicate the mutant proteins are 
unable to properly form functional complexes. Additionally, suppressor 
alterations within AcrA or the intragenic suppressor AcrB∆L1, Q737L were able to 
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stabilize these defective interactions and supported the notion that suppression is 
primarily mediated by stabilizing the functional complex. 
 By monitoring vancomycin sensitivity, it was possible to ascertain that a 
secondary means of restoring functionality of the complex was mediated by 
opening of the TolC aperture/channel. When analyzing suppressor mutations of 
TolC147AGSG150 which mapped to acrA, it was seen that opening of the TolC 
aperture was specific to TolC147AGSG150 and completely dependent on the presence 
of AcrB. This AcrA-induced TolC aperture opening appears to show that AcrA’s 
conformation has been constitutively fixed into an “activated” state, which wild 
type AcrA protein transiently adopts during normal drug transport. 
 Limited protease sensitivity of constitutively activated forms of AcrA 
showed little to no difference compared to wild type. Altered steady state levels of 
certain mutants of AcrA, as well as differences in the gel mobility pattern gave 
some hint that the mutant AcrA proteins have adopted different conformations 
than wild type AcrA. Additionally, secondary site alterations within AcrAL222Q 
can stabilize this labile AcrAL222Q protein, indicating the conformation has been 
altered further to allow the protein to be more stable, but still significantly less so 
than wild type. It is possible through further biochemical tests or structural 
determination to know how various alterations within AcrA affect its 
conformation. 
 The inability to distinguish by proteolysis between wild type and activated 
forms of AcrA compares to the inability of cross-linking data to distinguish 
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between defects in functional vs. physical interactions between TolC and AcrB 
mutants. If one were to solely analyze chemical cross-linking, the inability to 
distinguish between TolCWT and TolC147AGSG150 would suggest no defect in 
physical interactions with the other members of the complex. However by 
utilizing a labile AcrA variant (AcrAL222Q), it can be seen that as antibiotic 
resistance is lost by TolC alterations, the labile AcrA protein is readily degraded. 
This leads to the conclusion that the mutational defect may have impeded 
functional interaction between mutant TolC and AcrA or AcrB, while physical 
interactions of the complex shows limited defects. Likewise, alterations in the 
hairpin loop regions of AcrB do not alter the ability of AcrA to co-purify, yet 
TolC is no longer able to co-purify with the AcrB mutants. Also, the inability of 
mutant AcrB proteins to stabilize TolCP246R, S350C gives more solid evidence that 
these hairpin loop alterations interfere with the proper assembly of the complex. 
Furthermore, AcrA suppressor mutations are able to restore stability of this 
mutant TolC. 
 The proposed docked model of interaction between AcrAB-TolC shows a 
single monomer of AcrA interacting with both TolC and AcrB. However, the 
location of AcrA in the model is inconsistent with the idea that AcrB transmits 
conformational energy through AcrA to TolC. This is most likely not the case 
because without this energy transfer from AcrB to TolC through AcrA, TolC 
would remain in a resting closed state. It is assumed that AcrB does in fact 
transmit this conformational energy through AcrA because the suppressors 
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isolated against the TolC147AGSG150 turn 1 mutant cause permanent opening of 
TolC and therefore AcrA must be maintaining a conformation it only transiently 
adopts, as stated earlier. If this is the case, then this change in conformation most 
likely comes from the physical movement within AcrB. During drug binding and 
proton translocation, the surface of the AcrB porter domain goes through 
significant structural changes and would most likely be able to transfer the energy 
needed to AcrA to induce normal TolC aperture opening. If, as in the case of the 
copper efflux system CusABC, AcrA adopts a trimer of dimers encompassing 
TolC and AcrB, then AcrA would be situated in the proper location to receive this 
energy from AcrB to transmit to TolC.  
 After the tripartite complex model was proposed by Symmons et al. 
(2009), Tikhonova et al. (2009) showed two discrete binding affinities of AcrA, 
as well as other membrane fusion proteins, to TolC. Later they showed AcrA 
similarly binds AcrB in a 2:1 ratio (Tikhonova et al., 2011). The co-crystal 
structure of CusAB, as well as the functional covalently linked AcrA dimer 
indicates that the membrane fusion proteins act as in a multimeric state, placing 
the membrane fusion protein in the appropriate location to receive conformational 
energy (Su et al., 2011).  
 Tikhonova et al. (2011) showed direct binding affinity of TolC to 
immobilized AcrB with similar binding coefficients as either TolC-AcrA or 
AcrA-AcrB, other reports suggest interaction only occurs via outer membrane 
factor and membrane fusion protein. This notion stems from studies of the 
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MacAB-TolC complex, where the periplasmic domain of MacB is unable to co-
purify with TolC, whereas MacA can. These studies also show a physiologically 
relevant hexameric state of MacA in which the hairpin of MacA intermesh 
completely in the turns of TolC. Later reports from this lab showed mutations in 
the tip of the α-helical domain of MacA or AcrA abolished interaction with TolC 
leading to decreased resistance to substrate inhibitors. Additionally, compensatory 
alterations in the turn regions of TolC restored interaction between AcrA and 
TolC as determined by increased antibiotic resistance and ability to be chemically 
cross-linked to one another.  
 If AcrB does not directly interact with TolC, how would mutations of the 
hairpin loops of AcrB cause a defect in functional interaction with TolC, as well 
as diminished ability of TolC to co-purify with AcrB? According to the AcrB-
TolC distal model of interaction, AcrB’s hairpin loops should be of little 
importance in interaction as the membrane proximal, β-barrel, and lipoyl domains 
of AcrA would directly interact with the surfaces of AcrB, thus leaving the 
hairpin loops with little to no purpose in interaction. In this research is has been 
shown that AcrB loop alterations have reduced ability to stabilize the labile 
TolCP246R, S350C mutant as well as the decreased ability to efflux antibiotics. Based 
on this, it can be proposed that there must be a direct interaction between TolC 
and AcrB in order to cause these phenotypes. Additionally, the intragenic AcrB 
suppressor, Q737L is located directly adjacent to the AcrB loop 1 within a groove 
where the TolC turn is predicted to sit. This suppressor partially stabilizes the 
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labile TolC protein in the presence of the AcrB loop 1 deletion. This genetic 
evidence points to a direct interaction between TolC and AcrB. Biophysical 
evidence came from Tikhonova et al. (2011), where they showed AcrB can bind 
TolC with the same affinity as to AcrA through Surface Plasmon Resonance.  
 Taken together, the data presented here and the Surface Plasmon 
Resonance data of Tikhonova et al. (2011) support a direct interaction between 
the periplasmic turns of TolC and loops of AcrB. Alterations in either protein 
abolish interaction as determined by increased antibiotic sensitivity and labile 
protein stability. Additionally, single amino acid substitutions within any member 
of the complex can partially restore antibiotic efflux, primarily through 
establishing functional complex assembly. In all cases, the final step of TolC 
aperture opening is disrupted and, therefore, alterations that force open the TolC 
aperture, either directly or indirectly, can restore antibiotic efflux or establish 
proper interaction between members of the complex. 
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Materials and Methods 
Strains and Chemicals 
 All the strains and plasmids used in this study are listed in Table X. Luria 
broth (LB) and LB agar (LBA) media were prepared as described by Tom Silhavy 
et al. (1984). When required, ampicillin (50 µg ml-1), chloramphenicol (12.5 µg 
ml-1), kanamycin (25 µg ml-1), and tetracycline (10 µg ml-1), isopropyl-β-D-
thiogalactopryanoside (IPTG; 0.4 mM), L-arabinose (0.2%) was added to 
bacterial cultures. All other chemicals were of analytical grade. 
 
DNA Manipulations 
 The acrA gene was cloned into pACYC184 (Chang and Cohen, 1978) and 
pBAD33 (Guzman et al., 1995) plasmid vectors as described previously 
(Augustus et al., 2004). Subsequently the acrB gene was cloned behind acrA on 
the pACYC184-acrA plasmid. The tolC gene was cloned into pTrc99a as 
described previously behind the IPTG inducible promoter (Vakharia et al., 2001, 
Augustus et al., 2004, Husain et al., 2004). Primers used for cloning, sequencing, 
and site-directed mutagenesis are listed in Table X. Primers ordered from IDT 
DNA. Deletion of the chromosomal tolC, acrA, and acrB genes were carried out 
as described previously (Augustus et al., 2004) and was carried out by the method 
described by Datsenko and Wanner (2000). Gene deletion was confirmed by PCR 
and DNA sequence anaylsis. Plasmid transformation and P1 transduction were 
performed according to the standard laboratory procedures. 
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 Site-Directed Mutagenesis was carried out using the QuickChange 
Lightning Site-Directed Mutagenesis Kit (Stratagene) according to 
manufacturer’s instructions. Sequencing of all chromosomal and plasmid borne 
mutations were sequenced using primers listed in Table X and sequencing was 
carried out by the ASU DNA Sequencing Lab. 
 
SDS-PAGE and Western Blot Analysis 
 Whole cell extracts, membrane fractions, or purified protein were analysed 
by mini sodium dodecyl sulfate (SDS)-polyacrylamide (7.5% or 11%) gel 
electrophesis (PAGE). When needed, gels were stained with Coomassie staining 
(25% (v/v) isolpropanol, 10% (v/v) glacial acetic acid, 2.5 mg ml-1 Coomassie 
brilliant blue) for 15min. The gels were then destained in 5% (v/v) methanol, 7% 
(v/v) acetic acid. Gels were imaged with Bio-Rad Molecular Imager ChemiDoc 
XRS System. For Western Blot analysis, samples were run on SDS-PAGE and 
transferred onto immobilon-P polyvinylidenedifluoride membranes (Milipore). 
Membranes were blocked overnight in 5% (w/v) non-dairy creamer in TBS. After 
blocking, membranes were washed and incubated for 1.5 hours in primary 
antibodies raised against TolC-MBP, AcrB-MBP, AcrA6His, and/or LamB, 
followed by two 15 minute washes and 1 h incubation in secondary antibodies 
(goat anti-rabbit horseradish peroxidase [HRP] conjugated IgG). Additionally, 6 
histadine tagged proteins were visualized by incubating for 1.5h with HisProbe-
HRP (Thermo Scientific). Detection of hybridized proteins was carried out using 
123 
 
immunostar HRP substrate. Protein bands were visualized with the Bio-Rad 
Molecular Imager ChemiDoc XRS System. When needed, relative protein levels 
were determined using the Quantity One software, MBP and LamB were used as 
loading controls to compare the relative amounts of AcrB or TolC (MBP) or 
AcrA (LamB). 
 
Antibiotic Sensitivity Assays 
 Sensitivity to antibiotics was analyzed by placing pre-soaked antibiotic 
disks (Becton Dickinson) on bacterial lawn grown on LBA. In cases where pre-
soaked disks were not available, 10µl of the antibiotic was added to a 6mm sterile 
Whatman disks to contain the following amounts of antibiotic; SDS – 1 mg, 
vancomycin – 75 µg. Zones of inhibition were measured after 16h of incubation at 
37°C. Zones were determined from two independent cultures and in duplicate or 
in triplicate and values vary by less than 10%. 
 Minimal Inhibitory Concentrations (MICs) were determined by measuring 
growth of bacterial cultures on media containing different concentrations of 
various inhibitors. Approximately 1 x 106 cells, mixed with twofold serial 
dilutions of inhibitors in microtiter plates, were incubated at 37°C for 18h. OD600 
was measured by a microtiter plate reader (Molecular Devices VERSAmax), and 
values were plotted against inhibitor concentrations. MIC values were 
extrapolated from linear regressions obtained from OD600/concentration plots. 
Growth was measured from two independent cultures and in duplicates. 
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 Relative growth in the presence of select inhibitors was done by streaking 
bacteria onto LBA plates containing specific concentrations of specific substrates 
of the AcrAB-TolC complex. Plates were grown for 16h at 37°C. Relative colony 
size of mutants was compared to null and wild type controls. To confirm lack of 
growth in the presence of a specific substrate combination/concentration was due 
specifically to the inhibitor, the same colony was simultaneously grown on a plate 
without substrates. 
 
Membrane Preparation and Protein Isolation 
 Equivalent amounts of cells from overnight cultures, based on OD600, were 
pelleted and resuspended in a lysis buffer and membranes were prepared as 
described by Gerken et al. (2010). Membranes were resuspended in 10mM Tris-
HCl pH 7.5. Membrane fractions were analyzed by SDS-PAGE followed by 
either Coomassie Staining or Western Blot. 
 Overnight cultures were diluted 1:100 and grown to log phase (OD600 0.6 
– 0.8) and induced with IPTG (0.4mM) for 4h (TolC) or overnight (AcrB). TolC 
cultures were lysed as described above and membranes were homogenized in 2X 
TolC Extraction Buffer (40 mM sodium phosphate pH 7.4, 250 mM NaCl, 40 mM 
imidazole). Post homogenization, equivalent volumes of 10% Triton was added. 
Samples were rocked at 4C for 1hr and subsequently centrifuged for 1h at 
105,000 X g, 4C. The soluble protein was then applied to a pre-equilibrated Ni-
nitrilotriacetic acid (NTA) column (HisTrap, GE Healthcare); the column was 
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equilibrated with TolC Binding Buffer (20 mM sodium phosphate pH 7.4, 125 
mM NaCl, 1% Triton X-100, 20 mM imidazole). After applying the solubilized 
proteins to the column, the column was washed with 6 column volumes of 
Binding Buffer, followed by 6 column volumes of TolC Wash Buffer 1 (20 mM 
sodium phosphate pH 7.4, 250 mM NaCl, 50 mM imidazole, 1% Triton X-100) 
and TolC Wash Buffer 2 (20 mM sodium phosphate pH 7.4, 250 mM NaCl, 50 
mM imidazole, 0.03% n-dodecyl-β-D-maltoside). The TolC was then eluted with 
13 column volumes of TolC Elution Buffer (20 mM sodium phosphate pH 7.4, 
250 mM NaCl, 300 mM imidazole, 0.03% n-dodecyl-β-D-maltoside). 
AcrB cultures were spun down and the cell pellet was resuspended in a 
plasmolysis buffer as described by Morona and Reeves (1981) with the following 
modifications. For a 500 ml culture, cells were pelleted and resuspended in 4 ml 
of 20% sucrose in 30mM Tris-HCl pH 7.5, 0.4 ml of 0.1 M PMSF 
[phenylmethylsufonyl floride] in DMSO, 0.4 ml of 10mg ml-1 lysozyme in 0.1 M 
EDTA pH 8.0, and 20 µl of 10 mg ml-1 Dnase I. Cells were incubated on ice for 
30 minutes, diluted in 15.2 ml of 3 mM EDTA pH 8.0, and then lysed by French 
press. Following a low speed spin to remove unlysed cells, cell lysates were 
centrifuged for 1h at 105,000 X g, 4°C to separate soluble from insoluble (inner 
and outer membranes). The insoluble fraction was resuspended in an AcrB 
extraction buffer (5 mM imidazole, 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 1% 
DDM) and rocked overnight to solubilize the protein from the insoluble fraction. 
The solution was centrifuged for 1h at 105,000 X g 4°C to separate the soluble 
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from insoluble fractions. The soluble fraction was then applied to a pre-
equilibrated Ni-NTA column. The column was equilibrated and washed with10 
column volumes of four buffers (20 mM Tris-HCl pH 8, 500 mM NaCl, 0.03% 
DDM, 2 mM PMSF) varying only in imidazole concentration; 5 mM, 20 mM, 50 
mM, 100 mM. The protein was finally eluted from the column using an extraction 
buffer (500 mM imidazole, 20 mM Tris-HCl pH 8, 500 mM NaCl, 0.03% DDM, 
2 mM PMSF). The protein was dialyzed to remove the Imidazole using dialysis 
buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.03% DDM, 0.1 mM PMSF), 
which it was then stored in. 
 Protein concentration was determined using a Coomassie (Bradford) 
Protein Assay Kit (Pierce) following the manufacturer’s instructions. Microtiter 
plates were read using a microtiter plate reader (Molecular Devices VERSAmax). 
Protein quantities were determined using exponential regression from a Bovine 
Serum Albumin (BSA) standard by the software SoftMax Pro 5.2. 
 
Chemical Cross-Linking 
 Cross-linking was carried out essentially as described by Vuong et al. 
(2008). Briefly, overnight cultures were diluted 1:100 in LB (40 ml). After an 
hour, cultures were induced with 0.4 mM IPTG and 0.2% arabinose, and grown 
for an additional 4 hours. Cells were spun down, washed with 20 mM sodium 
phosphate pH 7.4, resuspened in 10 ml of 20 mM sodium phosphate pH 7.4, and 
split into thirds cultures; 12.5 ml cultures were used for each treatment. The 
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cultures were treated with DSP [dithiobis (succinimidylpropionate)] (0.5 mM; 
Pierce), SPDP [N-succinimidyl 3-(2-pyridyldithio) propionate] (0.2 mM; Pierce), 
or Dimethyl Sulfoxide (DMSO) for 30min at 37°C on a rotating mixer. The 
reactions were quenched with 40 mM Tris-HCl pH 7.5/25 mM L-cysteine. Cells 
were spun down and solubilized in PUTTS Buffer (100 mM NaH2PO4, 8 M Urea, 
10 mM Tris-HCl pH 7.5, 1% Triton X-100, 0.2% sarkosyl) with 10 mM 
Imidazole for 1h at room temperature. Cross-linked proteins were purified using 
Ni-NTA spin columns (Qiagen). Briefly, 600 µl of sample was passed through 
Ni-NTA columns pre-equilibrated with PUTTS, 10 mM imidazole. The column 
was washed three times with PUTTS, 100 mM imidazole. Finally, the protein was 
eluted with 130 µl of PUTTS, 500 mM imidazole. All spins were done at 400 X g 
or 800 X g. Elutes were mixed with SDS sample buffer, boiled for 5 min, and 
resolved on an 11% SDS-polyacrylamide gel. Proteins were visualized by 
Western Blot using α-TolC/MBP or α-AcrA6His primary antibodies followed by 
goat anti-rabbit HRP conjugated IgG secondary antibodies. 
 
Limited Proteolysis 
 Limited proteolysis of AcrA was performed as described in Ge et al. 
(2009) with a few modifications. Overnight cultures were diluted 1:100 in LB and 
grown to OD600. 100 ml samples were taken and membranes were prepared by 
plasmolysis followed by French press. Samples were resuspended in 100 µl of 10 
mM Tris-HCl pH 7.5. 5 µl of membranes were mixed with 43 µl of 10 mM Tris-
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HCl pH 7.5, and 2 µl of trypsin (final concentrations of 0, 0.1, 1.0, and 10 µg µl-1) 
in 10 mM Tris-HCl pH 7.5. The digestion was left for 5min or 60min at 25°C and 
stopped with 2 µl of 0.05 M PMSF in isopropyl alcohol (final concentration 2 
mM). Samples were mixed with SDS sample buffer, boiled for 5min, and 
resolved on an 11% SDS-polyacrylamide gel. 
 Limited proteolysis of AcrB was performed using purified protein, as 
described previously. 4000 ng of protein was mixed with AcrB Storage Buffer 
without PMSF (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.03% DDM) to a final 
volume of 45µl and 5 µl of Proteinase K (final concentrations of 0, 1.0 and 10 µg 
µl-1). The reaction was allowed to proceed for 5min at 25°C. 5 µl of PMSF in 
isopropyl alcohol or 2.5 µl of PMSF in DMSO were added to stop the reaction. 
Sample were mixed in SDS sample buffer, heated to 60°C for 10min, and 
resolved by 7.5% SDS-polyacrylamide gels. 
 
Crystal Structures of Mutant Proteins 
 Molecular models were created of TolC, AcrA, and AcrB using the 
program PyMol. The following Protein Data Bank files were used; 1EK9 – TolC 
wild type, 2XMN – TolC open state, 2F1M – AcrA, and 2GIF – AcrB. All of the 
mutant proteins have been visualized and colored by chain. Point mutations are 
shown in stick form. Residue numbers are of the mature protein and missense 
mutations are listed. 
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Table 8. List of Strains. 
Strain 
Relavant Chromosomal 
genotypea Plasmid 1b Plasmid 2b Reference 
B51-1 MC4100 ∆tolC::Cmr  pTrc99a- tolC 
(TolC BspHI 
Clone) 
 Augustus et 
al., 2004 
B51-2 MC4100 ∆tolC::Cmr pTrc99a-   Augustus et 
al., 2004 
B51-3 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 Weeks et al., 
2010 
B51-4 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
  Augustus et 
al., 2004 
B51-5 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This study 
B51-6 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This study 
B51-7 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This study 
B51-8 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This study 
B51-9 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This study 
B51-10 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 This study 
B51-11 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 This study 
B51-12 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 This study 
B51-13 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 This study 
B51-14 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 This study 
B51-15 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a-  
TolC147AGSG150 
 This study 
B51-16 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- 
TolC147AGSG150 
 This study 
B51-17 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
  This study 
B51-18 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
  This study 
B51-19 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
  This study 
B51-20 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
  This study 
B51-21 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
  This study 
B51-22 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
  This study 
B51-23 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
  This study 
B51-24 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, A128V 
 This study 
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B51-25 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, I133S 
 This study 
B51-26 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, D153E 
 This study 
B51-27 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, S350A 
 This study 
B51-28 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, R390C 
 This study 
B51-29 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-30 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-31 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-32 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-33 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-34 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-35 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a-   This study 
B51-36 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-37 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-38 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-39 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-40 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-41 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-42 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-43 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(NcoI clone) 
 This study 
B51-44 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(NcoI clone) 
 This study 
B51-45 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(NcoI clone) 
 This study 
B51-46 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(NcoI clone) 
 This study 
B51-47 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(NcoI clone) 
 This study 
B51-48 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a-  TolC 
(NcoI clone) 
 This study 
B51-49 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
(NcoI clone) 
 This study 
B51-50 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
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B51-51 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
B51-52 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
B51-53 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
B51-54 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
B51-55 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
B51-56 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 This study 
B51-57 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a- TolC 
[147AGSG150, 6 His] 
 This study 
B51-58 MC4100 ∆tolC::Cmr    Augustus et 
al., 2004 
B51-59 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a- TolC6 
His 
pACYC184-  
AcrAL222Q 
Weeks et al., 
2010 
B51-60 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
147AGSG150, 6 His 
pACYC184-  
AcrAL222Q 
Weeks et al., 
2010 
B51-61 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a- TolC 
147AGSG150, A128V 
 This study 
B51-62 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a- TolC 
147AGSG150, I133S 
 This study 
B51-63 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a- TolC 
147AGSG150, D153E 
 This study 
B51-65 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a- TolC 
147AGSG150, R390C 
 This study 
B51-66 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
147AGSG150 
 Weeks et al., 
2010 
B51-67 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
  Gerken and 
Misra, 2004 
B51-68 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
(NcoI clone) 
 Augustus et 
al., 2004 
B51-69 MC4100 ∆tolC::Cmr pTrc99a- TolC 
[P246R, S350C] NCOI 
 Gerken and 
Misra, 2004 
B51-70 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-   Gerken and 
Misra, 2004 
B51-71 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 Weeks et al., 
2010 
B51-72 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
(NcoI clone) 
 Gerken and 
Misra, 2004 
B51-73 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
[P246R, S350C] NCOI 
 Gerken and 
Misra, 2004 
B51-74 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
  Augustus et 
al., 2004 
B51-75 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a-   This Study 
B51-76 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-77 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a-  TolC 
147AGSG150 
 This Study 
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B51-78 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
pTrc99a- TolC 
(NcoI clone) 
 This Study 
B51-79 MC4100 ∆recA::Kmr pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-80 MC4100 ∆recA::Kmr pTrc99a-   This Study 
B51-81 MC4100 ∆recA::Kmr pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-82 MC4100 ∆recA::Kmr pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-83 MC4100 ∆recA::Kmr pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-84 MC4100 ∆recA::Kmr pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-86 MC4100 ∆recA::Kmr pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-87 MC4100 ∆recA::Kmr   This Study 
B51-88 MC4100   Casaban, 1976 
B51-89 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
  This Study 
B51-90 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTCR- TolC6 His pACYC184-  
AcrA 
This Study 
B51-91 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, 6 His] 
pACYC184-  
AcrA 
This Study 
B51-92 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTCR- TolC6 His  This Study 
B51-93 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrA 
 This Study 
B51-94 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrAL222Q 
 This Study 
B51-95 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[A128C, 6 His] 
pACYC184-  
AcrA 
This Study 
B51-96 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[A128C, 6 His] 
pACYC184-  
AcrAL222Q 
This Study 
B51-97 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC-
147AGSG150, 6 His] 
 This Study 
B51-98 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[A128C, 6 His] 
 This Study 
B51-99 XL1 Blue   Stratagene 
B51-100 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
 This Study 
B51-101 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
pACYC184-  
AcrA 
This Study 
B51-102 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
pACYC184-  
AcrAL222Q 
This Study 
B51-103 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, Q142C, 
6 His] 
 This Study 
B51-104 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, Q142C, 
6 His] 
pACYC184-  
AcrA 
This Study 
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B51-105 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, Q142C, 
6 His] 
pACYC184-  
AcrAL222Q 
This Study 
B51-106 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA6 His 
 This Study 
B51-107 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[L222Q, 6 His] 
 This Study 
B51-108 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[A79C, 6 His] 
 This Study 
B51-109 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[A79C, 6 His] 
pTrc99a- TolC 
(BspHI clone) 
This Study 
B51-110 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[A79C, 6 His] 
pTrc99a-  
TolC147AGSG150 
This Study 
B51-111 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[A79C, L222Q, 
6 His] 
 This Study 
B51-112 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- AcrA 
[A79C, L222Q, 6 His] 
pTrc99a- TolC 
(BspHI clone) 
This Study 
B51-113 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- AcrA 
[A79C, L222Q, 6 His] 
pTrc99a- TolC 
147AGSG150 
This Study 
B51-114 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[S83C, 6 His] 
 This Study 
B51-115 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[S83C, 6 His] 
pTrc99a- TolC 
(BspHI clone) 
This Study 
B51-116 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[S83C, 6 His] 
pTrc99a- TolC 
147AGSG150 
This Study 
B51-117 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- AcrA 
[S83C, L222Q, 6 His] 
 This Study 
B51-118 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[S83C, L222Q, 6 
His] 
pTrc99a- TolC 
(BspHI clone) 
This Study 
B51-119 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[S83C, L222Q, 6 
His] 
pTrc99a- TolC 
147AGSG150 
This Study 
B51-120 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, A128C, 
6 His] 
 This Study 
B51-121 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, A128C, 
6 His] 
pACYC184-  
AcrA 
This Study 
B51-122 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
[147AGSG150, A128C, 
6 His] 
pACYC184-  
AcrAL222Q 
This Study 
B51-123 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-124 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-125 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-127 MC4100 ∆tolC::Cmr 
AcrA[S83G, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-128 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
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B51-129 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-130 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-132 MC4100 ∆tolC::Cmr 
AcrA[G110A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-133 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-134 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-135 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-137 MC4100 ∆tolC::Cmr 
AcrA[G110D, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-138 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-139 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-140 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-142 MC4100 ∆tolC::Cmr 
AcrA[T111A, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-143 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-144 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-145 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-147 MC4100 ∆tolC::Cmr 
AcrA[T111S, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-148 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-149 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-150 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-152 MC4100 ∆tolC::Cmr 
AcrA[A135V, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-153 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-154 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-155 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-157 MC4100 ∆tolC::Cmr 
AcrA[N146Y, L222Q] Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-158 MC4100 ∆tolC::Cmr pTrc99a- TolC6 
His 
 This Study 
B51-159 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a - TolC6 
His 
 This Study 
B51-160 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
[147AGSG150, 6 His] 
 This Study 
     
135 
 
B51-161 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
[147AGSG150, 6 His] 
 This Study 
B51-162 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
[Q142C, 6 His] 
 This Study 
B51-163 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  
TolC[Q142C, 6 His] 
 This Study 
B51-164 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[A128C, 6 His] 
 This Study 
B51-165 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  
TolC[A128C, 6 His] 
 This Study 
B51-166 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
[147AGSG150, Q142C, 
6 His] 
 This Study 
B51-167 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
[147AGSG150, Q142C, 
6 His] 
 This Study 
B51-168 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
[147AGSG150, A128C, 
6 His] 
 This Study 
B51-169 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
[147AGSG150, A128C, 
6 His] 
 This Study 
B51-170 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-171 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC147AGSG150 
 This Study 
B51-172 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA6 His 
pTrc99a-  
TolC (BspHI 
clone) 
This Study 
B51-173 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA6 His 
pTrc99a-  
TolC147AGSG150 
This Study 
B51-174 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[L222Q, 6 His] 
pTrc99a-  
TolC (BspHI 
clone) 
This Study 
B51-175 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pBAD33- 
AcrA[L222Q, 6 His] 
pTrc99a-  
TolC147AGSG150 
This Study 
B51-176 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
  Gerken and 
Misra, 2004 
B51-177 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
  Gerken and 
Misra, 2004 
B51-178 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
  Weeks et al., 
2010 
B51-179 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
  Weeks et al., 
2010 
B51-180 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-181 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a-  
TolC147AGSG150 
 This Study 
B51-182 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-183 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
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B51-184 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-185 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This Study 
B51-186 MC4100 ∆tolC::Cmr AcrAT30A 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-187 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-188 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a-  
TolC147AGSG150 
 This Study 
B51-189 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-190 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-191 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-192 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This Study 
B51-193 MC4100 ∆tolC::Cmr 
AcrAN146T Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-194 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-195 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-196 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-197 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-198 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-199 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This Study 
B51-200 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-201 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-202 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-203 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-204 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-205 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-206 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This Study 
B51-207 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a- TolC  
147AGSG150, R390C 
 This Study 
B51-208 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
  Gerken and 
Misra, 2004 
B51-209 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
  Gerken and 
Misra, 2004 
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B51-210 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-211 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a-  
TolC147AGSG150 
 This Study 
B51-212 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-213 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-214 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This Study 
B51-215 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This Study 
B51-216 MC4100 ∆tolC::Cmr 
AcrAP265R Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-217 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-218 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150 
 This Study 
B51-219 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This Study 
B51-220 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This Study 
B51-221 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E  
 This Study 
     
B51-222 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This Study 
B51-223 MC4100 ∆tolC::Cmr 
AcrA∆217-218 Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This Study 
B51-224 MC4100 ∆tolC::Kmr   Augustus et 
al., 2004 
B51-225 MC4100 pSF4000- 
hlyCABD 
 Welch et al., 
1981 
B51-226 MC4100 ∆tolC::Kmr pTrc99a-   This Study 
B51-227 MC4100 ∆tolC::Kmr pTrc99a-  TolC 
(BspHI clone) 
 This Study 
B51-228 MC4100 ∆tolC::Kmr pTrc99a-  
TolC147AGSG150 
 This Study 
B51-229 MC4100 ∆tolC::Kmr pTrc99a-  pSF4000- 
hlyCABD 
This Study 
B51-230 MC4100 ∆tolC::Kmr pTrc99a-  TolC 
(BspHI clone) 
pSF4000- 
hlyCABD 
This Study 
B51-231 MC4100 ∆tolC::Kmr pTrc99a-  TolC 
147AGSG150 
pSF4000- 
hlyCABD 
This Study 
B51-232 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-233 MC4100 ∆tolC::Cmr 
AcrAT111P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-234 MC4100 ∆tolC::Cmr 
AcrAA135T Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-235 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
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B51-236 MC4100 ∆tolC::Cmr 
AcrAL252R Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This Study 
B51-237 MC4100 ∆ara714    Werner and 
Misra, 2005 
B51-238 MC4100 ∆tolC-scar ∆ara714    Augustus et 
al., 2004 
B51-239 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
  Augustus et 
al., 2004 
B51-240 MC4100 ∆acrAB::Kmr 
∆ara714  
  Augustus et 
al., 2004 
B51-241 MC4100 ∆tolC::Cmr pTrc99a- TolC 
R367E BSPHI 
 This Study 
B51-242 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
R367E BSPHI 
 This Study 
B51-243 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
147AGSG150, R367E 
 This Study 
B51-244 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-TolC 
147AGSG150, R367E 
 This Study 
B51-245 MC4100 ∆tolC::Cmr pTrc99a- TolC 
R390E-BSPHI 
 This Study 
B51-246 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
R390E-BSPHI 
 This Study 
B51-247 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, R390E 
 This Study 
     
B51-248 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390E 
 This Study 
B51-249 MC4100 ∆tolC::Cmr pTrc99a-  TolC 
[R367E, R390E]-BSPHI 
 This Study 
B51-250 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
[R367E, R390E]-BSPHI 
 This Study 
B51-251 MC4100 ∆tolC::Cmr pTrc99a- TolC 
147AGSG150, R367E, 
R390E 
 This Study 
B51-252 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R367E, 
R390E 
 This Study 
B51-253 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
  This Study 
B51-254 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
 This Study 
B51-255 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a-  This Study 
B51-256 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
(BspHI clone) 
This Study 
B51-257 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a-  
TolC147AGSG150 
This Study 
B51-258 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, A128V 
This Study 
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B51-259 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, I133S 
This Study 
B51-260 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, D153E 
This Study 
B51-261 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, S350A 
This Study 
B51-262 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, R390C 
This Study 
B51-263 BW25113 pKD3- Cmr 
gene 
 Datsenko and 
Wanner, 2000 
B51-264 BW25113 pKD4- Kmr 
gene 
 Datsenko and 
Wanner, 2000 
B51-265 BW25113 pKD46- λ rec 
genes 
 Datsenko and 
Wanner, 2000 
B51-266 W4573 (F- lac ara mal xyl mtl 
gal rpsL) ∆emrB::Kmr 
  Thanassi et 
al., 1997 
B51-267 MC 4100 ∆emrAB::Cmr   This study 
B51-268 MC 4100 ∆emrAB::Kmr   This study 
B51-269 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a-  This study 
B51-270 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
(BspHI clone) 
This study 
B51-271 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-272 MC4100 ∆tolC::Kmr 
AcrAS83G Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-273 MC4100 ∆tolC::Kmr 
AcrAT111P Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-274 MC4100 ∆tolC::Kmr 
AcrAA135T Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-275 MC4100 ∆tolC::Kmr 
AcrAT153P Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-276 MC4100 ∆tolC::Kmr 
AcrAL252R Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-277 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, A128V 
This study 
B51-278 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, I133S 
This study 
B51-279 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, D153E 
This study 
B51-280 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, S350A 
This study 
B51-281 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, R390C 
This study 
B51-282 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  
TolC147AGSG150 
 This study 
B51-283 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  TolC 
(BspHI clone) 
pACYC184-  
AcrA 
This study 
B51-284 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  
TolC147AGSG150 
pACYC184-  
AcrA 
This study 
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B51-285 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  
TolC147AGSG150 
pACYC184-  This study 
B51-286 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  
TolC147AGSG150 
pACYC184-  
AcrAT111P 
This study 
B51-287 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  TolC 
147AGSG150 
pACYC184-  
AcrAA135T 
This study 
B51-288 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆acrB::Km
r Tn10 
@ 10.5  
  This study 
B51-289 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆acrB::Km
r Tn10 
@ 10.5  
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-290 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆acrB::Km
r Tn10 
@ 10.5  
pTrc99a-  TolC 
147AGSG150 
 This study 
B51-291 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆acrB::Km
r Tn10 
@ 10.5  
pTrc99a-  TolC 
147AGSG150, I133S 
 This study 
B51-292 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆acrB::Km
r Tn10 
@ 10.5  
pTrc99a-  TolC 
147AGSG150, R390C 
 This study 
B51-293 MC 4100 ∆ara714  
∆emrAB::Cmr 
  This study 
B51-294 MC 4100 ∆ara714  
∆emrAB::Kmr 
  This study 
B51-295 MC4100 ∆ara714  
∆acrAB::Kmr ∆emrAB::Cmr 
  This study 
B51-296 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-   This study 
B51-297 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-298 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This study 
     
B51-299 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, A128V 
 This study 
B51-300 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, I133S 
 This study 
B51-301 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, D153E 
 This study 
B51-302 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, S350A 
 This study 
B51-303 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390C 
 This study 
B51-304 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆emrAB::Km
r Tn10 
@ 10.5 
  This study 
B51-305 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a-   This study 
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B51-306 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-307 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a-  
TolC147AGSG150 
 This study 
B51-308 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a-  TolC 
147AGSG150, I133S 
 This study 
B51-309 MC4100 ∆tolC::Cmr 
AcrAL222Q ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a-  TolC 
147AGSG150, R390C 
 This study 
B51-310 MC4100 ∆tolC::Cmr 
∆emrAB::Kmr 
  This study 
B51-311 MC4100 ∆tolC::Cmr 
∆emrAB::Kmr 
pTrc99a-   This study 
B51-312 MC4100 ∆tolC::Cmr 
∆emrAB::Kmr 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-313 MC4100 ∆tolC::Cmr 
∆emrAB::Kmr 
pTrc99a- TolC 
147AGSG150 
 This study 
B51-314 MC4100 ∆tolC::Cmr 
AcrAT111P Tn10 @ 10.5 
  This study 
B51-315 MC4100 ∆tolC::Cmr 
AcrAT111P ∆emrAB::Km
r Tn10 
@ 10.5 
  This study 
B51-316 MC4100 ∆tolC::Cmr 
AcrAT111P ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a- TolC 
147AGSG150 
 This study 
B51-317 MC4100 ∆tolC::Cmr 
AcrAL252R Tn10 @ 10.5 
  This study 
B51-318 MC4100 ∆tolC::Cmr 
AcrAL252R ∆emrAB::Km
r Tn10 
@ 10.5 
  This study 
B51-319 MC4100 ∆tolC::Cmr 
AcrAL252R ∆emrAB::Km
r Tn10 
@ 10.5 
pTrc99a- TolC 
147AGSG150 
 This study 
B51-320 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
 This study 
B51-321 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
 This study 
B51-322 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
pACYC184-  
AcrAB 
This study 
B51-323 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-TolC 
147AGSG150, Q142C, 6 
His 
 This study 
B51-324 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a- TolC 
147AGSG150, Q142C, 
6His 
pACYC184-  
AcrAB 
This study 
B51-325 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆araTn10 
pTrc99a- TolC6 
His 
pACYC184-  
AcrAB 
This study 
B51-326 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara::Tn10 
pTrc99a- TolC 
147AGSG150, 6 His 
pACYC184-  
AcrAB 
This study 
B51-327 MC4100 ∆emrB::Kmr   This study 
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B51-328 MC4100 ∆ara714  
∆emrB::Kmr 
  This study 
B51-329 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
  This study 
B51-330 MC4100 ∆tolC::Kmr 
AcrAL222Q Tn10 @ 10.5 
pSF4000- 
hlyCABD 
 This study 
B51-331 MC4100 ∆tolC::Kmr ∆acrAB-
scar 
pTrc99a-  TolC 
(BspHI clone) 
pACYC184-   This study 
B51-332 MC4100 ∆tolC::Kmr ∆acrA-
scar 
pTrc99a-  TolC 
(BspHI clone) 
pACYC184-  
AcrA 
This study 
B51-333 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-   This study 
B51-334 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
(BspHI clone) 
 This study 
B51-335 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150 
 This study 
B51-336 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, A128V 
 This study 
B51-337 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, I133S 
 This study 
B51-338 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, D153E 
 This study 
B51-339 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, L169V 
 This study 
B51-340 MC4100 ∆ara714  ∆tolC-scar 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R390C 
 This study 
B51-341 JM109   This study 
B51-342 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABH1 
(252ESESGWF258) 
 Husain, 2006 
B51-343 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB[H1, R259A] 
 This study 
B51-344 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABFFS 
(252ESESGWFPR260) 
 Husain, 2006 
B51-345 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB[FFS, E254A] 
 This study 
B51-346 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[K383D, 6 His] 
 Bavro et al., 
2008 
B51-347 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[R390E, 6 His] 
 Bavro et al., 
2008 
B51-348 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184-  
AcrAB 
 This study 
B51-349 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184-  
AcrAE118R AcrB 
 Bavro et al., 
2008 
B51-350 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184-  
AcrAD125K AcrB 
 Bavro et al., 
2008 
B51-351 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
 This study 
B51-352 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-   This study 
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B51-353 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC6 
His 
 This study 
B51-354 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
 Bavro et al., 
2008 
B51-355 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
 Bavro et al., 
2008 
B51-356 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  pACYC184-  This study 
B51-357 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a- TolC6 
His 
pACYC184-  
AcrAB 
This study 
B51-358 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a- TolC6 
His 
pACYC184-  
AcrAD125K 
AcrB 
Bavro et al., 
2008 
B51-359 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
pACYC184-  
AcrAD125K 
AcrB 
Bavro et al., 
2008 
B51-360 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
pACYC184-  
AcrAB 
Bavro et al., 
2008 
B51-361 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrAE118R 
AcrB 
This study 
B51-362 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  
AcrAE118R 
AcrB 
This study 
B51-363 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  
AcrAB 
Bavro et al., 
2008 
B51-364 MC4100 ∆acrAB-scar 
∆ara714  
  Augustus et 
al., 2004 
B51-365 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  This study 
B51-366 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
pACYC184-  This study 
B51-367 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  This study 
B51-368 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-   This study 
B51-369 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC6 
His 
 This study 
B51-370 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
 This study 
B51-371 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
 This study 
B51-372 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-   This study 
B51-373 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrA 
 This study 
B51-374 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrAD125K 
 This study 
B51-375 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrAE118R 
 This study 
B51-376 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  pACYC184-  This study 
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B51-377 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrA 
This study 
B51-378 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrAD125K 
This study 
B51-379 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrAE118R 
This study 
B51-380 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
pACYC184-  
AcrA 
This study 
B51-381 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
pACYC184-  
AcrAD125K 
This study 
B51-382 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  
AcrA 
This study 
B51-383 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  
AcrAE118R 
This study 
B51-384 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  This study 
B51-385 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrAD125K 
pTrc99a-  This study 
B51-386 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pACYC184-  
AcrAE118R 
pTrc99a-  This study 
B51-387 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-   This study 
B51-388 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-    This study 
B51-389 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  TolC6 
His 
 This study 
B51-390 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[K383D, 6 His] 
 This study 
B51-391 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[R390E, 6 His] 
 This study 
B51-392 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, 6 His] 
 This study 
B51-393 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L2, 6 His] 
 This study 
B51-394 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, ∆L2, 6 
His] 
 This study 
B51-400 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
  This study 
B51-411 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[D121R, 6 His] 
 This study 
B51-412 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[D121R, 6 His] 
 This study 
B51-413 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[R390D, 6 His] 
 This study 
B51-414 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[R390D, 6 His] 
 This study 
B51-415 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[D121R, R390D, 
6 His] 
 This study 
B51-416 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[D121R, R390D, 
6 His] 
 This study 
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B51-417 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[R367E, 6 His] 
 This study 
B51-418 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[R367E, 6 His] 
 This study 
B51-419 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[R367E, R390E, 
6 His] 
 This study 
B51-420 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[R367E, R390E, 
6 His] 
 This study 
B51-421 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, R367E, 6 
His] 
 This study 
B51-422 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L1, R367E, 6 
His] 
 This study 
B51-423 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, R390E, 6 
His] 
 This study 
B51-424 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L1, R390E, 6 
His] 
 This study 
B51-425 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, R367E, 
R390E, 6 His] 
 This study 
B51-426 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L1, R367E, 
R390E, 6 His] 
 This study 
B51-427 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L2, R367E, 6 
His] 
 This study 
B51-428 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L2, R367E, 6 
His] 
 This study 
B51-429 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L2, R390E, 6 
His] 
 This study 
B51-430 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L2, R390E, 6 
His] 
 This study 
B51-431 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L2, R367E, 
R390E, 6 His] 
 This study 
B51-432 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L2, R367E, 
R390E, 6 His] 
 This study 
B51-433 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, L2, 
R367E, 6 His] 
 This study 
B51-434 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L1, L2, 
R367E, 6 His] 
 This study 
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B51-435 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, L2, 
R390E, 6 His] 
 This study 
B51-436 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L1, L2, 
R390E, 6 His] 
 This study 
B51-437 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[∆L1, L2, 
R367E, R390E, 6 His] 
 This study 
B51-438 MC4100 ∆tolC::Cmr 
∆degP::Kmr 
pTrc99a-  
TolC[∆L1, L2, 
R367E, R390E, 6 His] 
 This study 
B51-439 MC4100 ∆tolC::Cmr pTrc99a-  
TolC[K383D, 6 His] 
 This study 
B51-440 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pTrc99a-  
TolC[K383D, 6 His] 
pACYC184-  
AcrA 
This study 
B51-441 JM109 pBAD33-   This study 
B51-442 MC4100 ∆acrA-scar ∆ara714    This study 
B51-443 MC4100 ∆acrB-scar ∆ara714    Husain, 2006 
B51-444 MC4100 ∆acrA-scar ∆ara714  pBAD33- 
AcrA6 His 
 This study 
B51-445 MC4100 ∆acrA-scar ∆ara714  pBAD33- 
AcrA6 His 
 This study 
B51-446 MC4100 ∆acrA-scar ∆ara714  pBAD33- 
AcrA6 His 
 This study 
B51-507 MC4100 ∆tolC::Cmr Tn10 @ 
10.5 
  This study 
B51-508 MC4100 ∆tolC::Cmr 
∆acrA::Kmr 
  This study 
B51-518 K53 pColicin E1   
B51-519 CA42 pColicin E2   
B51-543 JM109 pACYC184-  
AcrAB 
 This study 
B51-544 JM109 pACYC184-  
AcrAB[H1, R259A]  
 This study 
B51-545 JM109 pACYC184-  
AcrAB  
(SDM 
Correct) 
This study 
B51-546 JM109 pACYC184-  
AcrAB 
(SDM 
Correct) 
This study 
B51-547 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB 
(SDM 
Correct) 
This study 
B51-548 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB 
(SDM 
Correct) 
This study 
B51-550 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-551 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1 
 This study 
B51-562 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-    This study 
B51-563 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
 This study 
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B51-564 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-565 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-   This study 
B51-566 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a- TolC6 
His 
 This study 
B51-567 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R367E, 6 His] 
 This study 
B51-568 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
 This study 
B51-569 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-  This study 
B51-570 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  
TolC6 His 
This study 
B51-571 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
pTrc99a-  
TolC6 His 
This study 
B51-572 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
pTrc99a- TolC 
[R367E, 6 His] 
This study 
B51-573 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
pTrc99a- TolC 
[R390E, 6 His] 
This study 
B51-574 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  pACYC184-   This study 
B51-575 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrAB 
This study 
B51-576 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrAB∆L1 
This study 
B51-577 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R367E, 6 His] 
pACYC184-  
AcrAB∆L1 
This study 
B51-578 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  
AcrAB∆L1 
This study 
B51-579 MC4100 ∆tolC-scar 1   This study 
B51-580 MC4100 ∆tolC-scar 2   This study 
B51-591 MC4100 ∆acrAB-scar pACYC184- 
AcrABD256A, 
D795A 
 This study 
B51-592 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  This study 
B51-593 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  
TolC[R367E, 6 
His] 
This study 
B51-594 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  
TolC[R390E, 6 
His] 
This study 
B51-607 acrF::Tn10    
B51-608 MC4100 ∆ara714  
acrF::Tn10 
  This study 
B51-609 MC4100 ∆ara714  
acrF::Tn10 
  This study 
B51-610 MC4100 ∆tolC-scar ∆ara714  
acrF::Tn10 
  This study 
B51-611 MC4100 ∆tolC-scar ∆ara714  
acrF::Tn10 
  This study 
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B51-612 MC4100 ∆acrAB::Kmr 
∆ara714  acrF::Tn10 
  This study 
B51-613 MC4100 ∆acrAB::Kmr 
∆ara714  acrF::Tn10 
  This study 
B51-614 MC 4100 ∆ara714  
∆emrAB::Cmr acrF::Tn10 
  This study 
B51-615 MC 4100 ∆ara714  
∆emrAB::Cmr acrF::Tn10 
  This study 
B51-616 MC4100 ∆ara714  
∆acrAB::Kmr ∆emrAB::Cmr 
acrF::Tn10 
  This study 
B51-617 MC4100 ∆ara714  
∆acrAB::Kmr ∆emrAB::Cmr 
acrF::Tn10 
  This study 
B51-737 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-738 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-739 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrA73DP74→ET 
AcrB∆L1 
 This study 
B51-740 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAE237V 
AcrB∆L1 
 This study 
B51-741 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-742 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-743 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-744 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC6 His 
This study 
B51-745 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC[R367E, 6 
His] 
This study 
B51-746 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC[R390E, 6 
His] 
This study 
B51-747 JM109 pBAD24-  This study 
B51-748 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L2 
 This study 
B51-750 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL2 
 This study 
B51-752 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2 
 This study 
B51-754 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2 
 This study 
B51-756 JM109 pACYC184-   This study 
B51-757 JM109 pACYC184-  
AcrAB∆L1 
 This study 
B51-758 JM109 pACYC184-  
AcrABPAL1 
 This study 
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B51-759 JM109 pACYC184-  
AcrAB∆L2 
 This study 
B51-760 JM109 pACYC184-  
AcrABPAL2 
 This study 
     
B51-761 JM109 pACYC184-  
AcrABPAL1/L2 
 This study 
B51-762 JM109 pACYC184-  
AcrABPAL1/L2 
 This study 
B51-765 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAT224S 
AcrB∆L1 
 This study 
B51-766 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrB∆L1 
 This study 
B51-767 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrB∆L1 
 This study 
B51-768 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222R 
AcrB∆L1 
 This study 
B51-769 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrA∆222-224 
AcrB∆L1 
 This study 
B51-770 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAF230S 
AcrB∆L1 
 This study 
B51-771 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAF230S 
AcrB∆L1 
 This study 
B51-772 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAF230S 
AcrB∆L1 
 This study 
B51-773 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAF230S 
AcrB∆L1 
 This study 
B51-774 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrB∆L1 
 This study 
B51-775 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAE43K 
AcrB∆L1 
 This study 
B51-776 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAV44I 
AcrB∆L1 
 This study 
B51-777 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS195P 
AcrB∆L1 
 This study 
B51-778 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS249C 
AcrB∆L1 
 This study 
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B51-779 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS83G 
AcrB∆L1 
 This study 
B51-780 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAT111P 
AcrB∆L1 
 This study 
B51-781 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAA135T 
AcrB∆L1 
 This study 
B51-782 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAN146T 
AcrB∆L1 
 This study 
B51-783 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABHis 
 This study 
B51-784 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABHis 
 This study 
B51-785 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2 
 This study 
B51-786 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2 
 This study 
B51-787 MC4100 ∆recA::Kmr pACYC184-    
 
This study 
B51-788 MC4100 ∆recA::Kmr pACYC184-    This study 
B51-789 MC4100 ∆recA::Kmr pACYC184-  
AcrAB (old) 
 This study 
B51-790 MC4100 ∆recA::Kmr pACYC184-  
AcrAB (old) 
 This study 
B51-791 MC4100 ∆recA::Kmr pACYC184-  
AcrABH1 
(252ESESGWF258) 
 This study 
B51-792 MC4100 ∆recA::Kmr pACYC184-  
AcrABH1 
(252ESESGWF258) 
 
 
 
This study 
B51-793 MC4100 ∆recA::Kmr pACYC184-  
AcrAB (new) 
 
 
This study 
B51-794 MC4100 ∆recA::Kmr pACYC184-  
AcrAB (new) 
 
 
 
 
 
This study 
B51-795 MC4100 ∆recA::Kmr pACYC184-  
AcrAB∆L1 
This study 
B51-796 MC4100 ∆recA::Kmr pACYC184-  
AcrAB∆L1 
This study 
B51-797 MC4100 ∆tolC::Cmr pTrc99a-  
TolC147GAAA150 
This study 
B51-798 MC4100 ∆tolC::Cmr pTrc99a-  
TolC147AAAA150 
This study 
B51-799 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  
TolC147GAAA150 
This study 
B51-800 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  
TolC147AAAA150 
This study 
B51-817 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABKAAAAL1/P
AL2 
 
 
This study 
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B51-818 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAANAAL1/P
AL2 
This study 
B51-819 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAAAQAL1/P
AL2 
This study 
B51-820 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAAAADL1/P
AL2 
This study 
B51-821 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAAAAKL1/P
AL2 
This study 
B51-822 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/AADA
AL2 
 This study 
B51-823 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/AAAA
QL2 
 This study 
B51-824 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABD256A 
 This study 
B51-825 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABD795A 
 This study 
B51-826 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABD256A, 
D795A 
 This study 
B51-827 MC4100 ∆tolC::Cmr pTrc99a-  
TolCG147A 
1 This study 
B51-828 MC4100 ∆tolC::Cmr pTrc99a-  
TolCG147A 
2 This study 
B51-829 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS83G 
AcrBPAL1/L2 
 This study 
B51-830 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAA135T 
AcrBPAL1/L2 
 This study 
B51-831 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrBPAL1/L2 
 This study 
B51-832 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrBPAL1/L2 
 This study 
B51-833 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABR971A 
 This study 
B51-834 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrBR971A 
 This study 
B51-835 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrBR971A 
 This study 
B51-836 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABD407A 
 This study 
     
     
152 
 
B51-837 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrBD407A 
 This study 
B51-838 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrBD407A 
 This study 
B51-839 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABF136A 
 This study 
B51-840 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABF610A 
 This study 
B51-841 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABF615A 
 This study 
B51-842 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABHis 
 This study 
B51-843 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, His 
 This study 
B51-844 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-    This study 
B51-845 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
 This study 
B51-846 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2 
 This study 
B51-847 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
 This study 
B51-848 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL222Q 
AcrB∆L1 
 This study 
B51-849 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAG248E 
AcrB∆L1 
 This study 
B51-850 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q AcrB 
 This study 
B51-851 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E AcrB 
 This study 
B51-852 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrBF136A 
 This study 
B51-853 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrBF136A 
 This study 
B51-854 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrBF610A 
 This study 
B51-855 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrBF610A 
 This study 
B51-856 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrBF615A 
 This study 
B51-857 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAG248E 
AcrBF615A 
 This study 
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B51-858 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-   pACYC184-  
AcrABPAL1/L2 
This study 
B51-859 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC6 
His 
pACYC184-  
AcrABPAL1/L2 
This study 
B51-860 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R367E, 6 His] 
pACYC184-  
AcrABPAL1/L2 
This study 
B51-861 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[R390E, 6 His] 
pACYC184-  
AcrABPAL1/L2 
This study 
B51-862 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABHis (Cys less) 
 This study 
B51-863 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, His (Cys 
less) 
1 This study 
B51-864 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, His (Cys 
less) 
2 This study 
B51-865 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1, His 
(Cys less) 
 This study 
B51-866 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
 This study 
B51-867 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAK58C 
AcrBHis (Cys less) 
 This study 
B51-868 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS196C 
AcrBHis (Cys less) 
 This study 
B51-869 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, His (Cys 
less) 
 This study 
B51-870 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAK58C 
AcrB∆L1, His (Cys 
less) 
 This study 
B51-871 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS196C 
AcrB∆L1, His (Cys 
less) 
 This study 
B51-872 MC4100 AcrAL222Q 
∆acrB::Kmr Tn10 @ 10.5 
∆ara714  
 1 This study 
B51-873 MC4100 AcrAL222Q 
∆acrB::Kmr Tn10 @ 10.5 
∆ara714  
 2 This study 
B51-874 MC4100 ∆tolC::Cmr pTrc99a-  
TolCG147C 
 This study 
B51-875 MC4100 ∆tolC::Cmr pTrc99a-  
TolCG365C 
 This study 
B51-876 MC4100 ∆acrB::Kmr 
∆ara714  
pACYC184-   This study 
B51-877 MC4100 ∆acrB::Kmr 
∆ara714  
pACYC184-  
AcrB 
 This study 
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B51-878 MC4100 ∆acrB::Kmr 
∆ara714  
pACYC184-  
AcrB∆L1 
 This study 
B51-879 MC4100 ∆acrB::Kmr 
∆ara714  
pACYC184-   This study 
B51-880 MC4100 ∆acrB::Kmr 
∆ara714  
pACYC184-  
AcrB 
 This study 
B51-881 MC4100 ∆acrB::Kmr 
∆ara714  
pACYC184-  
AcrB∆L1 
 This study 
B51-882 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
 This study 
B51-883 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
 This study 
B51-884 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
 This study 
B51-885 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
 This study 
B51-886 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  pTrc99a-   This study 
B51-887 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  pTrc99a- TolC 
(NcoI clone) 
This study 
B51-888 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-889 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrB 
pTrc99a-   This study 
B51-890 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrB 
pTrc99a- TolC 
(NcoI clone) 
This study 
B51-891 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrB 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-892 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrB∆L1 
pTrc99a-   This study 
B51-893 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrB∆L1 
pTrc99a- TolC 
(NcoI clone) 
This study 
B51-894 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-895 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
 This study 
B51-896 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1, His 
 This study 
B51-897 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
  This study 
B51-898 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
  This study 
B51-899 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-    This study 
     
     
155 
 
B51-900 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
Corrected by 
SDM (JW) - 
AcrAN244D 
This study 
B51-901 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
Corrected by 
SDM (JW) - 
AcrAN244D 
This study 
B51-902 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA 
Corrected by 
SDM (JW) - 
AcrAN244D 
This study 
B51-903 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
Corrected by 
SDM (JW) - 
AcrAN244D 
This study 
B51-904 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-   pTrc99a-   This study 
B51-905 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-906 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC147AGSG150 
This study 
B51-907 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-   This study 
B51-908 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-909 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  
TolC147AGSG150 
This study 
B51-910 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-   This study 
B51-911 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-912 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC147AGSG150 
This study 
B51-913 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-   This study 
B51-914 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-915 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC147AGSG150 
This study 
B51-916 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-   This study 
B51-917 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-918 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  
TolC147AGSG150 
This study 
B51-919 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-   This study 
B51-920 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC (BspHI 
clone) 
This study 
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B51-921 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC147AGSG150 
This study 
B51-922 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-   pTrc99a-   This study 
B51-923 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-924 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-   pTrc99a-  
TolC147AGSG150 
This study 
B51-925 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-   This study 
B51-926 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-927 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
pTrc99a-  
TolC147AGSG150 
This study 
B51-928 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-   This study 
B51-929 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC (BspHI 
clone) 
This study 
B51-930 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC147AGSG150 
This study 
B51-931 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-    This study 
B51-932 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrA 
Corrected by 
SDM (JW) - 
AcrAN244D 
This study 
     
B51-933 MC4100 ∆tolC-scar 
∆acrA::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
Corrected by 
SDM (JW) - 
AcrAN244D 
This study 
B51-934 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
pACYC184-  
AcrAB 
This study 
B51-935 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
pACYC184-  
AcrA 
This study 
B51-936 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  
TolC[Q142C, 6 His] 
pACYC184-  
AcrB 
This study 
B51-937 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC-
147AGSG150, 
Q142C, 6 His] 
pACYC184-  
AcrAB 
This study 
B51-938 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC-
147AGSG150, 
Q142C, 6 His] 
pACYC184-  
AcrA 
This study 
B51-939 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pTrc99a-  TolC-
147AGSG150, 
Q142C, 6 His] 
pACYC184-  
AcrB 
This study 
B51-940 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
2 This study 
B51-941 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolC 
This study 
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B51-942 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-943 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-944 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-945 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-946 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-947 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-948 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-949 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-950 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-951 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-952 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-953 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-954 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-955 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-956 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-957 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-958 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolCG365C 
This study 
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B51-959 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAE43K 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-960 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAV44I 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-961 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS195P 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-962 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL222Q 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-963 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL222R 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-964 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA∆222-224 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-965 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAT224S 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-966 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAF230S 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-967 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAG248E 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-968 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS249C 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C] NCOI 
This study 
B51-969 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC147AGSG150 
This study 
B51-970 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
pTrc99a-  
TolC147AGSG150 
This study 
B51-971 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G AcrB 
pTrc99a-  
TolC147AGSG150 
This study 
B51-972 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G AcrB 
pTrc99a-  
TolC147AGSG150 
This study 
B51-973 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
AcrBD407A 
pTrc99a-  
TolC147AGSG150 
This study 
B51-974 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS83G 
AcrBD407A 
pTrc99a-  
TolC147AGSG150 
This study 
B51-975 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolC 
This study 
B51-976 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1, His 
pTrc99a-  
TolC 
This study 
B51-979 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  
TolC147AGSG150 
This study 
B51-980 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  
TolC147AGSG150 
This study 
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B51-981 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD407A 
pTrc99a-  
TolC147AGSG150 
This study 
B51-982 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD407A 
pTrc99a-  
TolC147AGSG150 
This study 
B51-983 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL252R 
pTrc99a-  
TolC147AGSG150 
This study 
B51-984 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL252R 
pTrc99a-  
TolC147AGSG150 
This study 
B51-985 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL252R AcrB 
pTrc99a-  
TolC147AGSG150 
This study 
B51-986 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL252R AcrB 
pTrc99a-  
TolC147AGSG150 
This study 
B51-987 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL252R 
AcrBD407A 
pTrc99a-  
TolC147AGSG150 
This study 
B51-988 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL252R 
AcrBD407A 
pTrc99a-  
TolC147AGSG150 
This study 
B51-989 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R367E 
 This study 
B51-990 MC4100 ∆tolC::Cmr AcrAS83G 
Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R390E 
 This study 
B51-991 MC4100 ∆tolC::Cmr 
AcrAT111P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R367E 
 This study 
B51-992 MC4100 ∆tolC::Cmr 
AcrAT111P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R390E 
 This study 
B51-993 MC4100 ∆tolC::Cmr 
AcrAA135T Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R367E 
 This study 
B51-994 MC4100 ∆tolC::Cmr 
AcrAA135T Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R390E 
 This study 
B51-995 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R367E 
 This study 
B51-996 MC4100 ∆tolC::Cmr 
AcrAT153P Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R390E 
 This study 
B51-997 MC4100 ∆tolC::Cmr 
AcrAL252R Tn10 @ 10.5 
pTrc99a-  TolC 
147AGSG150, R367E 
 This study 
B51-998 MC4100 ∆tolC::Cmr 
AcrAL252R Tn10 @ 10.5 
pTrc99a- TolC 
147AGSG150, R390E 
 This study 
B51-999 BL21   Novogen 
B51-1000 BL21 (DE3)   Novogen 
B51-1001 BL21 (DE3) pLys  Novogen 
B51-1002 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1003 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1004 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
     
160 
 
B51-1005 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAE43K 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1006 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAV44I 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1007 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS195P 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1008 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL222Q 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1009 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL222R 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1010 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA∆222-224 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1011 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAT224S 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1012 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAF230S 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1013 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAG248E 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1014 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS249C 
AcrB∆L1 
pTrc99a- 
TolC[P246R, 
S350C, 6 His] BspHI 
This study 
B51-1015 JM109 pET24a(+) -   This study 
B51-1016 JM109 pET24a(+) - 
AcrB[G288C, F615A, 
His] 
 This study 
B51-1017 JM109 pET24a(+) - 
AcrB[G288C, F615A, 
His] 
 This study 
B51-1018 JM109 pET24a(+) - 
AcrB[G288C, F615A, 
His] 
 This study 
     
B51-1019 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1020 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolCG365C 
This study 
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B51-1021 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1022 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1023 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1033 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
  This study 
B51-1034 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
  This study 
B51-1035 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
  This study 
B51-1036 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
  This study 
B51-1037 MC4100 ∆ara714 714 
rfa2057 
  This study 
B51-1038 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC  This study 
B51-1039 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  TolC  This study 
B51-1040 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG147C 
 This study 
B51-1041 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  
TolCG147C 
 This study 
B51-1042 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG365C 
 This study 
B51-1043 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  
TolCG365C 
 This study 
B51-1044 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1045 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1046 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  TolC pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1047 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC pACYC184-  
AcrABQ255C, His 
(Cys less) 
This study 
B51-1048 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC pACYC184-  
AcrABQ255C, His 
(Cys less) 
This study 
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B51-1049 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  TolC pACYC184-  
AcrABQ255C, His 
(Cys less) 
This study 
B51-1050 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC pACYC184-  
AcrABD795C, His 
(Cys less) 
This study 
B51-1051 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  TolC pACYC184-  
AcrABD795C, His 
(Cys less) 
This study 
B51-1052 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  TolC pACYC184-  
AcrABD795C, His 
(Cys less) 
This study 
B51-1053 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG147C 
pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1054 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG147C 
pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1055 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  
TolCG147C 
pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1056 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG147C 
pACYC184-  
AcrABQ255C, His 
(Cys less) 
This study 
B51-1057 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG147C 
pACYC184-  
AcrABQ255C, His 
(Cys less) 
This study 
B51-1058 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  
TolCG147C 
pACYC184-  
AcrABQ255C, His 
(Cys less) 
This study 
B51-1059 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG365C 
pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1060 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG365C 
pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1061 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  
TolCG365C 
pACYC184-  
AcrABHis (Cys 
less) 
This study 
B51-1062 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG365C 
pACYC184-  
AcrABD795C, His 
(Cys less) 
This study 
B51-1063 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
pTrc99a-  
TolCG365C 
pACYC184-  
AcrABD795C, His 
(Cys less) 
This study 
B51-1064 MC4100 ∆acrAB-scar 
∆ara714  ∆tolC::Tn10 
∆dsbA::Kmr 
pTrc99a-  
TolCG365C 
pACYC184-  
AcrABD795C, His 
(Cys less) 
This study 
B51-1065 MC4100 tolC::Tn10   Morano and 
Reeves, 1981 
B51-1066 MC4100 ∆tolC::Kmr   Augustus et 
al., 2004 
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B51-1070 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolC 
This study 
B51-1071 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolC 
This study 
B51-1072 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolCG365C 
This study 
B51-1073 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolCG365C 
This study 
B51-1074 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolC 
This study 
B51-1075 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolC 
This study 
B51-1076 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1077 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1078 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-1079 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-1080 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1081 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABD795C, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1082 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolCG147C 
This study 
B51-1083 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis 
pTrc99a-  
TolCG147C 
This study 
B51-1084 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1085 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABHis (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1086 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-1087 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-1088 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1089 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABQ255C, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1090 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
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B51-1091 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolC 
This study 
B51-1092 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1093 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1094 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1095 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, His 
(Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1096 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-1097 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-1098 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1099 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A255C, His (Cys less) 
pTrc99a-  
TolCG147C 
This study 
B51-1100 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-1101 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolC 
This study 
B51-1102 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1103 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrABPAL1/L2, 
A795C, His (Cys less) 
pTrc99a-  
TolCG365C 
This study 
B51-1155 BL21(DE3) pET24d- 
AcrA45-312  
1.2 This study 
B51-1156 BL21(DE3) pET24d- 
AcrA45-312  
2.1 This study 
B51-1157 BL21(DE3) pLysS pET24d- 
AcrA45-312  
This study 
B51-1158 BL21(DE3) pLysS pET24d- 
AcrA45-312  
This study 
B51-1159 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC-
147AGSG150, 
S350A 
 This study 
B51-1160 MC4100 ∆tolC::Cmr 
AcrAL222Q Tn10 @ 10.5 
pTrc99a-  TolC-
147AGSG150, 
S350A 
 This study 
165 
 
B51-1161 BL21 (DE3) pET24d- 
AcrAHis (full 
length) 
 This study 
B51-1162 JM109 pET24d- 
AcrAHis (full 
length) 
 This study 
B51-1163 JM109 pBAD18- Kmr  This study 
B51-1164 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184-  
AcrAB 
 This study 
B51-1165 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184-  
AcrA 
 This study 
B51-1166 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrA 
 This study 
B51-1167 MC4100 ∆acrAB-scar 
∆ara714  ∆degP::Kmr 
pACYC184-   pTrc99a-  This study 
B51-1168 MC4100 ∆acrAB-scar 
∆ara714  ∆degP::Kmr 
pACYC184-   pTrc99a- TolC This study 
B51-1169 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a- 
TolCR367E 
This study 
B51-1170 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-   pTrc99a- 
TolCR390E 
This study 
B51-1171 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a-  This study 
B51-1172 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a- TolC This study 
B51-1173 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a- 
TolCR367E 
This study 
B51-1174 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAB 
pTrc99a- 
TolCR390E 
This study 
B51-1175 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAR104D B 
pTrc99a-  This study 
B51-1176 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAR104D B 
pTrc99a- TolC This study 
B51-1177 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAR104D B 
pTrc99a- 
TolCR367E 
This study 
B51-1178 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAR104D B 
pTrc99a- 
TolCR390E 
This study 
B51-1179 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL108D B 
pTrc99a-  This study 
B51-1180 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL108D B 
pTrc99a- TolC This study 
B51-1181 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL108D B 
pTrc99a- 
TolCR367E 
This study 
B51-1182 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAL108D B 
pTrc99a- 
TolCR390E 
This study 
B51-1183 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS115D B 
pTrc99a-  This study 
B51-1184 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS115D B 
pTrc99a- TolC This study 
B51-1185 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS115D B 
pTrc99a- 
TolCR367E 
This study 
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B51-1186 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184-  
AcrAS115D B 
pTrc99a- 
TolCR390E 
This study 
B51-1187 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAR104D B 
 This study 
B51-1188 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS115D B 
 This study 
B51-1189 MC4100 ∆tolC::Cmr pTrc99a-  
TolCA269C, 6His 
 This study 
B51-1190 MC4100 ∆tolC::Cmr pTrc99a-  
TolCT272C, 6His 
 This study 
B51-1191 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABS1043C, His 
(Cys less) 
 This study 
B51-1192 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, S1043C, 
His (Cys less) 
 This study 
B51-1193 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, Q737L, 
His (Cys less) 
 This study 
B51-1194 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABPAL1/L2, 
S1043C, His (Cys less) 
 This study 
B51-1195 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAANAA 
L1/PAL2, His (Cys less) 
 This study 
B51-1196 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAAAAD 
L1/PAL2, His (Cys less) 
 This study 
B51-1197 RAM1009 lamB+ Linked with 
Tn10 (62.3%) 
  This study 
B51-1198 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAB∆L1, 
Q737L,S1043C, His (Cys 
less) 
 This study 
B51-1199 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAANAA 
L1/PAL2, S1043C, His 
(Cys less) 
 This study 
B51-1200 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrABAAAAD 
L1/PAL2, S1043C, His 
(Cys less) 
 This study 
B51-1201 C43    Miroux and 
Walker, 1996 
B51-1202 C43    Miroux and 
Walker, 1996 
B51-1203 JM109 pET24d (+)  This study 
B51-1204 BL21(DE3) ∆acrAB::Kmr pLysS  This study 
B51-1205 BL21(DE3) ∆acrAB::Kmr pLysS  This study 
B51-1206 C43 ∆acrAB::Kmr   This study 
B51-1207 C43 ∆acrAB::Kmr   This study 
B51-1208 BL21(DE3) ∆acrAB::Kmr   This study 
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B51-1209 BL21(DE3) ∆acrAB::Kmr   This study 
B51-1210 C43 ∆acrAB-scar   This study 
B51-1211 C43 ∆acrAB-scar   This study 
B51-1212 BL21(DE3) ∆acrAB-scar   This study 
B51-1213 BL21(DE3) ∆acrAB-scar   This study 
B51-1214 BL21(DE3) ∆acrAB-scar pLysS  This study 
B51-1215 BL21(DE3) ∆acrAB-scar pLysS  This study 
B51-1216 JM109 pET16b- 
AcrBHis 
 Martin Pos 
B51-1217 JM109 pET16b- 
AcrBHis 
 Martin Pos 
B51-1218 JM109 pET24a- 
AcrBHis 
 Martin Pos 
B51-1219 JM109 pET24a- 
AcrBHis 
 Martin Pos 
B51-1220 BL21(DE3) ∆acrAB-scar pET16b- 
AcrBHis 
 This study 
B51-1221 BL21(DE3) ∆acrAB-scar pET16b- 
AcrBHis 
 This study 
B51-1222 C43 ∆acrAB-scar pET16b- 
AcrBHis 
 This study 
B51-1223 C43 ∆acrAB-scar pET16b- 
AcrBHis 
 This study 
B51-1224 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis 
 This study 
B51-1225 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis 
 This study 
B51-1226 C43 ∆acrAB-scar pET24a- 
AcrBHis 
 This study 
B51-1227 C43 ∆acrAB-scar pET24a- 
AcrBHis 
 This study 
B51-1228 JM109 pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1229 JM109 pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1230 JM109 pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1231 JM109 pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1232 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184- 
AcrAB 
 This study 
B51-1233 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184- 
AcrAB 
 This study 
B51-1234 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184- 
AcrAB 
 This study 
B51-1235 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184- 
AcrAB 
 This study 
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B51-1236 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184- 
AcrA 
 This study 
B51-1237 MC4100 ∆acrAB::Kmr 
∆ara714  
pACYC184- 
AcrA 
 This study 
B51-1238 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184- 
AcrA 
 This study 
B51-1239 MC4100 ∆tolC-scar 
∆acrAB::Kmr ∆ara714  
pACYC184- 
AcrA 
 This study 
B51-1240 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1241 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1242 C43 ∆acrAB-scar pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1243 C43 ∆acrAB-scar pET24a- 
AcrBHis, C493S, 
C887S 
 This study 
B51-1244 JM109 pET24a- 
AcrBHis, C/C ∆L1 
 This study 
B51-1245 JM109 pET24a- 
AcrBHis, C/C ∆L1 
 This study 
B51-1246 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1 
 This study 
B51-1247 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1 
 This study 
B51-1248 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1 
 This study 
B51-1249 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1 
 This study 
B51-1250 JM109 pET24a- 
AcrBHis, C/C ∆L1, 
Q737L 
 This study 
B51-1251 JM109 pET24a- 
AcrBHis, C/C ∆L1, 
Q737L 
 This study 
B51-1252 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1, 
Q737L 
 This study 
B51-1253 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1, 
Q737L 
 This study 
B51-1254 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1, 
Q737L 
 This study 
B51-1255 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C ∆L1, 
Q737L 
 This study 
B51-1256 JM109 pET24a- 
AcrBHis, C/C 
PAL1/L2 
 This study 
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B51-1257 JM109 pET24a- 
AcrBHis, C/C 
PAL1/L2 
 This study 
B51-1258 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C 
PAL1/L2 
 This study 
B51-1259 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C 
PAL1/L2 
 This study 
B51-1260 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C 
PAL1/L2 
 This study 
B51-1261 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C 
PAL1/L2 
 This study 
B51-1262 JM109 pET24a- 
AcrBHis, C/C 
AANAA L1/PAL2 
 This study 
B51-1263 JM109 pET24a- 
AcrBHis, C/C 
AANAA L1/PAL2 
 This study 
B51-1264 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AANAA L1/PAL2 
 This study 
B51-1265 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AANAA L1/PAL2 
 This study 
B51-1266 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AANAA L1/PAL2 
 This study 
B51-1267 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AANAA L1/PAL2 
 This study 
B51-1268 JM109 pET24a- 
AcrBHis, C/C 
AAAAD L1/PAL2 
 This study 
B51-1269 JM109 pET24a- 
AcrBHis, C/C 
AAAAD L1/PAL2 
 This study 
B51-1270 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AAAAD L1/PAL2 
 This study 
B51-1271 BL21(DE3) ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AAAAD L1/PAL2 
 This study 
B51-1272 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AAAAD L1/PAL2 
 This study 
B51-1273 C43 ∆acrAB-scar pET24a- 
AcrBHis, C/C 
AAAAD L1/PAL2 
 This study 
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B51-1274 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrB∆L1, His (Cys 
less) 
1 This study 
B51-1275 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAL222Q 
AcrB∆L1, His (Cys 
less) 
2 This study 
B51-1276 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAK58C, L222Q 
AcrB∆L1, His (Cys 
less) 
1 This study 
     
B51-1277 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAK58C, L222Q 
AcrB∆L1, His (Cys 
less) 
2 This study 
B51-1278 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS196C, L222Q 
AcrB∆L1, His (Cys 
less) 
1 This study 
B51-1279 MC4100 ∆acrAB-scar 
∆ara714  
pACYC184-  
AcrAS196C, L222Q 
AcrB∆L1, His (Cys 
less) 
2 This study 
B51-1280 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
 This study 
B51-1281 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- This study 
B51-1282 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
(BspHI clone) 
This study 
B51-1283 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150 
This study 
B51-1284 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, A128V 
This study 
B51-1285 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, I133S 
This study 
B51-1286 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, D153E 
This study 
B51-1287 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, S350A 
This study 
B51-1288 MC4100 ∆tolC::Kmr ∆acrA-
scar ∆ara714  
pSF4000- 
hlyCABD 
pTrc99a- TolC 
147AGSG150, R390C 
This study 
a Genotype of MC4100 is F- araD139 D(argF-lac)U139 rpsL150 flbB5301 
ptsF25 deoC1 thi-1 rbsR relA (Casadaban, 1976). 
b If no plasmid is listed, the strain does not contain a plasmid. Antibiotic 
resistance markers for plasmids are as follows: pTrc99a (Apr; Pharmacia), 
pACYC184 (Tcr, Cmr; Chang and Cohen, 1978); pCP20 (Apr, Cmr, ts replicon, 
thermal induction of FLP synthesis; Datsenko and Wanner, 2000); pKD46 (Apr; 
Lambda-red recombinase; Datsenko and Wanner, 2000); pKD4 (Kmr; Datsenko 
171 
 
and Wanner, 2000); pSF4000-hlyCABD+ (Cmr, expresses Haemolysin proteins 
Welch et al., 1981); pACYC184-acrA (Cmr; expresses wild type AcrA); pBAD33 
(Cmr; Guzman et al., 1995) 
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Table 9. List of primers used in this study 
Primer 
Name Gene SEQuencea Purposeb 
TolC147DE
L F 
tolC CCAACGTTTTAACGTGGCTGGTAGCGATCACCG SDM 
TolC147DE
L R 
tolC CGGTGATCGCTACCAGCCACGTTAAAACGTTGG SDM 
TolCA147G
1 F 
tolC CAACGTTTTAACGTGGGGGGTAGCGGCATCACC SDM 
TolCA147G
1 R 
tolC GGTGATGCCGCTACCCCCCACGTTAAAACGTTG SDM 
TolC147DE
L/150ins F 
tolC CCAACGTTTTAACGTGGCTGGTAGCGGCATCACCG
ACGTGCAGAACG 
SDM 
TolC147DE
L/150ins R 
tolC CGTTCTGCACGTCGGTGATGCCGCTACCAGCCACG
TTAAAACGTTGG 
SDM 
TolCG148L 
F 
tolC CCAACGTTTTAACGTGGGGCTGAGCGGCATCACCG
ACGTGC 
SDM 
TolCG148L 
R 
tolC GCACGTCGGTGATGCCGCTCAGCCCCACGTTAAAA
CGTTGG 
SDM 
TolCL148S 
F 
tolC CCAACGTTTTAACGTGGGCTCCGTAGCGATCACCG
ACGTGC 
SDM 
TolCL148S 
R 
tolC GCACGTCGGTGATCGCTACGGAGCCCACGTTAAAA
CGTTGG 
SDM 
TolCV149S 
F 
tolC CGTTTTAACGTGGGCCTGTCAGCGATCACCGACGT
GCAG 
SDM 
TolCV149S 
R 
tolC CTGCACGTCGGTGATCGCTGACAGGCCCACGTTAA
AACG 
SDM 
TolCA150G 
F 
tolC CGTTTTAACGTGGGCCTGTCAGGGATCACCGACGT
GCAGAACGC 
SDM 
TolCA150G 
R 
tolC GCGTTCTGCACGTCGGTGATCCCTGACAGGCCCAC
GTTAAAACG 
SDM 
#1 tolC CTACAAACAAGCCGTAGTTTGCGCTCAAAGCTCAT
TAGACG 
SDM 
#2 tolC CGTCTAATGAGCTTTGAGCGCAAACTACGGCTTGT
TTGTAG 
SDM 
R367E Top tolC GGCTACTCGGTCGGTACGGAAACCATTGTTGATGT
GTTGG 
SDM 
R367E R tolC CCAACACATCAACAATGGTTTCCGTACCGACCGAG
TAGCC 
SDM 
TolC-F1 tolC TTGATCCTTCAACACCGCGACCG SEQ 
TolC-F2 tolC TTGGCCTGAGCTTCTCGCTGCC SEQ 
TOLC-R1 tolC ACATTCAGCGCAGCCAGTTCCG SEQ 
TOLCF tolC GAATGCCCATGGGGAAATTGCTCCCCATTC CL 
TOLC 
BSPHI 
tolC CAGGAAACAGATCATGAGGAAATTGCTCCC CL 
TOLC-M- 
BSPHI 
tolC GAGCCAGGTCATGAACCTGATGC CL 
XBAI-
TOLC 
FWD. 
tolC GCTCTAGAGGAAACAGACCATGAAGAAATTG CL 
TOLCBGL tolC TCGTCGAGATCTGTTACGGAAAGGGTTATGACCG PCR 
TOLC- tolC ACGTAAGGCAACGTAAAGATACGGGTTATCTGTAG PCR 
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MARKER 
FWD 
GCTGGAGCTGCTTCG 
TOLC-
MARKER 
REV 
tolC TTCCGGGACCAGTGGTAAATACCCATCAGACATAT
GAATATCCTCCTTAG 
PCR 
TOLRX tolC CTTACGTCTAGACGGGGCCGAAGCC PCR 
TOLCR tolC GCGGCAGATAACCCGAAGCTTTACGTTGCC PCR 
TolC Q142C 
F 
tolC CCGTCAATTAGATCAAACCACCtgtCGTTTTAACGTG SDM 
TolC Q142C 
R 
tolC CACGTTAAAACGacaGGTGGTTTGATCTAATTGACG
G 
SDM 
TolC-1C 
Q142C F 
tolC GCGATCTACCGTCAATTAGATtgtACCACCCAACGTT
TTAACGTG 
SDM 
TolC-1C 
Q142C R 
tolC CGCTAGATGGCAGTTAATCTAacaTGGTGGGTTGCA
AAATTGCAC 
SDM 
TolC R390E 
F 
tolc GCAAGAGCTGGCGAATGCGgaaTATAACTACCTGAT
TAATC 
SDM 
TolC R390E 
R 
tolC GATTAATCAGGTAGTTATAttcCGCATTCGCCAGCTC
TTGC 
SDM 
TolC 2Ala 
T1 FWD 
tolC CCAACGTTTTAACGTGGGCgcGGcAGCGATCACCGA
CGTGCAGAACGC 
SDM 
TolC 2Ala 
T1 REV 
tolC GCGTTCTGCACGTCGGTGATCGCTgCCgcGCCCACG
TTAAAACGTTGG 
SDM 
TolC PA T1 
FWD 
tolC CCACCCAACGTTTTAACGTGGcCgcGGcAGCGATCA
CCGACGTGCAGAACGC 
SDM 
TolC PA T1 
REV 
tolC GCGTTCTGCACGTCGGTGATCGCTgCCgcGgCCACG
TTAAAACGTTGGGTGG 
SDM 
TolC 
G147A 
FWD 
tolC CCCAACGTTTTAACGTGGcCCTGGTAGCGATCACC
G 
SDM 
TolC 
G147A REV 
tolC CGGTGATCGCTACCAGGGCCACGTTAAAACGTTGG
G 
SDM 
TolC G147C 
FWD 
tolC CCACCCAACGTTTTAACGTGtGCCTGGTAGCGATCA
CCGACG 
SDM 
TolC G147C 
REV 
tolC CGTCGGTGATCGCTACCAGGCACACGTTAAAACGT
TGGGTGG 
SDM 
TolC G365C 
FWD 
tolC GCGGGCTACTCGGTCtGTACGCGTACCATTGTTGAT
G 
SDM 
TolC G365C 
REV 
tolC CATCAACAATGGTACGCGTACAGACCGAGTAGCCC
GC 
SDM 
TolC A128C 
F 
tolC CGCTTATTTCAACGTGTTGAATGCTATTGACGTTCT
TTCCTATACAC3 
SDM 
TolC A128C 
R 
tolC GTGTATAGGAAAGAACGTCAATAcaATTCAACACG
TTGAAATAAGCG 
SDM 
TolC 
6HXHR 
tolC GCTCTAGAAGCTTAGTGATGGTGATGGTGATGGTT
ACGGAAAGGGTTATGACC 
CL 
TolCB-R tolC GTTCAGACGGATCCGAAGCCCCGTCG CL 
TolC G147C 
FWD 
tolC CCAACGTTTTAACGTGTGCCTGGTAGCGATCACC SDM 
TolC G147C 
REV 
tolC GGTGATCGCTACCAGGCACACGTTAAAACGTTGG SDM 
TolC G365C 
FWD 
tolC GAAGCGGGCTACTCGGTCTGTACGCGTACCATTGT
TG 
SDM 
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TolC G365C 
REV 
tolC CAACAATGGTACGCGTACAGACCGAGTAGCCCGCT
TC 
SDM 
TolC FS1 
FWD 
tolC CTACCGGGATTTCTGACACTCTTATAGCGGTTCGA
AAAC 
SDM 
TolC FS1 
REV 
tolC GTTTTCGAACCGCTATAAGAGTGTCAGAAATTAAG
AGTGTCAGAAATCCCGGTAG 
SDM 
DtolC FWD tolC ATCGCGCTAAATACTGCTTCACCACAAGGAATGCA
ATGTAGGCTGGAGCTGCTTCG 
DEL 
DtolC REV tolC TTATGACCGTTACTGGTGGTAGTGCGTGCGGATGT
TCATATCAATATCCTCCTTAG 
DEL 
TolC 
Promoter 
tolC CCGCACCTCATGACTCATTTGC PCR 
TolC BsphI 
hybrid Fwd 
tolC CAGGAAACAGATCATGAGGAAATTGCTCCC PCR 
TolC 
External 
tolC GTAACGGGCAGGTTGTCTGGC PCR 
TestingDELt
a-acrEF-F 
acrE
F 
ACGTCGGTGAACCGCAGGTTACC PCR 
TestingDELt
a-acrEF-R 
acrE
F 
TGGTTCCTGGCGCGGCTTCC PCR 
TestingDELt
a-acrEF-2R 
acrE
F 
TCATCAGGATAGGACGCAGACGC PCR 
TolC L169C 
FWD 
tolC CCGTGCTGGCGAACGAAtgtACCGCgCGTAATAACC
TTGATAACGC 
SDM 
TolC L169C 
REV 
tolC GCGTTATCAAGGTTATTACGCGCGGTACATTCGTT
CGCCAGCACGG 
SDM 
TolC A269C 
FWD 
tolC CGAAAACCCGTGGTtgCGCTGGTACCCAGTATGACG SDM 
TolC A269C 
REV 
tolC CGTCATACTGGGTACCAGCGCAACCACGGGTTTTC
G 
SDM 
TolC T272C 
FWD 
tolC CCCGTGGTGCCGCTGGTtgCCAGTATGACGATAGC SDM 
TolC T272C 
REV 
tolC GCTATCGTCATACTGGCAACCAGCGGCACCACGGG SDM 
TolC Ext 2 
fwd 
tolC CGCCAACCTTTTGCGGTAGCGGC PCR 
TolC Ext 2 
rev 
tolC GGAAGAATGCGGCAGATAACCCG PCR 
pBAD33_Re
v 
pBA
D33 
5'-ATCAGACCGCTTCTGCGTTC-3' SEQ 
pACYC184(
SalI)R 
pAcy
c184 
5'-GAAGGCTCTCAAGGGCATCGG-3' SEQ 
AcrB FWD 
NcoI for 
pET24d 
acrB gaCCATGgCTAATTTCTTTATCGATCGCCCG CL 
AcrB FWD 
BspHI for 
pET24d 
acrB gaTCATGaCTAATTTCTTTATCGATCGCCCG CL 
AcrA Cryst 
FWD 
acrA atccatggctGTCAAAACTGAACCTCTGCAGATCACAAC
CG 
CL 
AcrA Cryst 
Rev 
acrA gctcgagGCCCTGTTGCGGGACTAAAATAGCG CL 
AcrA acrA GTGACCCAGTCCAGCAACGACaTgaTGCGCCTGAAA SDM 
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FL223-
224MM 
FWD 
CAGGAACTGGC 
AcrA 
FL223-
224MM 
REV 
acrA GCCAGTTCCTGTTTCAGGCGCATCATGTCGTTGCTG
GACTGGGTCAC 
SDM 
AcrA 
LL287-
288MM 
FWD 
acrA CGGATCACACTaTGaTGCCGGGTATGTTCGTGCGC SDM 
AcrA 
LL287-
288MM 
REV 
acrA GCGCACGAACATACCCGGCATCATAGTGTGATCCG SDM 
AcrA-PCR-
F-KpnI 
acrA GACCAGGTACCAATTTGAAATCGGACACTCGAGG PCR 
AcrB-F-
D795A 
acrB GGTATGTTCGTGCTGCTGCGGGTCAGATGGTGCC SDM 
AcrB-R-
D795A 
acrB GGCACCATCTGACCCGCAGCAGCACGAACATACC SDM 
AcrB-F-
D256A 
acrB GCTGAAAGTGAATCAGGCAGGTTCCCGCGTGC SDM 
AcrB-R-
D256A 
acrB GCACGCGGGAACCTGCCTGATTCACTTTCAGC SDM 
acrBL1-
malE_Bam 
acrB ACGATCTCCGGATCCTACC PCR 
acrBL1-
malE_Hin 
acrB GAGGATGAAAGCTTAGACCAGCG PCR 
AcrB-BsphI-
F 
acrB CCGTTAAGTCATGACTAATTTTCTTTATCGAT PCR 
AcrB-F1 acrB CCATTATCATCATGTTGGCAGG SEQ 
AcrB-F2 acrB CGTTATCAACACCGATGGC SEQ 
AcrB-F3 acrB TCGAAGATTGAGCTGGGTGG SEQ 
AcrB-F4 acrB CCATCGGCCTGTTGGTGG SEQ 
AcrB-F5 acrB GCACCACTACACCGACAGC SEQ 
AcrB-F6 acrB GCAATCGTGGAACTGGGTAC SEQ 
AcrB-F7 acrB CGTTGGGAGTACGGTTCG SEQ 
AcrB-F8 acrB GACGTTTACTTCCAGGTAGG SEQ 
AcrB-R1 acrB CCAGACTCAAAGGTCAGG SEQ 
AcrB-R2 acrB CCACCAACAGGCCGATGG SEQ 
AcrA-F1 acrA CCGCAACAGGGCGTAACCCGT SEQ 
AcrA-F2 acrA GTATGTACCATAGCACGACG SEQ 
AcrA-F3 acrA GGTAGCGACATCGAAGCAGG SEQ 
AcrA-F4 acrA CATTGGTACAGAACGGTCAG SEQ 
AcrA-R1 acrA CATCAGAACGACCGCCAGAGG SEQ 
acrA rev acrA GTCTTAACGGATCCTGTTTAAGTTAAG PCR 
RacrAB-
HindIII 
acrA
B 
CTCCTTAAGCTTCGTAGGTTATGC CL 
FacrAB-
BspHI 
acrA
B 
AGATCTCATGAACAATCCGACTTGTC CL 
acrB fwd acrB CTTAACTTAAACAGGATCCGTTAAGAC CL 
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AcrB-PCR-
F-SphI 
acrB CTTAAGCATGCCAGGAGCCGTTAAGACATGCC CL 
AcrB-his-R-
HindIII 
acrB GCTCTAGAAGCTTAATGGTGATGGTGATGATGATC
GACAGTATGGCTGTGCTCG 
CL 
DacrAfwd acrA GACCAATTTGAAATCGGACACTCGAGGTTTACATT
GTAGGCTGGCGCTGCTTCG 
DEL 
DacrArev acrA GCAAAAATCGGGCGATCGATAAAGAAATTAGGCA
TATGAATATCCTCCTTAG 
DEL 
Matt1 acrB AGTCCAAGTCTTAACTTAAACAGGAGCCGTTAAGA
CTGTAGGCTGGAGCTGCTTCG 
DEL 
Matt2 acrB AGGCCGCTTACGCGGCCTTAGTGATTACACGTTGT
ACATATGAATATCCTCCTTAG 
DEL 
Stidham1 acrA TCAGATGGATCCGCGACCTATCAG PCR 
Stidham2 acrA GGTTTACTCATGAACAAAAACAGAGGG PCR 
Stidham3 acrA GCTCTAGAAGCTTAGTGATGGTGATGGTGATGAGA
CTTGGACTGTTCAGGCTGAGC 
PCR 
AcrB-R-
D795C 
acrB CGAGAATGGCACCATCTGACCGCAAGCAGCACGA
ACATACC 
SDM 
AcrB-F-
D795C 
acrB GGTATGTTCGTGCTGCTTGCGGTCAGATGGTGCCA
TTCTCG 
SDM 
AcrB-R-
Q255C 
acrB CAGCACGCGGGAACCATCGCAATTCACTTTCAGCA
GGATTTTGC 
SDM 
AcrB-F-
Q255C 
acrB GCAAAATCCTGCTGAAAGTGAATTGCGATGGTTCC
CGCGTGCTG 
SDM 
AcrAL222Q
-F 
acrA GCAAAGCCAAAGTGTCACAGATCACCAGTGACGG
C 
SDM 
AcrAL222Q
-R 
acrA GCCGTCACTGGTGATCTGTGACACTTTGGCTTTGC SDM 
AcrEPCRF
wdBspHI 
acrE CACCTCATGACTATTTATACGAGAGGC PCR 
AcrEPCRRe
vBamHI 
acrE GTCAGGATCCCTTACTTCGATGCAGTATCTGC PCR 
acrE_int_r acrE GCGAACTTCGGCTATACGATAAGC PCR 
dacrE-fwd acrE GTAAATAACGCGCTTTTGGTTTTTTGAGGAATAGT
ATGTAGGCTGGAGCTGCTTCG 
DEL 
AcrA A79C 
F 
acrA CCTGCGACCTATCAGtgtACATACGACAGTGCG SDM 
AcrA A79C 
R 
acrA CGCACTGTCGTATGTacaCTGATAGGTCGCAGG SDM 
acrA rev 
(His-
tagXbaI/Hin
dIII) 
acrA GCAAGCTTCTAGATTAGTGATGGTGATGGTGATGA
GACTTGGACTGTTCAGGCTGAGC 
CL 
acrB-XbaI-
Forward 
acrB ACGGTCTAGACAGGAGCCGTTAAGACATG CL 
AcrB correct 
A738 Fwd 
acrB GGAAAAAGCGCAGGCGCTGGGTGTTTCTATC SDM 
AcrB correct 
A738 Rev 
acrB GATAGAAACACCCAGCGCCTGCGCTTTTTCC SDM 
AcrA 
correct 
D244 Fwd 
acrA CTGACGTTACCGTTGATCAGACCACTGGGTC SDM 
AcrA acrA GACCCAGTGGTCTGATCAACGGTAACGTCAG SDM 
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correct 
D244 Rev 
AcrB 
R259A Fwd 
acrB CAGGATGGTTCCgcCGTGCTGCTGCGTG SDM 
AcrB 
R259A Rev 
acrB CACGCAGCAGCACGgcGGAACCATCCTG SDM 
AcrB DEL 
H1 Fwd 
acrB CGGCAAAATCCTGCTGGGTTCCCGCGTGCTG SDM 
AcrB DEL 
H1 Rev 
acrB CAGCACGCGGGAACCCAGCAGGATTTTGCCG SDM 
AcrB poly A 
H1 Fwd 
acrB CGGCAAAATCCTGCTGgcAGcGgcTgcgGcgGGTTCgC
GCGTGCTGC 
SDM 
AcrB poly A 
H1 Rev 
acrB GCAGCACGCGcGAACCcgCcgcAgcCgCTgcCAGCAGG
ATTTTGCCG 
SDM 
pACYC 
DEL AcrA 
Fwd 
pACY
C 
ccaatttgaaatcggacactcgaggtttacatATGCCTAATTTCTTTAT
CGATCGCCCGATTTTTGCG 
SDM 
pACYC 
DEL AcrA 
Rev 
pACY
C 
CGCAAAAATCGGGCGATCGATAAAGAAATTAGGC
ATatgtaaacctcgagtgtccgatttcaaattgg 
SDM 
AcrB DEL 
H2 Fwd 
acrB CGGCGACTGGTATGTTCGTATGGTGCCATTCTCGG
CG 
SDM 
AcrB DEL 
H2 Rev 
acrB CGCCGAGAATGGCACCATACGAACATACCAGTCGC
CG 
SDM 
AcrB poly A 
H2 Fwd 
acrB GGTATGTTCGTGCTGCTGcTGcTgctATGGTGCCATTC
TCGGCG 
SDM 
AcrB poly A 
H2 Rev 
acrB CGCCGAGAATGGCACCATagcAgCAgCAGCAGCACG
AACATACC 
SDM 
AcrA S83G 
FWD 
acrA CCTATCAGGCGACATACGACgGTGCGAAAGGTGAT
CTGGCG 
SDM 
AcrA S83G 
REV 
acrA CGCCAGATCACCTTTCGCACcGTCGTATGTCGCCTG
ATAGG 
SDM 
AcrA T111P 
FWD 
acrA GTTATCAGAAACTGCTCGGTcCTCAGTACATCAGTA
AGCAAG 
SDM 
AcrA T111P 
REV 
acrA CTTGCTTACTGATGTACTGAGgACCGAGCAGTTTCT
GATAAC 
SDM 
AcrA 
A135T 
FWD 
acrA GCTGCGGTAACTaCGGCGAAAGCTGCC SDM 
AcrA 
A135T REV 
acrA GGCAGCTTTCGCCGtAGTTACCGCAGC SDM 
AcrA 
N146T 
FWD 
acrA GAAACTGCGCGGATCAcTCTGGCTTACACC SDM 
AcrA 
N146T REV 
acrA GGTGTAAGCCAGAgTGATCCGCGCAGTTTC SDM 
AcrB 
KAAAA H1 
FWD 
acrB CGGCAAAATCCTGCTGaaAGcGgcTgcgGcgGGTTCg SDM 
AcrB 
KAAAA H1 
REV 
acrB CGAACCCGCCGCAGCCGCTTTCAGCAGGATTTTGC
CG 
SDM 
AcrB acrB CGGCAAAATCCTGCTGgcAGcGaaTgcgGcgGGTTCaC SDM 
178 
 
AANAA H1 
FWD 
GCGTGCTGC 
AcrB 
AANAA H1 
REV 
acrB GCAGCACGCGTGAACCCGCCGCATTCGCTGCCAGC
AGGATTTTGCCG 
SDM 
AcrB 
AAAQA H1 
FWD 
acrB CCTGCTGgcAGcGgcTcagGcgGGTTCgCGCGTGCTGC SDM 
AcrB 
AAAQA H1 
REV 
acrB GCAGCACGCGCGAACCCGCCTGAGCCGCTGCCAGC
AGG 
SDM 
AcrB 
AAAAD H1 
FWD 
acrB CCTGCTGgcAGcGgcTgcgGatGGTTCgCGCGTGCTGC SDM 
AcrB 
AAAAD H1 
REV 
acrB GCAGCACGCGCGAACCATCCGCAGCCGCTGCCAGC
AGG 
SDM 
AcrB 
AAAAK H1 
FWD 
acrB CGGCAAAATCCTGCTGgcAGcGgcTgcgaagGGcTCaCG
CGTGCTGC 
SDM 
AcrB 
AAAAK H1 
REV 
acrB GCAGCACGCGTGAGCCCTTCGCAGCCGCTGCCAGC
AGGATTTTGCCG 
SDM 
AcrB 
AADAA H2 
FWD 
acrB GGTATGTTCGTGCTGCTGaTGcTgctATGGTGCCATTC
TCGGCG 
SDM 
AcrB 
AADAA H2 
REV 
acrB CGCCGAGAATGGCACCATAGCAGCATCAGCAGCA
CGAACATACC 
SDM 
AcrB 
AAAAQ H2 
FWD 
acrB GTTCGTGCTGCTGcTGcTcagATGGTGCCATTCTCGG
CG 
SDM 
AcrB 
AAAAQ H2 
REV 
acrB CGCCGAGAATGGCACCATCTGAGCAGCAGCAGCA
CGAAC 
SDM 
AcrB 
AAACA H1 
FWD 
acrB CGGCAAAATCCTGCTGgcAGcGgcTtgcGggGGTTCaCG
CGTGCTGC 
SDM 
AcrB 
AAACA H1 
REV 
acrB GCAGCACGCGTGAACCCCCGCAAGCCGCTGCCAGC
AGGATTTTGCCG 
SDM 
AcrB 
AACAA H2 
FWD 
acrB GTTCGTGCTGCTtgTGcTgctATGGTGCCATTCTCGGC
G 
SDM 
AcrB 
AACAA H2 
REV 
acrB CGCCGAGAATGGCACCATAGCAGCACAAGCAGCA
CGAAC 
SDM 
AcrB 
D407A 
FWD 
acrB CCATCGGCCTGTTGGTGGcTGACGCgATCGTTGTGG
TAG 
SDM 
AcrB 
D407A REV 
acrB CTACCACAACGATCGCGTCAGCCACCAACAGGCCG
ATGG 
SDM 
AcrB acrB CGCTTGATGCGGTGCGcATGgcTTTACGTCCGATCC SDM 
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R971A 
FWD 
TGATG 
AcrB 
R971A REV 
acrB CATCAGGATCGGACGTAAAGCCATGCGCACCGCAT
CAAGCG 
SDM 
AcrA 
G248E 
FWD 
acrA CCGTTGATCAGACCACTGaGTCTATCACCCTACGCG SDM 
AcrA 
G248E REV 
acrA CGCGTAGGGTGATAGACTCAGTGGTCTGATCAACG
G 
SDM 
AcrA K58C 
FWD 
acrA GGATTATCCTGAAGCGTAATTTCtgcGAAGGTAGCG
ACATCGAAGCAGG 
SDM 
AcrA K58C 
REV 
acrA CCTGCTTCGATGTCGCTACCTTCGCAGAAATTACG
CTTCAGGATAATCC 
SDM 
AcrA K58C 
REV 
acrA CCTGCTTCGATGTCGCTACCTTCGCAGAAATTACG
CTTCAGGATAATCC 
SDM 
AcrA S196C 
FWD 
acrA GATGTGACCCAGTCCtGCAACGACTTCCTGC SDM 
AcrA S196C 
REV 
acrA GCAGGAAGTCGTTGCAGGACTGGGTCACATC SDM 
AcrB C493S 
FWD 
acrB GATCCTGACTCCAGCTCTTaGTGCCACCATGCTGAA
ACCG 
SDM 
AcrB C493S 
REV 
acrB CGGTTTCAGCATGGTGGCACTAAGAGCTGGAGTCA
GGATC 
SDM 
AcrB C887S 
FWD 
acrB GATTGTCGTGTTCCTGaGTCTGGCGGCGCTG SDM 
AcrB C887S 
REV 
acrB CAGCGCCGCCAGACTCAGGAACACGACAATC SDM 
AcrB F136A 
FWD 
acrB GCGTTGAGAAATCATCCAGtAGCgcgCTGATGGTTG
TCGGCGTTATC 
SDM 
AcrB F136A 
FWD 
acrB GCGTTGAGAAATCATCCAGtAGCgcgCTGATGGTTG
TCGGCGTTATC 
SDM 
AcrB F136A 
REV 
acrB GATAACGCCGACAACCATCAGCGCGCTACTGGATG
ATTTCTCAACGC 
SDM 
AcrB F610A 
FWD 
acrB GAACAACGTTGAGTCGGTGgcgGCgGTTAACGGCTT
CGGC 
SDM 
AcrB F610A 
REV 
acrB GCCGAAGCCGTTAACCGCCGCCACCGACTCAACGT
TGTTC 
SDM 
AcrB F610A 
REV 
acrB GCCGAAGCCGTTAACCGCCGCCACCGACTCAACGT
TGTTC 
SDM 
AcrB F615A 
FWD 
acrB GTTCGCCGTTAACGGggcaGGCTTTGCGGGACGTGG SDM 
AcrB F615A 
REV 
acrB CCACGTCCCGCAAAGCCTGCCCCGTTAACGGCGAA
C 
SDM 
EmrA DEL 
Forward 
emrA taagaagatcgtggagaacaatatgagcgcaaatgcggagTGTAGGCTG
GAGCTGCTTCG 
DEL 
EmrB DEL 
Reverse 
emrB aaatgaactggcttagttgtacttagtgcgcaccgcctccCATATGAATAT
CCTCCTTAG 
DEL 
EmrA PCR 
Forward 
emrA TGACTGGCCAGCATCGCAAC PCR 
EmrB PCR 
Reverse 
emrB GGAACTGCACATCTAGTCAG PCR 
AcrA 
L252R 
acrA GACCACTGGGTCTATCACacgcCGCGCTATCTTCCCG
AACCCGG 
SDM 
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FWD 
AcrA 
L252R REV 
acrA 5'-
CCGGGTTCGGGAAGATAGCGCGGCGTGTGATAGA
CCCAGTGGTC-3' 
SDM 
AcrB 
AAACA H1 
FWD 
acrB 5'-
CGGCAAAATCCTGCTGgcAGcGgcTtgcGcgGGTTCaCG
tGTGCTGC-3' 
SDM 
AcrB 
AAACA H1 
REV 
acrB 5'-
GCAGCACACGTGAACCCGCGCAAGCCGCTGCCAG
CAGGATTTTGCCG-3' 
SDM 
AcrB 
AAAGA H2 
FWD 
acrB 5'-
GTTCGTGCTGCTGcTGgTgctATGGTGCCATTCTCGG
CG-3' 
SDM 
AcrB 
AAAGA H2 
REV 
acrB 5'-
CGCCGAGAATGGCACCATAGCACCAGCAGCAGCA
CGAAC-3' 
SDM 
AcrB 
Q255C-
FWD 
acrB CAAAATCCTGCTGAAAGTGAATTGTGATGGTTCCC
GCGTGCTGCTG 
SDM 
AcrB 
Q255C-REV 
acrB CAGCAGCACGCGGGAACCATCACAATTCACTTTCA
GCAGGATTTTG 
SDM 
AcrB 
D795C-
FWD 
acrB CTGGTATGTTCGTCCTGCTTGTGGTCAGATGGTGCC
ATTC 
SDM 
AcrB 
D795C-REV 
acrB GAATGGCACCATCTGACCACAAGCAGCACGAACA
TACCAG 
SDM 
AcrA S83C 
FWD 
acrA CAGGCGACATACGACtGTGCGAAAGGTGATCTG SDM 
AcrA S83C 
REV 
acrA CAGATCACCTTTCGCACaGTCGTATGTCGCCTG SDM 
AcrB 
Q737L 
FWD 
acrB CGACCAGGAAAAAGCGCtcGCGCTGGGTGTTTCTAT
C 
SDM 
AcrB 
Q737L REV 
acrB GATAGAAACACCCAGCGCGAGCGCTTTTTCCTGGT
CG 
SDM 
0 acrB CGTTGAGTCGGTGTTCGCgGTTAACGGCTTCGGC SDM 
AcrB A610F 
REV 
acrB GCCGAAGCCGTTAACCGCGAACACCGACTCAACG SDM 
acrBfor 
pET24a 
acrB GGATCCCATATGCCTAATTTCTTTATCGATC CL 
acrBrev 
pET24a 
acrB AAGCTTCTCGAGATGATGATCGACAGTATGGCTG CL 
DELta 
acrEF FWD 
acrE
F 
GCTTATCGTATAGCCGAAGTTCGCCCACAGTGTAG
GCTGGAGCTGCTTCG 
DEL 
DELta 
acrEF REV 
acrE
F 
ATACACCCAATGTGAAGTGGTAAAGGCCGACATAT
GAATATCCTCCTTAG 
DEL 
DELta 
acrEF REV2 
acrE
F 
GTTTTTGGCCGACAAGCCAATTGTCGTTAGCATAT
GAATATCCTCCTTAG 
DEL 
N-terminal 
6His Tag 
bamHI AcrB 
acrB gcatacGGATCCGTTAAGACATGcatcaccatcaccatcacCCT
AATTTCTTTATCGATCGCCCG 
CL 
a All sequences are listed from 5’ to 3’. 
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b SDM indicates Site-directed mutagenesis, CL indicates cloning, DEL designates 
deletion primers, SEQ indicates sequencing primers, PCR indicates primers used 
for PCR 
  
182 
 
References: 
Andersen C., Koronakis E., Bokma E., Eswaran J., Humphreys D., Hughes C., 
and Koronakis V. (2002) Transition to the open state of the TolC 
periplasmic tunnel entrance. Proc Natl Acad Sci U S A 99: 11103-11108. 
Augustus A.M., Celaya T., Husain F., Humbard M., and Misra R. (2004) 
Antibiotic-sensitive TolC mutants and their suppressors. J Bacteriol 186: 
1851-1860. 
Bagai I., Rensing C., Blackburn N.J., and McEvoy M.M. (2008) Direct metal 
transfer between periplasmic proteins identifies a bacterial copper 
chaperone. Biochemistry 47: 11408-11414. 
Bagai I., Liu W., Rensing C., Blackburn N.J., and McEvoy M.M. (2007) 
Substrate-linked conformational change in the periplasmic component of a 
Cu(I)/Ag(I) efflux system. J Biol Chem 282: 35695-35702. 
Bai J., Mosley L., and Fralick J.A. (2010) Evidence that the C-terminus of OprM 
is involved in the assembly of the VceAB-OprM efflux pump. FEBS Lett 
584: 1493-1497. 
Bavro V.N., Pietras Z., Furnham N., Pérez-Cano L., Fernández-Recio J., Pei 
X.Y., et al. (2008) Assembly and channel opening in a bacterial drug 
efflux machine. Molecular Cell 30: 114-121. 
Bohnert J.A., Karamian B., and Nikaido H. (2010) Optimized nile red efflux 
assay of AcrAB-TolC multidrug efflux system shows competition between 
substrates. Antimicrob Agents Chemother 54: 3770-3775. 
Bokma E., Koronakis E., Lobedanz S., Hughes C., and Koronakis V. (2006) 
Directed evolution of a bacterial efflux pump: Adaptation of the E. coli 
TolC exit duct to the Pseudomonas MexAB translocase. FEBS Lett 580: 
5339-5343. 
Brandenburg K., Garidel P., Schromm A.B., Andra J., Kramer A., Egmond M., 
and Wiese A. (2005) Investigation into the interaction of the bacterial 
protease OmpT with outer membrane lipids and biological activity of 
OmpT:Lipopolysaccharide complexes. Eur Biophys J 34: 28-41. 
Bratu S., Landman D., George A., Salvani J., and Quale J. (2009) Correlation of 
the expression of acrB and the regulatory genes marA, soxS and ramA 
with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae 
endemic to New York City. J Antimicrob Chemother 64: 278-283. 
183 
 
Casadaban M.J. (1976) Transposition and fusion of the lac genes to selected 
promoters in Escherichia coli using bacteriophage lambda and mu. J Mol 
Biol 104: 541-555. 
Cascales E., Buchanan S.K., Duche D., Kleanthous C., Lloubes R., Postle K., et 
al. (2007) Colicin biology. Microbiol Mol Biol Rev 71: 158-229. 
Chang A.C., and Cohen S.N. (1978) Construction and characterization of 
amplifiable multicopy DNA cloning vehicles derived from the P15A 
cryptic miniplasmid. J Bacteriol 134: 1141-1156. 
Dastidar V., Mao W., Lomovskaya O., and Zgurskaya H.I. (2007) Drug-induced 
conformational changes in multidrug efflux transporter AcrB from 
Haemophilus influenzae. Journal of Bacteriology 189: 5550-5558. 
Datsenko K., and Wanner B. (2000) One-step inactivation of chromosomal genes 
in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 
97: 6640-6645. 
Deol, S. S., Bond, P. J., Domene, C., Sansom, M. (2004) Lipid-protein 
interactions of integral membrane proteins: a comparative simulation 
study. Biophys. J. 87:3737-3749. 
Duplay P., Bedouelle H., Fowler A., Zabin I., Saurin W., and Hofnung M. (1984) 
Sequences of the malE gene and of its product, the maltose-binding 
protein of Escherichia coli K12. J Biol Chem 259: 10606-10613. 
Elkins C.A., and Nikaido H. (2003) Chimeric analysis of AcrA function reveals 
the importance of its C-terminal domain in its interaction with the AcrB 
multidrug efflux pump. J Bacteriol 185: 5349-5356. 
Eswaran J., Hughes C., and Koronakis V. (2003) Locking TolC entrance helices 
to prevent protein translocation by the bacterial type I export apparatus. J 
Mol Biol 327: 309-315. 
Fabrega A., Roca I., and Vila J. (2010) Fluoroquinolone and multidrug resistance 
phenotypes associated with the overexpression of AcrAB and an 
orthologue of MarA in Yersinia enterocolitica. Int J Med Microbiol 300: 
457-463. 
Federici, L., Walas, F., and Luisi, B. (2004) The structure and mechanism of the 
TolC outer membrane transport protein. Curr. Sci. 87: 190-196.  
184 
 
Fernandez-Recio J., Walas F., Federici L., Venkatesh Pratap J., Bavro V.N., 
Miguel R.N., et al. (2004) A model of a transmembrane drug-efflux pump 
from gram-negative bacteria. FEBS Lett 578: 5-9. 
Fischer N., and Kandt C. (2011) Three ways in, one way out: Water dynamics in 
the trans-membrane domains of the inner membrane translocase AcrB. 
Proteins 79: 2871-2885. 
Fralick J. (1996) Evidence that TolC is required for functioning of the 
Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol 178: 5803-5805. 
Ge Q., Yamada Y., and Zgurskaya H. (2009) The C-terminal domain of AcrA is 
essential for the assembly and function of the multidrug efflux pump 
AcrAB-TolC. J Bacteriol 191: 4365-4371. 
German, G. J., Misra, R., and Kropinski, A. (2006). The T1-like bacteriophages. 
In The Bacteriophages. R. Calender (ed). 211-224. 
Gerken H., and Misra R. (2004) Genetic evidence for functional interactions 
between TolC and AcrA proteins of a major antibiotic efflux pump of 
Escherichia coli. Mol Microbiol 54: 620-631. 
Harwood J.L., and Russell N.J. (1984) Lipids in plants and microbes. London; 
Boston: G. Allen & Unwin. 
Herrera C.M., Hankins J.V., and Trent M.S. (2010) Activation of PmrA inhibits 
LpxT-dependent phosphorylation of lipid A promoting resistance to 
antimicrobial peptides. Mol Microbiol 76: 1444-1460. 
Husain F., and Nikaido H. (2010) Substrate path in the AcrB multidrug efflux 
pump of Escherichia coli. Mol Microbiol 78: 320-330. 
Husain F. (2006) Characterization of AcrAB-TolC antibiotic efflux complex of 
Escherichia coli. . 
Husain F., Humbard M., and Misra R. (2004) Interaction between the TolC and 
AcrA proteins of a multidrug efflux system of Escherichia coli. J 
Bacteriol 186: 8533-8536. 
Ip H., Stratton K., Zgurskaya H., and Liu J. (2003) pH-induced conformational 
changes of AcrA, the membrane fusion protein of Escherichia coli 
multidrug efflux system. J Biol Chem 278: 50474-50482. 
185 
 
Jane A. Colmer, Joe A. Fralick, Abdul N. Hamood. (1998) Isolation and 
characterization of a putative multidrug resistance pump from Vibrio 
cholerae. Molecular Microbiology 27: 63-72. 
Kim H.M., Xu Y., Lee M., Piao S., Sim S.H., Ha N.C., and Lee K. (2010) 
Functional relationships between the AcrA hairpin tip region and the TolC 
aperture tip region for the formation of the bacterial tripartite efflux pump 
AcrAB-TolC. J Bacteriol 192: 4498-4503. 
Kim S., Yum S., Jo W.S., Lee B.L., Jeong M.H., and Ha N.C. (2008) Expression 
and biochemical characterization of the periplasmic domain of bacterial 
outer membrane porin TdeA. J Microbiol Biotechnol 18: 845-851. 
Knowles T.J., Browning D.F., Jeeves M., Maderbocus R., Rajesh S., Sridhar P., et 
al. (2011) Structure and function of BamE within the outer membrane and 
the beta-barrel assembly machine. EMBO Rep 12: 123-128. 
Koronakis V. (2003) TolC--the bacterial exit duct for proteins and drugs. FEBS 
Lett 555: 66-71. 
Koronakis V., Eswaran J., and Hughes C. (2004) Structure and function of TolC: 
The bacterial exit duct for proteins and drugs. Annu Rev Biochem 73: 467-
489. 
Koronakis V., Sharff A., Koronakis E., Luisi B., and Hughes C. (2000) Crystal 
structure of the bacterial membrane protein TolC central to multidrug 
efflux and protein export. Nature 405: 914-919. 
Krishnamoorthy G., Tikhonova E.B., and Zgurskaya H.I. (2008) Fitting 
periplasmic membrane fusion proteins to inner membrane transporters: 
Mutations that enable Escherichia coli AcrA to function with 
Pseudomonas aeruginosa MexB. J Bacteriol 190: 691-698. 
Lobedanz S., Bokma E., Symmons M.F., Koronakis E., Hughes C., and 
Koronakis V. (2007) A periplasmic coiled-coil interface underlying TolC 
recruitment and the assembly of bacterial drug efflux pumps. Proc Natl 
Acad Sci U S A 104: 4612-4617. 
Lugtenberg E.J.J., and Peters R. (1976) Distribution of lipids in cytoplasmic and 
outer membranes of Escherichia coli K12. Biochimica Et Biophysica Acta 
(BBA) - Lipids and Lipid Metabolism 441: 38-47. 
186 
 
Masi M., Vuong P., Humbard M., Malone K., and Misra R. (2007) Initial steps of 
colicin E1 import across the outer membrane of Escherichia coli. J 
Bacteriol 189: 2667-2676. 
Mikolosko J., Bobyk K., Zgurskaya H.I., and Ghosh P. (2006) Conformational 
flexibility in the multidrug efflux system protein AcrA. Structure 14: 577-
587. 
Misra R., and Bavro V.N. (2009) Assembly and transport mechanism of tripartite 
drug efflux systems. Biochimica Et Biophysica Acta (BBA) - Proteins & 
Proteomics 1794: 817-825. 
Morona and Reeves. 1981.  Molecular cloning of the tolC locus of escherichia 
coli K-12 with the use of transposon Tn10. Mol Gen Genet 184: 430-433. 
Murakami S., Nakashima R., Yamashita E., Matsumoto T., and and Yamaguchi 
A. (2006) Crystal structures of a multidrug transporter reveal a 
functionally rotating mechanism. Nature 443: 173-179. 
Nehme D., and Poole K. (2007) Assembly of the MexAB-OprM multidrug pump 
of Pseudomonas aeruginosa: Component interactions defined by the study 
of pump mutant suppressors. J Bacteriol 189: 6118-6127. 
O’Keeffe, A. H., East, J. M., Lee, A. G. (2000) Seletivity in lipid binding to the 
bacterial outer membrane protein OmpF. Biophys J 79: 2066-2074. 
Pages J.M., and Amaral L. (2009) Mechanisms of drug efflux and strategies to 
combat them: Challenging the efflux pump of gram-negative bacteria. 
Biochim Biophys Acta 1794: 826-833. 
Pei X.Y., Hinchliffe P., Symmons M.F., Koronakis E., Benz R., Hughes C., and 
Koronakis V. (2011) Structures of sequential open states in a symmetrical 
opening transition of the TolC exit duct. Proc Natl Acad Sci U S A 108: 
2112-2117. 
Raetz C.R. (1990) Biochemistry of endotoxins. Annu Rev Biochem 59: 129-170. 
Raetz C.R., and Whitfield C. (2002) Lipopolysaccharide endotoxins. Annu Rev 
Biochem 71: 635-700. 
Ramakrishnan M., Pocanschi C.L., Kleinschmidt J., and Marsh D. (2004) 
Association of spin-labeled lipids with β-barrel proteins from the outer 
membrane of Escherichia coli. Biochemistry (N Y ) 43: 11630-11636. 
187 
 
Sansom M.S., Bond P.J., Deol S.S., Grottesi A., Haider S., and Sands Z.A. (2005) 
Molecular simulations and lipid-protein interactions: Potassium channels 
and other membrane proteins. Biochem Soc Trans 33: 916-920. 
Seeger M.A., Schiefner A., Eicher T., Verrey F., Diederichs K., and Pos K.M. 
(2006) Structural asymmetry of AcrB trimer suggests a peristaltic pump 
mechanism. Science 313: 1295-1298. 
Seeger M.A., von Ballmoos C., Eicher T., Brandstatter L., Verrey F., Diederichs 
K., and Pos K.M. (2008) Engineered disulfide bonds support the 
functional rotation mechanism of multidrug efflux pump AcrB. Nat Struct 
Mol Biol 15: 199-205. 
Srikumar R., Kon T., Gotoh N., and Poole K. (1998) Expression of Pseudomonas 
aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-
MexD-OprJ in a multidrug-sensitive Escherichia coli strain. Antimicrob 
Agents Chemother 42: 65-71. 
Su C.C., Long F., Zimmermann M.T., Rajashankar K.R., Jernigan R.L., and Yu 
E.W. (2011) Crystal structure of the CusBA heavy-metal efflux complex 
of Escherichia coli. Nature 470: 558-562. 
Swick M.C., Morgan-Linnell S.K., Carlson K.M., and Zechiedrich L. (2011) 
Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE 
in Escherichia coli clinical isolates as a function of fluoroquinolone and 
multidrug resistance. Antimicrob Agents Chemother 55: 921-924. 
Symmons M.F., Bokma E., Koronakis E., Hughes C., and Koronakis V. (2009) 
The assembled structure of a complete tripartite bacterial multidrug efflux 
pump. Proc Natl Acad Sci U S A 106: 7173-7178. 
Takatsuka Y., and Nikaido H. (2006) Threonine-978 in the transmembrane 
segment of the multidrug efflux pump AcrB of escherichia coli is crucial 
for drug transport as a probable component of the proton relay network. J 
Bacteriol 188: 7284-7289. 
Takatsuka Y., Chen C., and Nikaido H. (2010) Mechanism of recognition of 
compounds of diverse structures by the multidrug efflux pump AcrB of 
Escherichia coli. Proc Natl Acad Sci U S A 107: 6559-6565. 
Takeuchi Y., and Nikaido H. (1984) Physical interaction between lipid A and 
phospholipids: A study with spin-labeled phospholipids. Rev Infect Dis 6: 
488-492. 
188 
 
Tamura N., Murakami S., Oyama Y., Ishiguro M., and Yamaguchi A. (2005) 
Direct interaction of multidrug efflux transporter AcrB and outer 
membrane channel TolC detected via site-directed disulfide cross-linking. 
Biochemistry (N Y ) 44: 11115-11121. 
Thanassi, D. G., Cheng, L. W., Nikaido, H. (1997) Active efflux of bile salts by 
Escherichia coli. J Bacteriol 179: 2512-2518. 
Tikhonova E.B., Yamada Y., and Zgurskaya H.I. (2011) Sequential mechanism of 
assembly of multidrug efflux pump AcrAB-TolC. Chem Biol 18: 454-463. 
Tikhonova E.B., Dastidar V., Rybenkov V.V., and Zgurskaya H.I. (2009) Kinetic 
control of TolC recruitment by multidrug efflux complexes. Proc Natl 
Acad Sci U S A 106: 16416-16421. 
Tikhonova E.B., and Zgurskaya H.I. (2004) AcrA, AcrB, and TolC of Escherichia 
coli form a stable intermembrane multidrug efflux complex. J Biol Chem 
279: 32116-32124. 
Touzé T., Eswaran J., Bokma E., Koronakis E., Hughes C., and Koronakis V. 
(2004) Interactions underlying assembly of the Escherichia coli AcrAB–
TolC multidrug efflux system. Mol Microbiol 53: 697-706. 
Trepout S., Taveau J.C., Benabdelhak H., Granier T., Ducruix A., Frangakis A.S., 
and Lambert O. (2010) Structure of reconstituted bacterial membrane 
efflux pump by cryo-electron tomography. Biochim Biophys Acta 1798: 
1953-1960. 
Vaccaro L., Scott K.A., and Sansom M.S.P. (2008) Gating at both ends and 
breathing in the middle: Conformational dynamics of TolC. Biophys J 95: 
5681-5691. 
Vaccaro L., Koronakis V., and Sansom M.S.P. (2006) Flexibility in a drug 
transport accessory protein: Molecular dynamics simulations of MexA. 
Biophys J 91: 558-564. 
Vakharia H., German G.J., and Misra R. (2001) Isolation and characterization of 
Escherichia coli tolC mutants defective in secreting enzymatically active 
alpha-hemolysin. J Bacteriol 183: 6908-6916. 
Vediyappan G., Borisova T., and Fralick J.A. (2006) Isolation and 
characterization of VceC gain-of-function mutants that can function with 
the AcrAB multiple-drug-resistant efflux pump of Escherichia coli. J 
Bacteriol 188: 3757-3762. 
189 
 
Vuong P., Bennion D., Mantei J., Frost D., and Misra R. (2008) Analysis of YfgL 
and YaeT interactions through bioinformatics, mutagenesis, and 
biochemistry. J Bacteriol 190: 1507-1517. 
Weeks J.W., Celaya-Kolb T., Pecora S., and Misra R. (2010) AcrA suppressor 
alterations reverse the drug hypersensitivity phenotype of a TolC mutant 
by inducing TolC aperture opening. Mol Microbiol 75: 1468-1483. 
Welch A., Awah C.U., Jing S., van Veen H.W., and Venter H. (2010) 
Promiscuous partnering and independent activity of MexB, the multidrug 
transporter protein from Pseudomonas aeruginosa. Biochem J 430: 355-
364.  
Welch R.A., Dellinger E.P., Minshew B., and Falkow S. (1981) Haemolysin 
contributes to virulence of extra-intestinal E. coli infections. Nature 294: 
665-667 
Xu Y., Sim S.H., Song S., Piao S., Kim H.M., Jin X.L., et al. (2010) The tip 
region of the MacA alpha-hairpin is important for the binding to TolC to 
the Escherichia coli MacAB-TolC pump. Biochem Biophys Res Commun 
394: 962-965. 
Xu Y., Sim S., Nam K.H., Jin X.L., Kim H., Hwang K.Y., et al. (2009) Crystal 
structure of the periplasmic region of MacB, a noncanonic ABC 
transporter, Biochemistry (N Y ) 48: 5218-5225. 
Xu Y., Lee M., Moeller A., Song S., Yoon B., Kim H., et al. (2011) Funnel-like 
hexameric assembly of the periplasmic adapter protein in the tripartite 
multidrug efflux pump in gram-negative bacteria. Journal of Biological 
Chemistry 286: 17910-17920. 
Yu, E. W., McDermott, G., Zgurskaya, H. I., Nikaido, H., Koshland, D. E., Jr. 
(2003) Structural basis of multiple drug-binding capacity of the AcrB 
multidrug efflux pump. Science 300: 976-980. 
Yum, S., Xu, Y., Piao, S., Sim, S. H., Kim, H. M., Jo, W. S., Kim, K. J., Kweon, 
H. S., Jeong, M. H., Jeon, H., Lee, K., Ha, N. C. (2009) Crystal structure 
of the periplasmic component of a tripartite macrolide-specific efflux 
pump. J Mol Biol 387: 1286-1297. 
Zgurskaya H.I., Yamada Y., Tikhonova E.B., Ge Q., and Krishnamoorthy G. 
(2009) Structural and functional diversity of bacterial membrane fusion 
proteins. Biochimica Et Biophysica Acta (BBA) - Proteins & Proteomics 
1794: 794-807. 
190 
 
 
 
